Dysregulation of the Integrated Stress Response in Early Onset Dystonia (DYT16) Due to Mutations in Pact by Burnett, Samuel B.
University of South Carolina 
Scholar Commons 
Theses and Dissertations 
Spring 2020 
Dysregulation of the Integrated Stress Response in Early Onset 
Dystonia (DYT16) Due to Mutations in Pact 
Samuel B. Burnett 
Follow this and additional works at: https://scholarcommons.sc.edu/etd 
Recommended Citation 
Burnett, S. B.(2020). Dysregulation of the Integrated Stress Response in Early Onset Dystonia (DYT16) 
Due to Mutations in Pact. (Doctoral dissertation). Retrieved from https://scholarcommons.sc.edu/etd/
5864 
This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in 
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please 
contact dillarda@mailbox.sc.edu. 
DYSREGULATION OF THE INTEGRATED STRESS RESPONSE IN EARLY 
ONSET DYSTONIA (DYT16) DUE TO MUTATIONS IN PACT 
 
by 
 
Samuel B. Burnett 
 
Bachelor of Science 
University of South Carolina, 2015 
 
 
 
Submitted in Partial Fulfillment of the Requirements 
 
For the Degree of Doctor of Philosophy in 
 
Biological Sciences 
 
College of Arts and Sciences 
 
University of South Carolina 
 
2020 
 
Accepted by: 
 
Rekha C. Patel, Major Professor  
 
Johannes W. Stratmann, Committee Member  
 
Shannon W. Davis, Committee Member 
 
Jason A. Stewart, Committee Member 
 
Maksymilian Chruszcz, Committee Member 
 
Cheryl L. Addy, Vice Provost and Dean of the Graduate School
ii 
© Copyright by Samuel B. Burnett, 2020 
All Rights Reserved.
iii 
DEDICATION
 This work is ultimately dedicated to my incredible wife and loving family, 
who have shaped me into the person I am today, while providing both 
encouragement and support in my pursuit of science.  
To my late but unconditionally loving sister, Megan Danielle Burnett, I will 
always cherish our time together and will carry your example of authenticity and 
love for the rest of my life. 
To the truly amazing person that is my wife, Dr. Crystal Hankin Burnett, 
who is the driving force in my life and the benchmark for what it means to be a 
genuine and loving person. I am beyond fortunate to call you my best friend and 
life partner. Without your steadfast love and support I would not be the man or 
scientist I am today. 
Finally, to my parents, Paul and Kasey Burnett, my siblings, Megan and 
Asher Burnett, my grandmothers, Cherry Krest and Shirley Burnett, and all the 
members of my extended family, I am grateful for the influence each of you have 
had on my life. To my mother, Kasey, I am grateful for instilling in me the value of 
pursuing “a lifetime of learning” from a young age thus setting me on the path 
pursue higher education.
iv 
ACKNOWLEDGEMENTS
I would first like to thank my advisor, Dr. Rekha Patel, for the continual 
mentorship she has provided over years. I am truly grateful for the degree to 
which she pushed me to pursue excellence and perfection in every aspect of my 
training. The constructive criticism and feedback provided by Dr. Patel has not 
only taught me how to relentlessly pursue solutions to real world problems but 
also how to communicate the value of my work to any audience. Under her 
guidance I have grown as scientist and a person. I will forever be grateful for the 
opportunities and the training she has provided me over the years.  
 I would also like to thank my thesis committee, Drs. Johannes Stratmann, 
Shannon Davis, Jason Stewart, and Maksymilian Chruszcz for their thought 
provoking and rigorous insight into all of my projects. Each member of this 
committee has given provided me with an amazing example of what it means to 
be a person and scientist to which I will always be thankful. I would like to extend 
an additional token of gratitude to Dr. Johannes Stratmann for allowing me to find 
my passion for research as an undergraduate student in his laboratory.  
 I am also grateful each member of the Patel Lab I have had the pleasure 
of working with during my time here. This truly talented group of scientists 
includes Dr. Evelyn Chukwurah who very patiently taught me many techniques 
while simultaneously becoming a surrogate sister within the lab. To my friends 
Benedicth “Bennie” Ukhueduan and Kenneth “Ken” Frederick, I am truly grateful 
v 
for the support and encouragement provided by you both on a daily basis. 
Finally, to Mrs. Carmel “Indhira” Handy, the patron saint of the Patel Lab, I am 
thankful for the overflowing wisdom and generosity she provides everyone who 
has the privilege of meeting. While working in the Patel Lab I have had the 
privilege of mentoring several brilliant junior scientists, Joelle Strom, Matthew 
Lucius, Kevin Harper, Ronit Kulkarni, and Ashley Francois. Watching these 
students gain competencies and independence in highly technical areas has 
been one of the major highlights to my time in graduate school. 
I am truly indebted to the genuine community of people I have the 
privilege of calling friends. To Chad Vess, Zach Steinhauser, Matt Zdradzinski, 
Yogin Patel, Harsh Soni, Claire Hann, Lyndsay Busler, Allie Culver, Olivia Spead, 
Stephanie Ackerson, Danielle Colón, Ben and Clessie Pigott, Ben and Lyndsey 
Peele, Nick and Emily Tyler, Drew and Kristen Hogan, Robert and Kelsey 
Earnest and many more. It is beyond my ability to thank these people for being 
part of my life in both times of celebration and in times of great tragedy.  
 While I would consider myself rich in friends, the well that is my family is 
much deeper. I would like to thank all the extended members of both the Burnett 
and Krest families instilling values of hard work and discipline in me throughout 
my life. 
Finally, I want to acknowledge my amazing wife and best friend, Dr. 
Crystal Hankin Burnett. I am so thankful for such a kind, loving, and intelligent 
person I get to spend every day of my life with. Thank you for the overwhelming 
love and support, without you I would not be where I am today.  
v 
ABSTRACT 
Early onset primary dystonia 16 (DYT16) is a subtype of the 
neuromuscular movement disorder, dystonia. The resultant phenotypes of 
DYT16 consist of both agonist and antagonist muscles firing simultaneously, 
compromised posture and gait, as well as chronic repetitive movements. DYT16 
has been shown to result from mutations in the protein activator of PKR, PACT. 
Under conditions of viral infection, ER stress, oxidative stress, and serum 
starvation, PKR phosphorylates eIF2α resulting in the attenuation of general 
protein synthesis. Transient eIF2α phosphorylation is favorable for cell survival, 
however, when prolonged leads to apoptosis. In the absence of stress, both 
PACT and PKR are in an inhibitory heterodimeric complex with TRBP thus 
preventing PKR’s activation. In response to stress stimuli, PKR is activated 
through the disassociation of these inhibitory heterodimers which promotes the 
formation of PACT homodimers, a critical intermediate for activating PKR, and 
PACT-PKR heterodimers that result in PKR activation. Here we describe how 
DYT16 mutations dysregulate eIF2α stress response signaling through PKR. 
Our results indicate that a dominantly inherited DYT16 frameshift mutation 
truncating PACT within its first functional motif ablates PACT’s ability to bind 
dsRNA and interact with PKR. We then describe how this truncated protein not 
only retains its ability to interact with TRBP and PACT but is also capable of 
dissociating PACT-TRBP heterodimers. Furthermore, when expressing an N-
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terminally tagged mCherry-FS fusion protein in mammalian cells we observe the 
accumulation of cytosolic protein aggregates, the induction of apoptosis through 
activation of caspases 3/7, and dysregulation in eIF2α stress signaling kinetics.  
We also describe the effect 3 recessive (C77S, C213F, C213R) and 2 
dominant (N102S, T34S) DYT16 point mutations have on the biochemical 
properties of PACT. Our results reveal that PACT with dominant mutations 
interact more efficiently with PKR and all DYT16 mutations have an increased 
capacity to homodimerize resulting in their enhanced ability to activate PKR 
relative to wild type PACT. We then describe how DYT16 patient lymphoblasts 
form stronger PACT-PKR interactions, have high basal levels of active PKR, 
have dysregulated eIF2α stress response signaling, and heightened sensitivity to 
ER stress relative to control cells. We further show that the increased sensitivity 
to ER stress can be partially rescued by disrupting PACT-PKR interactions. 
Finally, we investigate a novel DYT16 mouse model resulting from a 
frameshift mutation, Prkralear-5J (referred to as lear-5J), in the mouse homolog of 
PACT. We demonstrate that although the mRNA is being targeted for nonsense 
mediated decay, we still detect residual mRNA and the truncated lear-5J protein 
in the mouse brain, however, not in mouse embryonic fibroblasts. We show that 
lear-5J protein retains its ability to interact with PKR but is a less efficient 
activator PKR. We also identified defects in the development of the folia within 
the cerebellum and reduced levels of p-eIF2α in DYT16 mice. Finally, we further 
demonstrate dramatic defects in the arborization of the Purkinje neuron layer 
within the cerebellum of these mice.  
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CHAPTER 1:  
INTRODUCTION
2 
1.1 THE INTEGRATED STRESS RESPONSE 
Eukaryotic cells have evolved a complex network of protective pathways 
called the integrated stress response (ISR) in order to regulate protein synthesis 
to maintain homeostasis in response to unfavorable environmental or intracellular 
stimuli1,2. The primary node of this signaling network is the heterotrimeric 
eukaryotic translation initiation factor 2 (eIF2) (Fig 1.1)2. This highly conserved 
protein complex consists of an α, β, and γ subunit2. As a mechanism to initiate 
general protein synthesis, eIF2 binds the methionyl charged initiator tRNA (Met-
tRNAi) in order to form the ternary complex (TC)3,4. This TC then directly interacts 
with the 40S ribosomal subunit to form the pre-initiation complex (PIC)3,4. 
Interactions between the PIC and other multi-protein complexes within the 
eukaryotic translation initiation factor family (eIF) stimulate translation through the 
recognition of and assembly at the 5’m7-G-cap of mature mRNAs3,4. The ability of 
eIF2 to stay in its active form capable of initiating the formation of TC is 
dependent on the guanine exchange factor (GEF) activity of the eIF2B3,4. Prior to 
the formation of the ternary complex, a GDP bound to the gamma subunit of eIF2 
is substituted for a GTP through the enzymatic activity of eIF2B1,2. Binding of the 
TC to 5' cap on mRNAs requires activity of cap-binding initiation factor eIF4 
complex and is the mechanism used by the majority of cellular mRNAs.  
In response to stress stimuli, the translation of cap-dependent transcripts is 
negatively regulated by a family of four serine/threonine protein kinases by 
directing their enzymatic activity to the alpha subunit of eIF2 (Fig 1.1)1,2. This 
family of kinases consists of Heme Regulated Inhibitor (HRI), double-stranded 
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RNA activated Protein Kinase (PKR), PKR-like Endoplasmic Reticulum Kinase 
(PERK), and the General Control Non-derepressible 2 (GCN2) (Fig 1.1)1,2. 
Although these kinases share a substrate and a very conserved kinase domain 
(KD), they have been well characterized for their role in responding to specific 
stress stimuli (Fig 1.1)1. The subsequent eIF2α phosphorylation (p-eIF2α) event 
serves two functions: (i) stimulates the binding of eIF2B to p-eIF2α, (ii) inhibits 
the GEF activity of eIF2B2,5,6. The inhibition of eIF2B’s GEF activity ultimately 
blocks the formation of the TC resulting in the attenuation of general protein 
synthesis while simultaneously promoting the translation of stress specific 
mRNAs (Fig 1.1)2.  
The first responder to conditions of cellular stress is the activating 
transcription factor 4 (ATF4), which is constitutively expressed in cells. The ATF4 
mRNA is kept untranslated until cells encounter a stress signal which activates 
its preferential translation when eIF2α is phosphorylated (Fig 1.1)2. This 
preferential translation is facilitated by the recruitment of ribosomes to an internal 
ribosome entry site (IRES) and a short upstream open reading frame (uORF) in 
the 5’ untranslated region (5’UTR) in the ATF4 mRNA2. Under conditions of acute 
or moderate stress, ATF4 is responsible for the induction of many stress 
response genes necessary to ameliorate the assault1,2. The resultant stress 
response transcripts are then preferentially translated in the 5’m7-G-cap 
independent manner described above2. One such ATF4 induced gene is a 
regulatory subunit of protein phosphatase 1 (PP1), GADD34 (Fig 1.1)7,8. The 
GADD34-PP1 holoenzyme functions to restore eIF2α function after a successful 
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ISR by dephosphorylating eIF2α (Fig 1.1)7,8. Under conditions of severe or 
chronic stress, however, the bioenergetic demands required of the cell to recover 
are too great and ATF4 induces the expression of pro-apoptotic transcripts such 
as CHOP2. Ultimately, the phosphorylation state of eIF2α plays a seminal role in 
cell fate decisions through the regulation of protein synthesis and either 
promoting recovery and homeostasis or the accumulation of pro-apoptotic 
transcripts and cell death.   
1.2 THE DOUBLE-STRANDED RNA ACTIVATED PROTEIN KINASE (PKR) 
Interferons (IFNs) are a family of ubiquitously expressed cytokines that play a 
critical component in both innate and adaptive immune response as well as 
inflammatory signaling. There are three classes of IFNs (Type I, Type II, and 
Type III). Each class binds to a specific receptor and Type I interferons are the 
largest class, consisting of seven members: IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ω, 
IFN-δ, and IFN-τ 9,10. Each member of the Type I interferons serves as a ligand 
for the heterodimeric transmembrane receptor, IFNAR9,10. A common stimulus for 
a Type I IFN response begins when a pathogen (usually a virus) associated 
molecular pattern (PAMP) is recognized by a pathogen recognition receptor 
(PRR) as well as well as through cytokine signaling9-12. The PRRs stimulate an 
intrinsic antiviral response as well as the production and secretion of Type I IFNs, 
thus creating an amplification loop via this signaling cascade9,10. The IFNs 
produced by the initial virus infected cell are secreted and stimulate the 
expression of over 300 interferon stimulated genes (ISGs) in surrounding 
uninfected cells9. These ISGs confer viral resistance to cells by enabling them to 
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successfully combat either being infected or inhibit the virus replication. IFNs and 
ISGs thus form the first line of defense as part of our innate immune system. 
During viral infections, increased interferon levels lead to enhanced 
expression of ISGs, which have established anti-viral activity9,11. As an ISG, PKR 
expression is enhanced during viral infections due to the elevated type I IFN 
production13. Although PKR expression is stimulated in by IFNs, PKR’s kinase 
activity stays latent until it is bound by double-stranded (ds) RNA, a replication 
intermediate of many viruses13-15. For this reason, PKR was initially characterized 
for its role in stimulating the ISR in response to viral infections by targeting its 
kinase activity to eIF2α13,15,16. Since the original identification and 
characterization of PKR, its kinase activity has also been shown to be stimulated 
by a wide variety of stress signals including heat shock, endoplasmic reticulum 
(ER) stress, oxidative stress, and serum starvation in a dsRNA independent 
manner through interactions with its protein activator (PACT)1,17-19. 
Structure of PKR 
In addition to the conserved carboxy-terminal KD, PKR contains two highly 
conserved amino-terminal dsRNA binding motifs (dsRBMs): dsRBM1 (amino acid 
residues 10-72) and dsRBM2 (amino acid residues 100-165) (Fig 1.2)13,20-22. 
Structural studies have demonstrated both dsRBMs have similar secondary 
structures consisting of a central hydrophobic core and form a dumbbell 
conformation flanking a 22-residue linker region23. These dsRBMs serve as 
important functional domains to mediate PKR’s protein-dsRNA interactions as 
well as protein-protein interactions16,23-25. Both dsRBM1 and dsRBM2 share high 
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sequence and structural homology to other dsRNA binding proteins and include 
an α-β-β-β-α fold such that the α-helices are positioned on the face of a three-
stranded antiparallel β-sheet23. Extensive mutation studies have been conducted 
to identify critical residues involved in mediating PKR-dsRNA interaction and 
have revealed highly conserved dsRNA binding sites within each motif26-28. 
These studies suggest a partially positive charge within dsRBM1 located on the 
PKR-dsRNA binding interface. Certain hydrophobic residues within the 
amphipathic α-helices located in these dsRBMs have been shown to be 
indispensable for the inter- and intramolecular interactions that are necessary to 
facilitate PKR activation.  
Prior to interaction with one of its molecular activators, PKR exists in an 
inhibitory conformation such that PKR’s carboxy-terminal KD is bound to the 
amino terminal dsRBM2 via intramolecular interactions29. Mechanistic studies 
have demonstrated that both dsRBM1 and dsRBM2 within PKR contribute to the 
molecular interactions. Interactions with these activators to induce a 
conformational change in PKR such that the KD is released from dsRBM2 which 
then unveils the ATP binding site within the activation loop of the KD15,23. PKR is 
then able to undergo a trans-autophosphorylation to become catalytically 
active30.  
Activation of PKR 
One of the most potent and well characterized activators of PKR is 
dsRNA1,26,27. DsRNA binds PKR via high affinity interactions facilitated by the 
amino terminal dsRBMs. While dsRBM1 is indispensable for PKR’s ability to bind 
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dsRNA, both dsRBM1 and dsRBM2 are necessary for optimal binding of PKR to 
dsRNA and induce an allosteric change and trans autophosphorylation required 
to activate PKR15,23. Collectively, representative data from biochemical and 
structural studies point to a mechanism where the dsRBMs of PKR wrap around 
the dsRNA duplex15,23. This interaction is stabilized by the electrostatic 
interactions of the dsRBMs with 2’-OH groups and the polyanionic phosphate 
backbone of the dsRNA31. Interestingly, in vitro and in vivo studies evaluating 
alternative polyanionic compounds’ ability to activate PKR identified heparin, 
dextran sulfate, and chondroitin sulfate as effective PKR activators independent 
of dsRNA27,32,33. Of these compounds, heparin was the most potent activator. 
Further analysis of heparin mediated PKR activation in our lab suggest that it is 
facilitated through interactions with PKR’s carboxy-terminal KD, as opposed to 
the dsRBMs32.  
PACT activates PKR in a dsRNA-independent manner in response to stress 
signals other than a virus infection17,25,34-36. Similar to PKR, PACT is also a 
dsRNA binding protein that is ubiquitously expressed in all cell types, however, it 
is not an ISG product25,37. PACT activates PKR via direct stress-dependent high 
affinity interaction with PKR25,34,35,37-39. These protein-protein interactions are 
mediated through amino terminal dsRBMs located on each protein. A critical 
intermediate step for PACT’s ability to interact with and activate PKR is formation 
of PACT-PACT homodimers40. PKR then binds these stress induced PACT 
homodimers to facilitate the catalytic activation described above.  
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Downregulation of PKR 
While a significant effort has been made to understand the mechanisms 
behind how PKR is activated, the mechanisms behind the downregulation of 
PKR’s kinase activity are poorly understood. Interestingly, Tan et al. 
demonstrated the catalytic subunit of PP1 (PP1C) both directly interacts with and 
dephosphorylates PKR returning the kinase to its inactive basal state41. This 
interaction was facilitated via a short PP1C binding motif that overlaps with end 
of PKR’s dsRBM2 (residues 164-167). As PP1C regulates a wide array of cellular 
processes, the substrate specificity of this enzyme is facilitated by various 
regulatory subunits. Interactions between PP1C and a regulatory subunit results 
in the formation of the highly specific functional holoenzyme. While the inhibitory 
nature of the PP1C-PKR interactions is clear, the cellular context under which 
this negative regulation operates is not, and whether or not any regulatory 
subunits of PP1C are required remains unknow.  
The trans-activation response (TAR) RNA binding protein (TRBP), which was 
first identified in the context of HIV infected cells, is a strong inhibitor of 
PKR18,42,43. Similar to PKR, TRBP contains two amino terminal dsRBMs 
(dsRBM1 and dsRBM2) that facilitate interactions with both dsRNA and other 
proteins containing such motifs (Fig 1.2)42,44,45. Additionally, TRBP also contains 
a third carboxy-terminal dsRBM (dsRBM3) that does not bind dsRNA but 
mediates the protein-protein interactions with merlin, dicer, and PACT and thus is 
termed the medipal domain46. TRBP inhibits PKR is by the sequestration of its 
cellular activators, dsRNA and PACT, as well as through direct interaction with 
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PKR43,44,47. Mechanistic biochemical studies indicate that in the absence of 
stress, the basal state of PKR activation remains low due to the prevalence of 
both TRBP-PACT and TRBP-PKR inhibitory heterodimers48. Stress signals result 
in the dissociation of PACT-TRBP as well as PKR-TRBP heterodimers thereby 
allowing PKR activation. Further studies have also shown that TRBP plays a 
critical role in the downregulation of PKR after a successful ISR through 
reassociation with PACT and PKR48.  
1.3 PACT: THE PROTEIN ACTIVATOR OF PKR 
Identification and Transcriptional Regulation 
PACT is a 313 amino acid protein encoded for by the PRKRA gene (Fig 
1.2)25. PACT was initially identified through yeast two-hybrid screening of human 
placenta cDNA library for interaction with the trans-dominant negative PKR 
(K296R)25. Further studies on the physiological functions of PACT demonstrated 
through a series of in vivo and in vitro studies that PACT directly interacts with 
PKR via the amino terminal dsRBMs of PKR and activates its kinase 
activity25,34,35,37,38,49. The mouse homologue of PACT was subsequently identified 
and characterized in a similar series of assays34,36. These proteins all share an 
exceptional degree of conservation as they differ only in six amino acid residues 
of which four are conservative replacements. Orthologs of PACT have since 
been identified across numerous taxa including prominent model organisms such 
as, Danio rerio, Drosophila melanogaster, rat, mouse, and monkey. The 
extensively high degree of conservation of PACT between species indicates it 
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could be playing a universal role in development and the maintenance of cellular 
homeostasis.  
Unlike PKR, the PRKRA gene is not induced by IFNs. Interestingly, primer 
extension studies to map the transcription start site and analysis of the promoter 
region of the PRKRA gene revealed the absence of a conventional TATA 
box50,51. These studies identified regulatory GC boxes which are known binding 
sites for the general transcription factor, Sp150,51. Six Sp1 binding sites were 
identified within the 300 base pairs (bp) upstream of the PRKRA transcriptional 
start site50. Through the generation of PRKRA nested promoter deletion 
constructs upstream of a firefly luciferase reporter gene, the minimal promoter 
was mapped within -101 bp to -1 bp, although all six GC boxes contribute to 
some extent for the maximal promoter activity50. A CCAAT box between positions 
-404 bp to -400 bp further boosted the promoter activity, but the effect of point 
mutations in this region was not studied and the transcription factor that binds at 
this site was also not identified50. Finally, these studies not only characterized 
PRKRA promoter, they also demonstrated that PRKRA is most abundantly 
expressed in the placenta, colon, and testis25,34,50.  
Domain Structure of PACT 
The extensive degree of sequence conservation observed in PACT among 
various species is largely localized to the three dsRBMs that serve as important 
functional domains (Fig 1.2). PACT’s two amino terminal dsRBMs, dsRBM1 and 
dsRBM2, are not only evolutionarily conserved among species within the PACT 
protein, but also share sequence homology to the amino terminal dsRBMs found 
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in both PKR and TRBP 25,38,39. Additionally, PACT contains a comparatively less 
conserved third carboxy-terminal dsRBM, dsRBM325,38. This dsRBM3 is 
incapable of binding dsRNA, however, is indispensable for PACT’s ability to 
activate PKR29,38.  
Further investigation into these functional motifs revealed that PACT’s dsRNA 
binding and protein-protein interactions were largely attributed to the amino 
terminal dsRBMs25,37,39,52. In order to investigate this question, a series of PACT 
deletion constructs was generated and followed by co-immunoprecipitation and 
yeast two-hybrid studies. The studies demonstrated that PACT’s ability to interact 
with TRBP, PACT homodimerization, and PKR interactions were resultant of a 
cooperative effort between dsRBM1 and dsRBM2 while dsRBM3 was largely 
dispensable for these high affinity interactions37-39. Following these results, the 
contribution of individual hydrophobic amino acids within each domain was 
evaluated. Through mutagenetic studies and a similar series of assays, it was 
determined that specific hydrophobic residues within dsRBM1 were most critical 
for PACT’s protein-protein interactions, while dsRBM2 serves to stabilize and 
enhance these interactions39. Of particular note, the leucine at position 99 (L99) 
of PACT’s dsRBM1 was found to be indispensable for PACT-PACT 
homodimerization52. To address the question if PACT homodimerization was 
required for PKR activation, site specific mutagenesis substituting this leucine for 
glutamate (L99E) was utilized to generate a PACT construct incapable of 
homodimerizing52. Surprisingly, this mutation had no consequence on PACT-
PKR interactions, but was completely inactive for PKR activation in in vitro kinase 
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assays thus indicating the requirement for PACT-PACT interactions for PKR 
activation.  
The PACT deletion constructs outlined above describe how the two amino 
terminal dsRBMs are responsible for the formation of PACT-PKR heterodimers. 
Further analysis into these functional domains revealed that while dsRBM1 and 
dsRBM2 are required for the interaction, deletion constructs lacking PACT’s 
dsRBM3 were incapable of activating PKR. Furthermore, PACT’s dsRBM3 alone 
is capable of activating PKR albeit moderately and only at high concentrations 
because this domain interacts within PKR's KD to bring about PKR activation. 
Investigation into the KD of PKR has revealed a short binding region spanning 
residues 326-337 in PKR that bind PACT’s dsRBM3 with low affinity29. This low 
affinity interaction was demonstrated to be a product of five residues within PKR 
(D328, D333, D331, G329, Y332) and this has been termed the PACT binding 
motif (PBM) (Fig 1.2)29. However, interaction of dsRBM3 with the PBM is fairly 
weak and the dsRBM1 and 2 are required for efficient PKR activation in cells and 
in vitro as they direct PACT-PKR interaction even at low PACT concentrations. 
Interestingly, additional studies utilizing chimeric proteins where the carboxy-
terminal dsRBM3 of PACT was linked to the two amino terminal dsRBD of TRBP 
showed that the chimeric protein was capable of stimulating PKR’s kinase activity 
in vitro47.  
While the mechanistic and biochemical studies outlined above gave 
tremendous insight into the underlying properties dictating PACT’s interaction 
with PKR, the post-translational modifications that regulate the hetero- and 
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homomeric interactions of PACT remains relatively less studied. Mutagenic 
studies have given some insight to this question and identified two serine 
residues, S246 and S287, within PACT’s dsRBM3 that serve as phosphorylation 
sites17,49,53. Results from these studies suggest that S246 is constitutively 
phosphorylated, whereas S287 is phosphorylated in a stress-dependent context. 
Utilizing phosphomimetic or phosphodefective mutant constructs at each of the 
sites demonstrates that the high affinity PACT-TRBP interactions occur only in 
the absence of the stress induced phosphorylation on S28749. In agreement with 
this data, these studies have shown that phosphomimetic mutations at both of 
these serine residues significantly increase PACT’s ability to homodimerize as 
well as to form PACT-PKR heterodimers.  
PACT: A Stress Dependent Negative Regulator of Translation 
The studies outlined above describe the mechanism whereby PACT mediates 
PKR activation in a dsRNA independent manner (Fig 1.3). These studies 
demonstrate that in the absence of stress, PACT is constitutively phosphorylated 
on S246 and is in an inhibitory heterodimeric complex with TRBP. In response to 
stress stimuli, PACT is phosphorylated by a yet to be characterized kinase on 
S287 resulting in the dissociation of PACT-TRBP heterodimers while 
simultaneously promoting the formation of PACT-PACT homodimers. These 
PACT-PACT homodimers then interact with PKR via the highly conserved amino 
terminal dsRBMs on each protein. We speculate that the resultant conformational 
change induced in PKR may then be stabilized through low affinity interactions 
between the PBM in PKR’s KD with PACT’s dsRBM3. Once activated, PKR’s 
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enzymatic activity is then directed toward eIF2 resulting in the attenuation of 
general protein synthesis while promoting the preferential translation of a subset 
of transcripts whose protein products are crucial in promoting cellular recovery 
(Fig 1.1, Fig 1.2). In response to chronic or severe stress, eIF2α phosphorylation 
is prolonged and the cell begins to undergo apoptosis as more pro-apoptotic 
transcripts and proteins are synthesized. For this reason, both PACT-PACT 
homodimers and PACT-PKR heterodimers are considered pro-apoptotic while 
TRBP-PACT and TRBP-PKR heterodimers are considered to favor cell survival.  
PACT mediated PKR activation has been observed in response to the 
accumulation of misfolded proteins in the endoplasmic reticulum (ER) stress, 
oxidative stress, starvation, and heat shock17,43,49. PKR phosphorylation has also 
been identified in the pathology of many neurodegenerative disorders including, 
Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease54-58. While 
dimeric and phosphorylation state of PACT in these diseases remains an open 
question, it is highly plausible PACT is mediating PKR’s activation in these 
diseases.  
1.4 PACT AND PRIMARY EARLY ONSET DYSTONIA 
Primary Dystonia 
The dystonias (DYT1-DYT26) are a group of heterogenous movement 
disorders directly linked to mutations in 25 genes59-61. While the age of onset and 
severity of the symptoms vary between each DYT subtype, the patient 
populations commonly present with involuntary, sustained and often painful 
repetitive movements of the dystonic limb, twisted posture, and compromised 
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gait which drastically inhibits their mobility59. A hallmark in identifying primary 
dystonia is the consistent directionality of the associated movements. This 
consistency is due to the firing of both agonist and antagonist muscles 
simultaneously in response to a single stimulus59. Although secondary and 
pseudo forms of dystonia often present in the clinic, these forms of dystonia are 
symptomatic of either an alternative disease or a side effect of certain drugs59. 
Primary dystonia, however, is distinguished from these forms of dystonia by 
being the result of a specific genetic mutation and a primary symptom as 
opposed to being a symptom of an alternative disease59.  
PACT in Early Onset Dystonia and Parkinsonism (DYT16) 
Early onset dystonia and parkinsonism subtype 16 (DYT16) is severe form of 
primary dystonia which typically presents in patients during early childhood or 
adolescence and follows both autosomal recessive as well as dominant 
inheritance patterns60. DYT16 was first described by Camargos and colleagues 
who identified a homozygous mutation in PACT as the causative mutation 
through whole exome sequencing in seven Brazilian patients62. This was a 
missense mutation in PACT resulting in the substitution of a proline residue at 
position 222 for leucine (P222L), located between PACT’s dsRBM2 and dsRBM3 
(Fig 1.4). The cohort in which the P222L mutation was identified consisted of 
seven individuals from two unrelated Brazilian families. The analysis of 
asymptomatic family members of individuals within this cohort revealed those 
who are heterozygous for the P222L mutation were unaffected.  
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After the initial identification of a causative mutation in the PRKRA gene 
leading to DYT16 dystonia, further investigations were carried out worldwide in 
evaluating primary dystonia patients. This led to the discovery of the 
homozygous P222L mutation in two Polish brothers and the novel discovery of a 
dominantly inherited frameshift mutation in one German patient63-65. This 
frameshift (FS) mutation was resultant from the deletion of two nucleotides within 
PACT’s first dsRBM1 (c.266_267delAT) which introduced a premature stop 
codon into the reading frame of the PRKRA mRNA (Fig 1.4). The FS mutation 
truncates the protein after 88 amino acids immediately followed by 21 extraneous 
amino acids before a premature stop codon. 
The identification of new causative DYT16 mutations in PACT continues to 
increase. The identification of a novel de novo C213R mutation in PACT in a 
male patient in USA was recently identified66. While the mother of this patient 
carries the P222L mutation, his father showed no mutation in PACT. Thus, the 
patient inherited the P222L mutation from his mother and a de novo C213R 
mutation that occurred in the proband manifesting in DYT16 symptoms and 
development of dystonia at a very early age. Two recessively inherited mutations 
were identified in a compound heterozygous patient such that one allele had a 
C77S mutation and the other allele had a C213F mutation66. Additionally, three 
more dominantly inherited mutations were identified such that two were located 
within PACT’s coding region (N102S and T34S), while one was in the 5’ UTR (-
14A>G)65, which is likely to change the coding region in the longer isoform of 
PACT that has not been studied so far but has been described to exist based on 
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cDNA sequencing in the NCBI database. Most recently, another mutation was 
described within PACT’s dsRBM3 (S265R) as a compound heterozygote with 
P222L mutation causing early-onset DYT1667. Interestingly, a spontaneous 
frameshift mutation was reported in a mouse by the Jackson Laboratory that was 
described to cause dystonia in the mouse (Fig 1.4)67,68. The identification of 10 
DYT16 mutations in PACT, 9 of which are in humans and 1 in a novel mouse 
model establishes the causative role of PACT in DYT16 disease etiology (Fig 
1.4).  
In their 2015 study, Vaughn et al. describe that the lymphoblasts derived from 
patients homozygous for the most prevalent P222L mutation have dysregulated 
eIF2α stress response signaling and these cells are hypersensitive to ER 
stress69. They further demonstrated that as compared to wild type (wt) PACT, the 
P222L mutation has a significantly higher affinity for both PKR and TRBP, while 
also exhibiting stronger PACT-PACT interactions. Finally, they demonstrated that 
the DYT16 patient cells show delayed but more prolonged PKR activation and 
eIF2α phosphorylation in response to ER stress. Studies that were performed on 
other forms of dystonia after Vaughn et al.'s first report of dysrergulated eIF2 
signaling in DYT16, also implicated misregulation of ER stress and eIF2 
signaling in the etiology of both DYT1 and DYT670,71. DYT1 is caused by 
mutations in the torsin A gene. Torsin A is an ER resident chaperone and the 
DYT1 mutations have been shown to chronically induce ER stress at low 
levels72,73. This manifests in both the accumulation of misfolded proteins as well 
as secretory defects. The underlying genetic cause of DYT6 has been identified 
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to be mutations in the gene coding for thanatos-associated domain-containing 
apoptosis associated protein-1 (THAP1)60,71. THAP1 is a transcription factor with 
both cytosolic and nuclear localization. Interestingly, THAP1 shares an amino 
terminal motif found in a protein inhibitor of PKR. While the mechanistic studies 
still need to be pursued, it is plausible that THAP1 induces low levels of ER 
stress through the de-repression of PKR’s kinase activity. Thus, we propose that 
the dysregulation of eIF2α signaling may be a generalized mechanism driving the 
etiology for some forms of primary dystonia74.  
The dysregulation of protein synthesis by affecting the eIF2 axis is quickly 
becoming an emerging theme in the pathology of movement disorders, 
neurodegenerative disorders, as well as intellectual disability disorders. Clinical 
studies have identified elevated kinase activity of the eIF2α kinases, PERK and 
PKR in Alzheimer’s disease, ALS, and certain forms of autism75-79. Conversely, 
both in vivo and in vitro studies have implicated deficient phosphatase activity of 
PP1 in severe neurodevelopment disorders7,8,80,81. Patients and disease models 
deficient in the regulatory subunits of PP1 present with reduced body size, 
microcephaly, intellectual disability, and in some cases, Alzheimer’s disease82,83. 
Most recently, mutations in the  subunit of eIF2, a critical component in the 
formation of the ternary complex, have been identified to be a causative factor 
driving mental intellectual disability, epileptic seizures, hypogenitalism, 
microcephaly, and obesity (MEHMO) syndrome84. Samples taken from patients 
with MEHMO show signs of chronic stress markers as the causative mutations 
lead to a defect in ternary complex formation84. A noteworthy symptom in a 
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severe form of MEHMO syndrome is lower limb ataxia84. This ultimately results in 
the expression of stress response transcripts and constitutively stimulates the 
ISR in these patients84. Taken in concert with various DYT subtypes 
dysregulating protein synthesis through the alpha subunit of eIF2, aberrancies in 
translation surrounding the eIF2 signaling hub can have dramatic and severe 
consequences. Because PACT regulates protein synthesis through eIF2α stress 
response signaling, the studies outlined in this thesis suggest a common 
mechanism shared between DYT16 and many debilitating neurological disorders.  
1.5 STRUCTURE OF DISSERTATION 
Chapter 2 of this dissertation describes the biochemical properties of a 
dominantly inherited DYT16 frameshift (FS) mutation and its effect on 
mammalian cells. Our results indicate the truncated protein is both incapable of 
binding dsRNA as well as void of its ability to interact with PKR. Our results 
further demonstrate that despite this truncation occurring in PACT’s dsRBM1, the 
mutant polypeptide surprisingly retains its ability to interact with wild type PACT 
and TRBP. When overexpressing this FS mutation as a fusion protein containing 
an amino-terminal fluorescent mCherry tag we observe the formation of insoluble 
cytosolic aggregates. Furthermore, we describe that overexpression of this 
mutation in mammalian cells induces apoptosis via activation of caspases. 
Through utilizing PACT-/- or PKR-/- null cells we establish that the apoptosis 
results from both PACT/PKR dependent and independent mechanisms. Lastly, 
by utilizing competition assays we demonstrate that the interaction of the FS 
mutant protein with TRBP can dissociate wild type PACT from the inhibitory 
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PACT-TRBP complex, possibly causing PKR activation in cells and inducing 
apoptosis. Our results indicate a mechanism where PKR is activated by the 
accumulation of insoluble protein aggregates possibly adding to the list of recent 
studies implicating increased PKR activity in the pathology of neurodegenerative 
diseases resulting from protein aggregation.  
Chapter 3 of this dissertation describes the biochemical properties 
associated with five previously uncharacterized DYT16 point mutations (C77S, 
C213F, C213R, N102S, and T34S) and studies the biological consequences of 
these mutations. Our results demonstrate that these DYT16 mutations have no 
consequence on PACT’s dsRNA binding, however, are more efficient PKR 
activators. We further address the impact these DYT16 mutations have on 
PACT’s network of protein-protein interactions. We further establish that while 
the dominantly inherited mutations bind PKR with higher affinity as compared to 
wt PACT, the recessive mutations show no difference in their ability to form 
PACT-PKR heterodimers. All of the DYT16 mutant proteins form PACT-PACT 
homodimers with significantly higher affinity relative to that of wt PACT. Finally, 
using DYT16 patient derived lymphoblast cells we show the dysregulation of 
eIF2α signaling kinetics in response to ER stress followed by enhanced 
apoptosis in patient cells as compared to wt cells from an unaffected family 
member. Surprisingly, in the patient cells we identified heightened PACT-PKR 
interaction as compared to the unaffected family members. The observed hyper-
sensitivity to ER stress was rescued in patient cells by disrupting the high-affinity 
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PACT-PKR interactions with luteolin treatment, an inhibitor of PACT-PKR 
interactions.  
Chapter 4 of this dissertation outlines our studies with a recessively inherited 
frameshift mutation, Lear5j, which results in severe developmental and DYT16-
like phenotypes in a novel DYT16 mouse model. We identify that this truncated 
variant of the PACT protein retains its ability to interact with PKR, however its 
ability to stimulate PKR’s kinase activity is significantly reduced in vitro. 
Furthermore, our results suggest the Lear5j mRNA is targeted for NMD only 
partially both in the brains of these mice as well as MEFs, and that we can still 
detect significant amounts of the mutant transcripts as well as the truncated 
protein in the brains of these affected mice. Finally, we show the presence of a 
severe lack of dendritic arborization in the Purkinje neuron layer of the 
cerebellum and reduced eIF2α phosphorylation in Lear5j mice.  
Chapter 5 of this dissertation provides an overall discussion, conclusions, and 
future directions. 
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Figure 1.1 The Integrated Stress Response (ISR): Four kinases (GCN2, 
HRI, PERK, and PKR) have evolved to attenuate general protein synthesis by 
phosphorylating the  subunit of the eukaryotic translation initiation factor 2 
(eIF2) in response to specific stress stimuli. This post translational 
modification blocks the formation of ternary complex, a critical component for 
the translation initiation. This results in a block in translation initiation from 
most cellular mRNAs. However, some specific mRNAs containing internal 
ribosomal entry sites (IRES) or upstream open reading frames (uORFs) such 
as ATF4 are preferentially translated under these conditions. These mRNAs 
code for proteins that will either ameliorate the stress or induce apoptosis 
depending on the level and duration of stress. The ISR is downregulated 
through the phosphatase activity of PP1. PP1’s enzymatic activity on eIF2α is 
dependent on one of two regulatory subunits, CreP or GADD34. The PP1-
CreP holophosphatase is critical for maintaining low basal levels of eIF2α 
phosphorylation in the absence of stress, while the PP1C GADD34 
holophosphatase is mainly responsible for downregulating the ISR[2]. 
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Figure 1.2 Schematic Representation of Domain Structures of PKR, TRBP, and PACT: PKR, 
TRBP, and PACT are members of a family of dsRNA binding proteins that regulate cell survival or 
death under conditions of cellular stress. All three proteins share the evolutionarily conserved amino 
terminal motifs, dsRBM1 and dsRBM2. These amino terminal motifs serve as functional domains 
mediating dsRNA binding and protein-protein interactions. Additionally, PKR contains a c-terminal 
catalytic domain containing a PACT-binding motif (PBM) and two critical threonine residues that serve 
as phosphorylation sites required to activate PKR. In the absence of stress, TRBP interacts with PACT 
and PKR via the shared amino terminal dsRBMs and keeps its kinase activity latent. Similar to TRBP, 
PACT also contains three copies of the dsRBMs. Under conditions of cellular stress, PACT dissociates 
from TRBP and undergoes homodimerization, which is required to bind PKR with higher affinity. PACT 
then activates PKR via the low-affinity interactions between the PBM in PKR’s KD and PACT’s 
dsRBM3. Finally, PACT’s dsRBM3 contains two serine residues (S246 and S287) that serve as 
phosphorylation sites to cause a shift in the relative abundance of PACT-TRBP, PACT-PACT, and 
PACT-PKR interactions towards PKR activation. 
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 Figure 1.3 Schematic Representation of PKR Regulatory Mechanisms: Under homeostatic conditions, 
PKR’s kinase activity remains latent due to the inhibitory effect of TRBP heterodimerization with PKR and 
PACT independently. In the absence of stress, PACT is constitutively phosphorylated on S246 which 
promotes the PACT-TRBP heterodimers. In response to viral stress, dsRNA outcompetes TRBP for PKR’s 
amino terminal dsRBMs resulting in the activation of the kinase. Under conditions of ER stress, oxidative 
stress, or serum starvation, PACT gets phosphorylated on S287 resulting in the dissociation of the 
inhibitory PACT-TRBP heterodimers and simultaneously promoting PACT-PACT homodimers. PKR then 
binds the stress-induced PACT homodimers to facilitate catalytic activation. While PACT-PKR 
heterodimers are facilitated through the amino terminal motifs of each protein, PACT’s c-terminal dsRBM3 
is for activating PKR. Once activated, PKR then phosphorylates eIF2 on S51 resulting in the attenuation 
of cap-dependent general protein synthesis. If the stress stimulus persists or is too severe, the cell 
undergoes apoptosis. In response to weak or transient stress, however, the cell is able to initiate a 
successful ISR, reestablish homeostasis and survive.  
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Figure 1.4 Schematic Representation of DYT16 mutations in PACT 
(A) Human genetic screenings have implicated mutations in the PRKRA 
gene which codes for the protein PACT to be the driving cause of early 
onset dystonia DYT16. The recessively inherited mutations are indicated 
in green, and dominantly inherited mutations indicated in red. (B) 
Schematic representation of the spontaneously arisen mutation in the 
mouse homolog of PACT. This recessively inherited mutation truncates 
the protein within PACT’s dsRBM2.  
 
1Burnett SB, Vaughn LS, Strom JM, Francois A, Patel RC. 2018 Journal of 
Cellular Biochemistry 120(11):19004-19018  
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CHAPTER 2: 
A TRUNCATED PACT PROTEIN RESULTING FROM A FRAMESHIFT 
MUTATION REPORTED IN MOVEMENT DISORDER DYT16 TRIGGERS 
CASPASE ACTIVATION AND APOPTOSIS1. 
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2.1 ABSTRACT 
 PACT activates the interferon (IFN)-induced double-stranded (ds) RNA-
activated protein kinase (PKR) in response to stress signals. Oxidative stress 
and endoplasmic reticulum (ER) stress causes PACT mediated PKR activation, 
which leads to phosphorylation of translation initiation factor eIF2, inhibition of 
protein synthesis, and apoptosis. A dominantly inherited form of early-onset 
dystonia 16 (DYT16) has been identified to arise due to a frameshift (FS) 
mutation in PACT. In order to examine the effect of the resulting truncated 
mutant PACT protein on PKR pathway we examined the biochemical properties 
of the mutant protein and its effect on mammalian cells. Our results indicate that 
the FS mutant protein loses its ability to bind dsRNA as well as its ability to 
interact with PKR while surprisingly retaining the ability to interact with PACT and 
PKR-inhibitory protein TRBP. The truncated FS mutant protein, when expressed 
as a fusion protein with a N-terminal fluorescent mCherry tag aggregates in 
mammalian cells to induce apoptosis via activation of caspases both in a PKR- 
and PACT-dependent as well as independent manner. Our results indicate that 
interaction of FS mutant protein with PKR inhibitor TRBP can dissociate PACT 
from the TRBP-PACT complex resulting in PKR activation and consequent 
apoptosis. These findings are relevant to diseases resulting from protein 
aggregation especially since PKR activation is a characteristic of several 
neurodegenerative conditions. 
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2.2 INTRODUCTION 
PKR (protein kinase, RNA activated) is activated by binding to its Protein 
Activator PACT in human cells85 and its murine homolog in mouse cells34. PACT 
induces autophosphorylation and activation of the interferon (IFN)-inducible, 
serine/threonine protein kinase PKR in response to cellular stress34,35,86,87. 
Activation of PKR causes phosphorylation of the α subunit of the eukaryotic 
protein synthesis initiation factor 2 (eIF2α) leading to an inhibition of protein 
synthesis88.  
PKR is expressed in all cell types at low basal levels in the absence of virus 
infection, mediates IFN’s antiviral actions in virally infected cells and also 
regulates cellular survival and apoptosis in response to stress in uninfected 
cells89. Activation of PKR's kinase activity requires binding to one of its activators 
to bring about a conformational change causing enzymatic activation90. PKR’s 
two dsRNA-binding motifs (dsRBMs) bind to the dsRNA produced during viral 
replication26,91 and activate PKR by unmasking the ATP-binding site92. These 
dsRBMs also mediate dsRNA-independent protein-protein interactions with other 
proteins that also carry dsRBMs93. Among such proteins, PACT functions to 
activate PKR in a dsRNA-independent manner in response to cellular stress35,85. 
There are three copies of dsRBM in PACT (Fig. 2.1 A), of these the two amino-
terminal motifs (M1 and M2) are involved in a direct interaction with the dsRBMs 
of PKR. The third, carboxy-terminal motif 3 (M3) is dispensable for a high-affinity 
interaction with PKR but is essential for PKR activation as it contacts a specific 
region in PKR's catalytic domain94,95. PACT-dependent PKR activation in cells 
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occurs only in response to oxidative stress signals, growth factor withdrawal, 
endoplasmic reticulum (ER) stress, to cause phosphorylation of the translation 
initiation factor eIF2 and cellular apoptosis34,86,87,96 although the purified, 
recombinant PACT activates PKR by direct interaction in vitro85. Once the stress 
conditions have resolved, PACT mediated PKR activation is possibly 
downregulated by the action of phosphatases that may dephosphorylate PACT. 
Although the identity of such phosphatases remains unknown, our recent work 
illustrates that a PKR inhibitory protein TRBP that complexes with PACT in the 
absence of stress signals is phosphorylated later during the stress response and 
is involved in the negative regulation of PKR activity at late time points after initial 
stress signal39,48,97.  
PACT is encoded by the Prkra gene and recently many mutations in this gene 
have been described to cause a movement disorder dystonia 16 (DYT16). Many 
different dystonia types exist, which result from several diverse genetic and 
physiological causes, thereby constituting a heterogeneous group of movement 
disorders in which affected individuals develop sustained and painful involuntary 
muscle contractions leading to twisted postures98. Recently a recessively 
inherited form of early-onset generalized dystonia (DYT16) has been described 
to arise from a homozygous missense mutation at amino acid position 222 in 
PACT62. Seven affected members from two unrelated families were originally 
identified to carry the same P222L mutation62, which lies between the conserved 
motifs M2 and M3 within PACT. The same mutation was later reported in many 
more patients with DYT1699. Subsequently, four more recessive mutations 
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(C77S, C213F, C213R, and S265R) have been identified in DYT16 
patients64,66,100. Among the dominant mutations, a frameshift mutation which 
results in truncation of the protein after 88 amino acids63 and three point 
mutations reported in Polish and German families (T34S, N102S, and c.-14A>G) 
indicate that PACT mutations lead to DYT16 in a worldwide distribution65.  
In spite of the identification of several PACT mutations, the molecular 
mechanisms involved in the DYT16 onset or progression have not been studied 
much60. We have previously analyzed the effect of the P222L mutation on 
PACT’s biochemical properties such as dsRNA binding, PKR interaction, and 
PKR activation69. The P222L mutation did not affect PACT’s dsRNA-binding, or 
PKR-interaction properties in vitro. However, in DYT16 patient cells the P222L 
mutant protein caused a delayed but prolonged activation of PKR in response to 
ER stress. The altered kinetics of eIF2 phosphorylation brought about by the 
changes in PKR activation led to defective downstream signaling and a lack of 
cell recovery and homeostasis. Thus, the DYT16 patient cells underwent 
enhanced apoptosis in response to the ER stressor tunicamycin in accordance 
with the altered biochemical properties of P222L protein.  
In this report, we analyzed the effect of a dominant acting frameshift mutation 
in PACT described in a single early onset dystonia case63. This frameshift 
mutation due to deletion of two nucleotides would produce a truncated PACT 
protein with 1-88 amino acids of the PACT followed by 21 new amino acids as a 
result of the frameshift. Our results indicate that when expressed transiently in 
mammalian cells, a fusion protein with N-terminal mCherry tag on the mutant 
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frameshift protein (mCherry-FS) forms aggregates to trigger apoptosis. 
Furthermore, the PKR+/+ as well as PACT+/+ MEFs show increased caspase 
activation in response to a transient overexpression of mCherry-FS protein and 
the caspase activation is reduced, but not absent, in PKR-/- and PACT-/- MEFs 
indicating that apoptosis caused by the FS mutant protein aggregation may result 
from both PKR-dependent and PKR-independent mechanisms.  
2.3 MATERIALS AND METHODS 
Reagent, Cell Lines, and Antibodies: HeLa (ATCC CCL-2) cells, PKR+/+, 
PKR-/- 101, PACT+/+, and PACT-/- mouse embryonic fibroblasts (MEFs) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM), containing 10%102 fetal 
bovine serum and penicillin/streptomycin. The anti-mCherry antibodies used 
were from Abcam (ab183628). Transfections were performed with Effectene 
Transfection Reagent (Qiagen) according to the manufacturer’s protocol. 
Generation of 2 nucleotide deletion frameshift mutation: The deletion 
mutation was generated using mutagenic primers for PCR amplification of PACT 
ORF in two parts to introduce a two-nucleotide deletion as reported in DYT16 
patient. The primer sequences were as follows: 
PACT-UP1: 5’-GCTCTAGACATATGGAAATGTCCCAGAGCAGGCAC-3’,  
DYT16-frameshift-DN1: 5’-GGCAGCCTCTGCAGCTCTGTTTCGCCAGC-3’ 
DYT16-frameshift-UP1: 5’-GCTGGCGAAACAGAGCTGCAGAGGCTGCC-3’ 
PACT313M3-AS: 5’-GGGGATCCTTACTTTCTTTCTGCTATTATC-3’ 
The two PCR products were sub-cloned into pgEMT-easy vector (Promega). 
Once the sequence of the frameshift mutation was verified, we generated full-
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length FS ORF in pcDNA3.1- by a three-piece ligation of XbaI–Pst1 restriction 
piece from the 5’ half of FS point mutant/pgEMT-easy, PstI-BamHI piece from 3’ 
half of FS point mutant/pgEMT-easy, and XbaI-BamH1 cut pcDNA3.1-. The full-
length FS mutant ORF in pcDNA3.1- has an amino-terminal flag tag that is added 
from the vector sequence. Full length FS mutant was sub-cloned into pET15b 
(Novagen) for producing hexahistidine tagged pure recombinant protein and into 
pmCherryC1 (Clontech) for expression in mammalian cells. The 
PACT/pmCherryC1 and PACT/pEGFPC1 constructs were generated by sub-
cloning the PACT ORF from PACT/pcDNA3.1- and the PKR/pEGFPC1 construct 
was generated by sub-cloning the PKR ORF with the kinase dead K296R 
mutation from K296R/pCDNA3.1-.. It is well established that the wt PKR 
overexpression in cells is not feasible as it induces apoptosis very rapidly and 
thus for all experiments using full length PKR in fluorescence microscopy and co-
localization experiments, we used the catalytically dead PKR mutant K296R 
expression construct. 
dsRNA-binding assay: The dsRNA-binding assay was performed with the in 
vitro translated, 35S-labeled PACT and FS proteins synthesized using the 
expression constructs in pcDNA3.1- and TNT-T7 coupled reticulocyte lysate 
system from Promega as described before 97.  
Protein–protein interaction assay: In vitro translated, 35S-labeled PKR, 
PACT, FS or TRBP proteins were synthesized using the TNT T7 coupled 
reticulocyte system from Promega as explained before. 5 µl of the in vitro 
translated 35S-labeled proteins were incubated with either 100 ng of pure 
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recombinant hexahistidine tagged PKR, PACT or FS mutant as indicated in the 
individual figures and 20 µl of Ni-agarose (Novagen) in 200 µl of binding buffer [5 
mM imidazole, 20 mM Tris–HCl pH 7.9, 200 mM NaCl, 0.2 mM 
phenylmethylsulfonyl fluoride (PMSF), 0.5% IGEPAL (Sigma)] at 250C for 30 min 
on a rotating wheel. The beads were washed four times in 500 µl of binding 
buffer each time and the washed beads were then boiled in 20 µl Laemmli buffer 
(150 mM Tris–HCl pH 6.8, 5% SDS, 5% -mercaptoethanol, 20% glycerol) for 2 
min and eluted proteins were analyzed by SDS–PAGE on a 12% gel. 
Fluorography was performed at 800C with intensifying screens. To assay if the 
FS mutant protein can dissociate TRBP-PACT complex, 5 µl of the in vitro 
translated 35S-labeled TRBP protein was incubated with 100 ng of pure 
recombinant hexahistidine tagged PACT and anti-PACT rabbit monoclonal 
antibody bound to 10 l of protein A sepharose beads in 200 µl of binding buffer 
[20 mM Tris–HCl pH 7.9, 200 mM NaCl, 0.2 mM phenylmethylsulfonyl fluoride 
(PMSF), 0.5% IGEPAL (Sigma)] at 250C for 30 min on a rotating wheel. 
Increasing amounts of pure recombinant FS protein was then added as indicated 
in Fig. 2.6B and the incubation was continued for 30 min longer. The beads were 
then washed four times in 500 µl of binding buffer each time and the washed 
beads were then boiled in 20 µl Laemmli buffer (150 mM Tris–HCl pH 6.8, 5% 
SDS, 5% -mercaptoethanol, 20% glycerol) for 2 min and eluted proteins were 
analyzed by SDS–PAGE on a 12% gel. The assays were quantified on Typhoon 
FLA7000 by analyzing the band intensities in the relevant lanes. 
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Caspase 3/7 assay: PKR+/+, PKR-/- 101, PACT+/+ and PACT-/-102 mouse 
embryonic fibroblasts (MEFs) were plated at in 6 well dishes and transfected with 
flag-FS mutant/pCDNA3.1- or empty vector pCDNA3.1-. Cells were collected at 
indicated time points and mixed with equal parts of Promega Caspase-Glo 3/7 
reagent and incubated for 45 min. Luciferase activity was measured with a 
negative control of cell culture medium alone used to normalize all readings. 
Western Blot analysis: HeLa cells were transfected in triplicates in 6 well 
dishes with 500ng DNA per well of pmCherryC1 empty vector, FS 
mutant/pmCherryC1, and PACT/pmCherryC1. Transfected cells were collected 
12 h after transfection and washed twice with ice cold 1× PBS. Harvested cells 
were lysed in western lysis buffer (2% Triton X-100, 20 mM Tris–HCl pH 7.5, 100 
mM KCl, 200 mM NaCl, 4 mM MgCl2, 40% glycerol, and phosphatase inhibitor 
cocktail 2 (Sigma) at 1:100 dilution) for 5 min on ice. Lysates were centrifuged at 
13,200 rpm for 2 min. Protein concentration in the supernatant was quantified 
using Bradford reagent. Western blot was performed with the anti-mCherry 
antibody and western blot images were analyzed using the Typhoon FLA 7000 
and ImageQuant LAS 4000 (GE Health). 
Expression and purification of recombinant PKR, wt PACT and FS 
mutant: The protein coding regions (PKR, wt PACT or FS mutant) were sub-
cloned into pET15b (Novagen) to generate PKR/pET15b, PACT/pET15b, and FS 
mutant/pET15b resulting in the in-frame fusion of the ORFs to the histidine tag. 
The recombinant proteins were expressed and purified as described85,103. 
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Visualization of aggregated FS mutant protein: HeLa cells were grown on 
coverslips and transfected with 500 ng of either PACT/pmCherryC1, FS 
mutant/pmCherryC1 empty vector pmCherryC1 using Effectene (Qiagen). 12 h 
after transfection, the cells were rinsed with ice-cold phosphate buffered saline 
(PBS) and fixed in 2% paraformaldehyde for 10 min. The cover slips were 
mounted in Vectashield mounting medium containing DAPI (Vector 
Laboratories). Cells were then viewed under the inverted fluorescence 
microscope (EVOS® FL Imaging System). 
Yeast Two-Hybrid Interaction Assay: To test TRBP-PACT and TRBP-FS 
interactions, PACT and FS were expressed as GAL4-activation domain fusion 
proteins from the pgADT7 vector and TRBP was expressed as GAL4 DNA-
binding domain fusion proteins from the pgBKT7 vector. We also tested these 
interactions with TRBP expressed as GAL4-activation domain fusion protein from 
the pgADT7 vector with PACT and FS proteins expressed as GAL4 DNA-binding 
domain fusion proteins from the pgBKT7 vector. The appropriate combinations of 
expression constructs were co-transformed into AH109 yeast cells (Clontech) 
and the transformed yeast cells were plated on double dropout SD minimal 
medium lacking tryptophan and leucine. In order to check for the transformants’ 
ability to grow on quadruple dropout media, transformed yeast cells were grown 
to an OD600 of 2 in YPD media (yeast extract, peptone, and dextrose). 500 µl of 
each culture was pelleted and resuspended in an appropriate amount of distilled 
water to yield an OD600 of 10. Serial dilutions were then made to yield OD600 
values of 1, 0.1, and 0.01. 10 µl of each dilution was then spotted onto quadruple 
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dropout SD minimal media lacking histidine, tryptophan, leucine, and adenine in 
the presence of 10 mM 3-amino-1,2,4-triazole (3-AT). Plates were incubated at 
30°C for 3 days to score the growth. 
Quantifications and Statistics: All binding assays and pull-down assays 
(Typhoon FLA7000) were quantified using GE Life Sciences ImageQuant TL 
software. To determine statistical significance of results of the dsRNA-binding, 
protein interaction and caspase assays a two-tailed Student’s T-test was 
performed, assuming equal variance. Each figure legend indicates p values as 
denoted by brackets and special characters. Note that our alpha level was 
p=0.05.  
2.4 RESULTS 
The FS mutation destroys PACT’s dsRNA binding as well as PKR 
interaction activity: The early onset dominant mutation causing DYT16 in one 
German patient is a deletion of two nucleotides (AT) in codon 89 (Fig. 2.1 B) of 
the PACT open reading frame (ORF). This results in a frameshift that would 
produce a 109 amino acid long truncated protein with 1-88 amino acids of 
original PACT protein followed by 21 extraneous amino acids due to the 
frameshift (Fig. 2.1 A and B). The resulting truncated (mutant FS) protein does 
not have a complete copy of the evolutionarily conserved dsRNA-binding motif 
(dsRBM1) and thus is missing the crucial part of the motif that is essential for 
binding dsRNA as well as protein-protein interactions52,97. Therefore, the FS 
mutant protein is expected to be devoid of dsRNA-binding ability, as well as 
interaction with PKR and PACT. In order to determine if the frameshift mutation 
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affects dsRNA binding activity, an in vitro dsRNA-binding assay previously well 
established for PKR and PACT85 was performed (Fig. 2.2 A and B). As seen in 
Figure 2 A, the wt PACT protein binds to dsRNA (lane 2) but the frameshift 
mutant protein shows no binding to dsRNA (lane 4). The binding of wt PACT to 
dsRNA immobilized on the beads could be competed out by exogenously added 
dsRNA (lane 6) but not ssRNA (lane 5) confirming specific binding to dsRNA. 
Firefly luciferase, a protein that does not bind dsRNA used as a negative control 
showed no binding to the beads further demonstrating the binding specificity. The 
quantification of percentage binding established that FS mutant protein has no 
dsRNA-binding activity as compared to wt PACT (Fig. 2.2 B). We next examined 
if the FS mutant protein can interact with PKR and PACT using protein-protein 
interaction pull down assay (Fig. 2.3 A-F). 35S-methionine labeled PKR, and 
PACT were in vitro translated using rabbit reticulocyte system and mixed with 
pure recombinant hexahistidine tagged PKR, PACT, or FS mutant proteins 
bound to Ni-charged sepharose beads to measure the pull down of 35S-labeled 
proteins. As seen in Fig. 2.3 A and B, PKR interacts efficiently with PACT (lane 
3) and PKR (lane 4) but not with FS mutant protein (lane 5). No 35S-labeled PKR 
was pulled down by Ni-agarose beads in the absence of any hexahistidine 
tagged protein (lane 2) indicating absence of any non-specific binding of PKR to 
the Ni-agarose beads and presence of a specific interaction with PACT and PKR. 
These results indicate that the mutant FS protein does not interact with PKR in 
vitro under the conditions of this assay. As seen in Fig. 2.3 C and D, PACT 
interacts efficiently with PACT (lane 3), PKR (lane 4) and surprisingly also with 
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mutant FS protein (lane 5). No 35S-labeled PACT was pulled down by Ni-agarose 
beads in the absence of any hexahistidine tagged protein (lane 2) indicating 
absence of any non-specific binding of PACT to the Ni-agarose beads and 
presence of a specific interaction with PACT, PKR, and FS mutant. We further 
tested the interaction of 35S-labeled, in vitro translated PKR, PACT and FS 
proteins with pure recombinant FS protein bound to Ni-charged sepharose beads 
to measure the pull down of 35S-labeled PKR, PACT and FS proteins. As seen in 
Fig. 2.3 E and F, in vitro translated PKR showed no interaction with the 
recombinant FS protein (lane 4), whereas in vitro translated PACT (lane 5) and 
FS (lane 6) proteins showed a strong interaction with recombinant FS protein 
bound to the Ni-agarose beads. There was no non-specific binding of PKR, 
PACT, or FS proteins to the Ni-agarose beads in the absence of FS protein 
bound to the beads (lanes 7-9) indicating specific interaction between PACT-FS 
and FS- FS under the conditions of this assay. 
FS mutant protein forms aggregates in mammalian cells: In order to test 
the effect of FS mutant protein expression on mammalian cells, we transfected 
HeLa cells with mCherry-PACT and mCherry-FS expression constructs. 
Observing the transfected cells under a fluorescence microscope 12 h after 
transfection indicated that mCherry-PACT protein shows primarily cytoplasmic 
localization without aggregates (Fig. 2.4 A, panel a), whereas the mCherry-FS 
mutant protein forms cytoplasmic aggregates (Fig. 2.4 A, panel b). The mCherry 
protein itself shows localization both to cytoplasm and nucleus (Fig. 2.4 A, panel 
c). The mCherry tag is known to be monomeric and any aggregation of mCherry-
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FS fusion protein observed in mammalian cells would thus be driven by the FS 
portion of the fusion protein and not by the mCherry tag. We also analyzed the 
expression of mCherry fusion proteins by a western blot analysis with anti-
mCherry antibody 12 h after transfection. As seen in Fig. 2.4B, the expression of 
mCherry fusion proteins can be detected on the western blot. The presence of 
higher molecular weight bands in mCherry-FS lane indicated that the aggregates 
formed by the mCherry-FS protein persist even in the presence of SDS and 
during gel electrophoresis (Fig 4 B, lane 2). Such aggregates could be formed by 
the mCherry-FS protein molecules alone or with endogenous PACT protein and 
at present we do not know the exact composition of these protein aggregates. At 
longer time points after transfection, the cells overexpressing mCherry-FS mutant 
protein showed cell death around 24-36h. Despite multiple efforts, it was not 
feasible to establish a stable expression of mCherry-FS to achieve 100% cells in 
transfected population expressing the mutant mCherry-FS. We also attempted to 
express the FS mutant protein using a smaller tag such as the 8-amino acid long 
flag tag. Expression of the flag tagged FS mutant protein was not detectable by 
either immunofluorescence or western blot in the transient transfection system, 
which may be due to more efficient and quicker induction of cell death or due to 
nonsense-mediated decay (NMD) of the mRNA104. Addition of the mCherry tag 
on the amino terminus makes the fusion protein size larger and this may allow 
the mRNA to escape NMD, making detection of the mCherry-FS mutant protein 
possible. In order to detect any change in PKR and eIF2 phosphorylation in 
response to FS mutant protein expression, we performed western blot analysis at 
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shorter time points after transfection. As seen in Fig. 2.5 A, we detected a time-
dependent small increase in eIF2 phosphorylation (lanes 2-4) in cells 
expressing mCherry-FS protein starting at 1-8 h (lanes 2-5) and the cells 
transfected with empty vector mCherry did not show a similar increase (lanes 7-
10). PKR phosphorylation also was detected in mCherry-FS transfected cells 
(lanes 2-5) but not in cells transfected with empty vector mCherry (lanes 7-10). 
These results suggest that expression of mCherry-FS protein causes PKR 
activation leading to eIF2 phosphorylation indicating that PKR activation could 
be the reason for cell death observed at later time points in response to mCherry-
FS expression.  
Transient overexpression of FS mutant protein activates caspase 3/7: 
Activation of PKR in mammalian cells causes apoptosis via activation of 
caspases 105. Thus, we tested if transient overexpression of mCherry-FS mutant 
protein results in activation of caspases. Overexpression of mCherry-FS mutant 
in mouse embryonic fibroblasts from PKR+/+ and PKR-/- mice resulted in 
significant induction of caspase activity and apoptosis of transfected cells. As 
seen in Figure 5 B, there is a significant increase in caspase 3/7 activity in 
PKR+/+ MEFs transfected with mCherry-FS mutant expression construct at 24 
and 30 h (red bars) as compared to the cells transfected with empty vector (blue 
bars). Compared to the PKR +/+ MEFs, the PKR -/- MEFs showed significantly 
less increase in caspase 3/7 activity at equivalent time points after the 
transfection. However, the PKR-/- cells overexpressing mCherry-FS mutant also 
underwent apoptosis similar to PKR +/+ cells, but with a slower kinetics. We also 
 
41 
tested if PACT was essential for caspase activation in response to FS mutant 
protein expression. Overexpression of mCherry-FS mutant in mouse embryonic 
fibroblasts from PACT+/+ and PACT-/- mice resulted in significant induction of 
caspase activity. As seen in Figure 5 C, similar to PKR+/+ MEFs, there is a 
significant increase in caspase 3/7 activity in PACT+/+ MEFs transfected with 
mCherry-FS mutant expression construct at 24 and 30h (red bars) as compared 
to the cells transfected with empty vector (blue bars). Compared to the PACT +/+ 
MEFs, the PACT -/- MEFs show significantly less increase in caspase 3/7 activity 
at equivalent time points after the transfection. These results suggest that the FS 
mutant protein aggregates depend on PACT and PKR only in part to induce 
caspase activation and apoptosis. 
In order to understand how the mutant FS mutant protein could bring about 
PKR activation in mammalian cells when it shows no interaction with PKR, we 
explored the possibility that FS mutant protein may promote PACT-PKR 
interaction by interacting with TRBP. Our previous work has suggested that in 
unstressed cells, PACT is complexed with TRBP, a PKR inhibitory protein69,106. 
TRBP inhibits PKR by directly interacting with PKR as well as by sequestering 
dsRNA and PACT107. In unstressed cells PACT-TRBP heterodimers prevail and 
PKR remains inactive. In response to stress signals, once PACT is 
phosphorylated, it dissociates from TRBP to form PACT-PACT homodimers 
which bind to PKR at higher affinity and activate PKR catalytically103. Thus, we 
investigated the possibility that mutant FS protein could interact with TRBP to 
prevent its association with PACT and thereby releasing PACT to activate PKR. 
 
42 
In order to investigate this, we first tested if FS mutant protein interacts with 
TRBP using protein-protein interaction pull down assay (Fig. 2.6 A). 35S-
methionine labeled TRBP was in vitro translated using rabbit reticulocyte system 
and mixed with pure recombinant hexahistidine tagged PKR, PACT, or FS 
mutant proteins bound to Ni-charged sepharose beads to measure the pull down 
of 35S-labeled TRBP. As seen in Fig. 2.6 A and B, TRBP interacts efficiently with 
PKR (lane 3), PACT (lane 4) as well as with FS mutant protein (lane 5). No 35S-
labeled TRBP was pulled down by Ni-agarose beads in the absence of any 
hexahistidine tagged protein (lane 2) indicating absence of any non-specific 
binding of TRBP to the Ni-agarose beads and presence of a specific interaction 
with PKR, PACT and FS. These results indicate that TRBP interacts with FS 
mutant protein similar to its interaction with PKR and PACT in vitro under the 
conditions of this assay. We reasoned that if FS mutant protein can displace 
PACT from PACT-TRBP complex, it may be able to activate PKR in cells by 
releasing PACT from TRBP. In order to test this, we explored if FS mutant 
protein can dissociate PACT-TRBP interaction. 35S-methionine labeled TRBP 
was in vitro translated using rabbit reticulocyte system and mixed with pure 
recombinant hexahistidine tagged PACT protein bound to anti-PACT monoclonal 
antibody attached to protein A-sepharose beads in the absence of any FS mutant 
protein. Increasing amounts of pure recombinant FS mutant protein was then 
added (lanes 4-7) to measure the pull down of 35S-labeled TRBP with PACT 
bound to beads. As seen in Fig. 2.6 C and D, the amount of TRBP pulled down 
with PACT was inversely correlated to the amount of FS mutant protein added 
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(lanes 4-7 compared to lane 3). In order to compare the relative strengths of 
TRBP-PACT and TRBP-FS interactions, we used the yeast two hybrid protein-
protein interaction assay. As seen in Fig. 2.6 E, TRBP-FS interaction was 
stronger than the TRBP-PACT interaction (compare TRBP-PACT panel with 
TRBP-FS panel in the TRBP/pgBKT7 set). When TRBP was expressed as the 
GAL4-activation domain fusion protein, similar results were seen (compare 
PACT-TRBP panel with FS-TRBP panel in the TRBP/pgADT7 set). These results 
indicate that FS mutant protein can bind to TRBP to release PACT, which than 
could bring about PKR activation leading to caspase activation and apoptosis. 
The FS protein also may bind to PACT to prevent PACT-TRBP association and 
the FS-PACT heteromeric interactions could bring about PKR activation. Figure 7 
depicts these possibilities in a schematic model 
2.5 DISCUSSION 
PKR activation in response to cellular stress is regulated by PACT and is 
involved in modulating cellular survival34,35,69,86,87. Although many mutations in 
PACT have now been identified in a worldwide occurrence of DYT16 cases, the 
pathomechanisms involved in DYT16 remain poorly understood. Our previous 
work on the most prevalent P222L mutation in DYT16 has revealed that this 
mutation leads to a dysregulation of eIF2 phosphorylation in response to 
cellular stress69. Cells homozygous for P222L mutation exhibited enhanced 
sensitivity to ER stressor tunicamycin due to a delayed but more robust eIF2 
phosphorylation. In this study, we aimed to examine the effect of a dominant 
PACT mutation reported in a single DYT16 patient. We started by characterizing 
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the biochemical properties of the FS mutant protein in vitro. The FS mutant 
protein exhibited no dsRNA-binding ability as it is truncated at residue 88 and 
lacks the carboxy-terminal part of M1, the first conserved motif, and also the 
amino acid residues critical for interaction with dsRNA85,91,97. We have previously 
characterized the contribution of individual amino acids in this motif to dsRNA-
binding and protein-protein interaction and the results obtained with FS mutant 
are in accordance with our previous work97. The mutant FS protein also showed 
no interaction with PKR, although it showed interaction with PACT. Based on our 
previous work on PACT-PKR and PACT-PACT interactions, it is expected that 
FS mutant protein may not interact with PKR or PACT as it lacks the alanine 
residues at positions 91 and 9252,97. Thus, it was surprising that the FS mutant 
protein interacted with PACT in vitro and the FS protein aggregates showed co-
localization of PKR and PACT in HeLa cells. It is worth noting here is that the 
pure recombinant hexahistidine tagged FS protein showed aggregate forms on 
an SDS-PAGE gel indicating that it forms aggregates and such aggregated forms 
are present in the FS mutant we used to bind to Ni-agarose beads in our pull-
down assays. This aggregation may possibly contribute to interaction with PACT 
in this assay and similarly also in mammalian cells. 
In order to study how FS protein affects the PACT-PKR pathway during 
cellular stress, we wanted to investigate the effect of FS mutant protein 
expression in mammalian cells. As the mutation is reported to be dominant, we 
wanted to establish a cell line with a stable expression of the mutant protein in 
order to analyze its effects on the PKR pathway. Despite multiple attempts with 
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several different smaller epitope tags (Flag, Myc, HA) on the FS mutant protein, 
we were unable to detect its expression at early or late time points post-
transfection using western blot analyses. Thus, we reasoned that an 
overexpression of the FS mutant protein may be toxic to cells or the mRNA may 
be undergoing NMD104. We next studied its expression by tagging the FS protein 
with a mCherry tag as the expression could be detected in live cells using 
fluorescence microscopy. We could detect mCherry-FS protein expression as 
early as 6 h after transfection and the cells expressing mCherry-FS protein 
showed increasing cell death at later time points. Most strikingly, the mCherry-FS 
protein showed aggregate formation in cells. The high molecular weight forms of 
aggregated FS protein observed by us on SDS-PAGE are similar to aggregate 
forms of other proteins such as mutant Cu/Zn superoxide dismutase that are 
aggregate prone and cause ALS108. The misfolded  -synuclein involved in the 
pathogenesis of Lewy body diseases isolated from the brains of dementia 
patients also shows similar aggregates that are not disaggregated in presence of 
SDS109. Since PKR shows no interaction with FS mutant protein but FS mutant 
protein can interact strongly with TRBP to dissociate PACT from the PACT-TRBP 
heterodimers, we propose that PKR is activated by PACT released from TRBP 
when FS mutant protein is present. A schematic model depicting this is 
presented in Fig. 2.7, which outlines PKR- and PACT-dependent processes 
leading to apoptosis. In the absence of FS mutant protein when PACT mediated 
PKR activation takes place in response to stress (Fig. 2.7 A), PACT is 
phosphorylated and forms homodimers efficiently after its dissociation from 
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TRBP. When overexpressed, the FS mutant protein can cause dissociation of 
PACT and the "free" PACT released from TRBP-PACT heterodimers could bring 
about PKR activation (Fig. 2.7 B). Any possible phosphorylation of PACT due to 
overexpression of FS mutant protein remains to be explored in future. Under 
such conditions, PKR activation leads to caspase activation and apoptosis as we 
observed in cells overexpressing mCherry-FS protein. Our results demonstrated 
that FS mutant protein expression led to caspase activation in murine fibroblasts 
which was partly dependent on the presence of PACT and PKR. However, the 
FS protein aggregates also induced caspase activation in a PKR and PACT 
independent manner as both PKR as well as PACT null cells showed a slower 
kinetics of caspase induction. These results are indicative that FS mutant protein 
aggregates induce apoptosis in both a PACT-PKR-dependent and PACT-PKR-
independent manner.  
Activation of PKR by protein aggregates observed with the FS mutant could 
be indicative of a more general process rather than a specific process driven by 
the FS mutation. In this regard, it could be worth investigating if known 
aggregation prone proteins involved in neurodegenerative diseases trigger PACT 
dependent PKR activation. A significant amount of evidence exists to indicate a 
possible connection between PACT and PKR recruitment to such aggregates. A 
number of studies have implicated PKR in the pathogenesis of 
neurodegenerative diseases, such as Alzheimer’s disease (AD)110, Parkinson's 
disease (PD)75,111, Huntington's disease (HD)75, and amyotrophic lateral sclerosis 
(ALS)112. Of these, PKR activation has been most investigated in Alzheimer’s 
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disease. The earliest reports of PKR activation in AD demonstrated an 
accumulation of activated (phosphorylated) PKR in degenerating neurons113 
mainly using histological methods. A direct implication of PKR activation in the 
pathology of the disease is indicated based on the recent evidence and inhibition 
of PKR prevents the neuronal apoptosis in AD mouse models as well as in 
neuronal cultures114,115. Activated PKR aggregates are reported in hippocampal 
neurons in PD and HD patient brains75. More relevantly, there is evidence for 
PACT being present in potential aggregates in addition to presence of activated 
PKR in the degenerating neurons. Immunohistochemical studies with the 
hippocampal neurons showed a co-localization of PACT with phosphorylated 
PKR in the post-mortem brains of AD patients116. A mass spectrometry analysis 
showed an increased association of PACT with the aggregation prone mutant 
HTT protein in the affinity-purified complexes from huntingtin mutant (HTT) 
juvenile mouse brain117. Elevated PKR expression or activation is also observed 
in ALS although co-localization of PACT and PKR has not been investigated so 
far for ALS112. There is no clear evidence for neurodegeneration in monogenic 
inherited forms dystonia. Although neurodegeneration has been investigated and 
found to be absent in DYT6118, evidence of neurodegeneration has been 
reported in X-linked dystonia-parkinsonism119 and in DYT1664. 
It also remains an open question if dysregulation of eIF2 pathway observed 
in a few primary dystonias is the primary cause of the pathology or a secondary 
effect related to activation of stress signaling pathways. Our research identified 
the dysregulation of PKR-eIF2 signaling pathway as a consequence of P222L 
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mutation in DYT1669. Subsequently DYT1, DYT6 as well as the sporadic cervical 
dystonia also were reported to show an impairment of the eIF2 signaling 
pathway74,120-122. Although we could not analyze eIF2 dysregulation with 
expression of FS mutant protein in the transient expression system, it is worth a 
mention that a spontaneously arisen, recessive insertion mutation in Prkra 
identified at the Jackson Laboratory results in a progressive dystonia123, kinked 
tails, and mortality in mice. Some neurons in the dorsal root ganglia and the 
trigeminal ganglion were apoptotic in the homozygous mutant mice, consistent 
with the observed neurodegenerative phenotype. The described mutation could 
result in the production of a truncated PACT protein with seven extraneous 
amino acids after first 178 AA before a premature stop codon. It remains to be 
determined if such a truncated protein is present in these mice and may cause 
the observed dystonia phenotype. The Prkra null mice show no dystonia 
symptoms51, thereby raising the possibility that the dystonia phenotype may be 
directly correlated to presence of mutant PACT proteins. On the contrary, it is 
also possible that the mutant truncated PACT protein is not produced in patient 
cells or in mice due to NMD of the mRNA due to the presence of an early 
termination codon. As no patient cells are available for the reported FS mutation, 
this spontaneously created mouse model can be utilized to detect if the truncated 
protein is present in brain or any other cell types and may help understand the 
pathomechanisms involved in DYT16. 
In summary, our results presented here report the biochemical properties of a 
truncated PACT protein resulting from a frameshift mutation in a DYT16 patient. 
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Interestingly, these results indicate that although the FS mutant protein shows no 
direct interaction with PKR, the aggregates of the FS mutant protein formed in 
mammalian cells result in PKR activation to cause caspase activation leading to 
apoptosis. In the context of neurodegenerative diseases caused by protein 
aggregates in neurons, these findings beg for more in depth investigations for the 
possible role of PKR activation in triggering neuronal loss.
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Figure 2.1: Schematic representation of the frameshift mutation in 
PACT. A. Domain structure of PACT and frameshift (FS) mutant. 
Orange boxes: conserved dsRNA-binding motifs dsRBM1 and dsRBM2 
that mediate dsRNA-independent high-affinity interaction with PKR, 
Green box: M3 motif that does not bind dsRNA and mediates low-affinity 
interaction with the PACT-binding motif (PBM) within PKR's catalytic 
domain. The residues added as a result of frameshift mutation in FS are 
indicated as a red box. B. FS mutation in PACT ORF. The first 330 
nucleotides of the PACT ORF are shown. The two-nucleotide deletion 
(266-267) is indicated in bold and underlined font. The shifted reading 
frame is indicated in red font. Thus, the frameshift mutation produces a 
protein that has amino acids 1-88 and 21 new amino acids (PACT88-21).  
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Figure 2.2: Effect of FS mutation on dsRNA-binding. dsRNA-binding 
activity of wt PACT and FS mutant was measured by poly(I)-poly(C)-
agarose binding assay with in vitro translated 35S-labeled proteins. The 
positions of PACT and FS bands are indicated by arrows and the molecular 
weights are as indicated. T, total input; B, proteins bound to poly(I)-poly(C)-
agarose. Competition lanes 5 and 6: competition with 100-fold molar 
excess of ssRNA (ss) or dsRNA (ds). The fainter bands below the parent 
PACT bands represent products of in vitro translation from internal 
methionine codons. The firefly luciferase, which does not bind dsRNA, was 
used as a negative control. B. Quantification of dsRNA-binding assay. 
Bands were quantified by phosphorimager analysis and % bound was 
calculated. Error bars: standard error of mean from 4 independent 
experiments. wt PACT: blue bar and FS mutant: red bar. 
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Figure 2.3: Effect of FS mutation on interaction with PKR and PACT. (A, C, and E) Pull down assay of in vitro 
translated proteins with pure recombinant PACT, PKR, and FS proteins. 5 µl of in vitro translated, 35S-labeled flag-
tagged PKR (A) or PACT (C) or FS (E) protein was mixed with 100 ng of purified, hexahistidine tagged recombinant PKR, 
PACT, and FS proteins immobilized in Ni-charged Sepharose beads. Pull down of 35S-labelled PKR, PACT and FS was 
analyzed by SDS-PAGE after washing the beads five times with wash buffer. Total lane: total input PKR, PACT, and FS 
as indicated (50% of the bound samples); Bound lanes: the pulled down PKR (A) or PACT (C) or PKR, PACT and FS (E). 
B, D, and F. Quantification of data in 3 A, 3 C, and 3E. The radioactivity present in the bands was measured by 
phosphorimager analysis and the % pull down was calculated as (radioactivity present in the pull down (bound) PKR, 
PACT, FS bands/the radioactivity present in the PKR, PACT, FS bands in the total lane) X 100. Error bars: standard error 
of mean from 4 independent experiments. Student T-tests were performed, and p values are as follows (B) * = 0.00018, ** 
= 0.00013, (D) * = 0.00019, and ** = 0.00009, (F) * = 0.00002 and ** = 0.00001, n=4. 
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Figure 2.4: A. The mCherry-FS mutant protein aggregates in 
mammalian cells. HeLa cells were transfected with mCherry-
PACT/pmCherryC1, Cherry-FS/pmCherryC1, and pmCherryC1 empty 
vector (EV). Expression of proteins was examined 12 h after 
transfection using a fluorescence microscope. a: overlay of mCherry-
PACT (red) and DAPI nuclear stain (blue), b: overlay of mCherry-FS 
fusion protein (red) DAPI nuclear stain (blue), c: overlay of mCherry 
(red) and DAPI nuclear stain (blue). B. Western blot analysis of 
mCherry tagged proteins. HeLa cells were transfected with 
mCherry-PACT/pmCherryC1, Cherry-FS/pmCherryC1, and 
pmCherryC1 empty vector (EV). 12 h post transfection, the cells were 
harvested, cell extracts were made and analyzed by western blot 
analysis with anti-mCherry antibody. Lane 1: mCherry-PACT, lane2: 
mCherry-FS, lane 3: mCherry EV. The positions of mCherry-PACT, 
mCherry-FS and mCherry are as indicated by arrows. The multimers 
of mCherry-FS seen in lane 2 are indicated by arrowheads. 
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Figure 2.5: A. PKR activation and eIF2α phosphorylation in response to 
transient overexpression of FS mutant protein.  
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Figure 2.5 (Continued): A. HeLa cells were transfected with Cherry-
FS/pmCherryC1, and pmCherryC1 empty vector. At 1h-8h post transfection the 
cells were harvested, cell extracts were made and analyzed by western blot 
analysis with the indicated antibodies. Lanes 1-5: mCherry-PACT/pmCherryC1 
transfected cell extracts, lanes 6-10: pmCherryC1 empty vector transfected cell 
extracts.B. mCherry-FS mutant induces caspase3/7 activation in a PKR-
dependent as well as PKR-independent manner. The PKR+/+ and PKR-/- 
mouse embryonic fibroblasts were transfected with either the mCherry-
FS/pmCherryC1 expression construct or empty vector pmCherryC1. Caspase 3 
and 7 activities were measured, at indicated time points. blue bars: EV 
(pmCherryC1) transfected cells and the red bars: mCherry-FS/pmCherryC1 
transfected cells. Student T-tests were performed, and p values are as follows * 
= 0.0073 (significant), ** = 0.0065 (significant), *** = 0.0027 (significant), **** = 
0.00051, and ***** = 0.00023 (significant), n=4. C. FS mutant induces 
caspase 3/7 activation in a PACT-dependent as well as PACT-independent 
manner. The PACT+/+ and PACT-/- mouse embryonic fibroblasts were 
transfected with either the mCherry-FS/pmCherryC1 expression construct or 
empty vector pmCherryC1. Caspase 3 and 7 activities were measured, at 
indicated time points. blue bars: EV (pmCherryC1) transfected cells and the red 
bars: mCherry-FS/pmCherryC1 transfected cells. Student T-tests were 
performed, and p values are as follows * = 0.0067 (significant), ** = 0.0051 
(significant), *** = 0.0043 (significant), **** = 0.00065, and ***** = 0.00027 
(significant), n=4. 
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Figure 2.6: Effect of FS mutation on TRBP-PACT interaction. (A) Pull 
down assay of in vitro translated TRBP protein with pure recombinant 
PKR, PACT, and FS proteins. 5 µl of in vitro translated, 35S-labeled flag-
tagged TRBP protein was mixed with 100 ng of purified, hexahistidine 
tagged recombinant PKR, PACT, and FS proteins immobilized in Ni-charged 
Sepharose beads. Pull down of 35S-labelled TRBP was analyzed by SDS-
PAGE after washing the beads five times with wash buffer. Total lane: total 
input TRBP (50% of the bound samples); Bound lanes: pulled down TRBP. 
The "-" lane shows TRBP pull down with no recombinant protein on Ni-
charged Sepharose beads as a negative control.  
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Figure 2.6 (Continued): (C) FS mutant protein can dissociate TRBP 
from PACT. 5 µl of the in vitro translated 35S-labeled TRBP protein was 
incubated with 100 ng of pure recombinant hexahistidine tagged PACT and 
anti-PACT rabbit monoclonal antibody bound to 10 l of protein A sepharose 
beads. Increasing amounts of pure recombinant FS protein was added as 
indicated in lanes 4-7. Pull down of 35S-labelled TRBP was analyzed by 
SDS-PAGE after washing the beads five times with wash buffer. Total lane: 
total input TRBP (50% of the bound samples); Bound lanes: pulled down 
TRBP. The "-" lane shows TRBP pull down with no recombinant protein on 
Ni-charged Sepharose beads as a negative control. Lanes 4-7: pure 
recombinant FS mutant protein added in increasing amounts (100 pg, 1 ng, 
10 ng, 20 ng). (B and D) Quantification of data in 6 A, and 6 C. The 
radioactivity present in the bands was measured by phosphorimager 
analysis and the % pull down was calculated as (radioactivity present in the 
pull down (bound) TRBP bands/the radioactivity present in the TRBP band in 
the total lane) X 100. Error bars: standard error of mean from 4 independent 
experiments. Student T-tests were performed, and p values are as follows 
(B) * = 0.00011, (D) * = 0.000012, n=4. E. TRBP-FS interaction is stronger 
than TRBP-PACT interaction in yeast two-hybrid assay. PACT/pGADT7, 
FS/pGADT7 or empty vector (EV) pGADT7 were co-transformed with 
TRBP/pGBKT7 into AH109 yeast cells and selected on SD double dropout 
media (-tryptophan, - leucine). Ten microliters of transformed yeast cells 
(OD600 = 10, 1, 0.1, 0.01) were spotted on SD quadruple dropout media (-
tryptophan, - leucine, - histidine, -adenine) containing 10 mM 3-amino-1,2,4-
triazole (3-AT). Plates were incubated for 3 days at 30°C. The assay was 
also performed with either PACT/pGBKT7 or FS/pGBKT7 and 
TRBP/pGADT7 in a similar manner (TRBP/pGADT7 panels). Co-
transformation of PACT or FS in pGBKT7 and empty vector pGADT7 served 
as negative controls. 
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Figure 2.7: A schematic model of PKR activation in cells expressing FS 
mutant. (A) wt cells. As previously established, in the absence of stress, 
PACT heterodimerizes with TRBP, PKR is catalytically inactive and eIF2α is 
not phosphorylated. In response to a stress signal, PACT dissociates from 
TRBP due to its phosphorylation, forms homodimers that bind to PKR with 
high affinity, activate its kinase activity leading to eIF2α phosphorylation. (B) 
Cells expressing FS mutant protein. In the absence of stress, FS mutant 
protein heterodimerizes with TRBP with high affinity (and possibly also with 
PACT) to displace PACT from TRBP-PACT heterodimers. Consequently, 
PACT homodimers form due to high affinity interactions between FS mutant 
protein molecules. Such homodimers bind to PKR with high affinity and 
activate its kinase activity leading to eIF2α phosphorylation leading to 
apoptosis via caspase activation. 
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CHAPTER 3: 
DYSTONIA 16 (DYT16) MUTATIONS IN PACT CAUSE ENHANCED PKR 
ACTIVATION LEADING TO A DYSREGULATION OF EIF2 SIGNALING AND A 
COMPROMISED STRESS RESPONSE1
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3.1 ABSTRACT 
Dystonia 16 (DYT16) is one of many types of dystonias, which are 
neuromuscular movement disorders characterized by involuntary movements 
and twisting or tensing of one or more muscles leading to abnormal and often 
painful postures. Although DYT16 can appear at any age, it most often is early-
onset and begins in childhood. DYT16 is caused by mutations in PACT, the 
protein activator of interferon-induced double-stranded RNA-activated protein 
kinase (PKR). PKR is one of the four mammalian protein kinases that regulates 
the integrated stress response (ISR) via phosphorylation of the translation 
initiation factor eIF2α. This post-translational modification attenuates general 
protein synthesis while concomitantly triggering the eIF2α-independent enhanced 
translation of a few specific transcripts leading either to recovery and 
homeostasis or cellular apoptosis depending on the intensity and duration of 
stress signals. PKR plays a regulatory role in determining the cellular response to 
viral infections, oxidative stress, endoplasmic reticulum (ER) stress, and growth 
factor deprivation. In the absence of stress, both PACT and PKR are bound by 
their inhibitor transactivation RNA-binding protein (TRBP) thereby keeping PKR 
inactive. Under conditions of cellular stress these inhibitory interactions 
dissociate thus facilitating PACT-PACT interactions that are critical for PKR 
interaction and activation. While both PACT-TRBP and PKR-TRBP interactions 
are pro-survival, both PACT-PACT and PACT-PKR interactions are pro-
apoptotic. We previously reported that the most prevalent DYT16 substitution 
mutation P222L activates PKR more robustly and for longer duration resulting in 
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enhanced apoptosis of patient cells in response to ER stress. To evaluate if the 
additional DYT16 mutations reported more recently also alter PKR activation and 
ISR, we examined the ability of five DYT16 mutants to activate PKR via these 
protein-protein interactions. Our results indicate that the mutant DYT16 proteins 
show stronger PACT-PACT interactions as well as enhanced PKR activation. 
Using DYT16 patient derived lymphoblasts we demonstrate that the enhanced 
PACT-PKR binding affinity and heightened PKR activation leads to a 
dysregulation of ISR and increased apoptosis in response to ER stress. More 
importantly, this enhanced sensitivity to ER stress can be partially rescued by 
luteolin, which disrupts PACT-PKR interactions. Our results not only demonstrate 
the impact of DYT16 mutations on regulation of ISR and a plausible disease 
etiology, but also indicate that therapeutic interventions for DYT16 could be 
possible in future after further careful research and evaluation of such strategies. 
3.2 INTRODUCTION 
Integrated stress response (ISR) is an evolutionarily conserved pathway 
activated in eukaryotic cells by many different types of stress stimuli in order to 
restore cellular homeostasis. The central event in this pathway is the 
phosphorylation of eukaryotic translation initiation factor 2 (eIF2α) on serine 51 
by one of the four members of a family of serine/threonine kinases1[1]. This post-
translational modification prevents the formation of the ternary complex essential 
for translation initiation, thus leading to a decrease in general protein synthesis 
while allowing induction of selected specific genes that promote cellular recovery 
1. While transient eIF2α phosphorylation is favorable for cellular survival, 
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prolonged eIF2α phosphorylation is pro-apoptotic due to the upregulation as well 
as preferential translation of pro-apoptotic transcripts1. Thus, although ISR is 
primarily a pro-survival response to restore cellular homeostasis, exposure to 
severe stress drives signaling towards cellular death due to induction of genes 
that promote apoptosis. The gene expression program regulated by ISR is thus 
central to tailoring the cellular response to stress in a manner that is dependent 
on the cellular context, as well as the nature and severity of the stress signal. 
The interferon (IFN) inducible double-stranded RNA (dsRNA)-activated 
protein kinase (PKR) is an eIF2α kinase that is ubiquitously expressed at low 
levels in all cell types1. While PKR’s kinase activity was initially characterized to 
be stimulated under conditions of viral stress, it has also been well documented 
to be active under conditions of oxidative stress, endoplasmic reticulum (ER) 
stress, and serum deprivation1,13,17,18,35,36. In virally infected cells, PKR is 
activated by direct interactions with dsRNA, a viral replication intermediate used 
by many viruses. However, in the absence of viral infections and in presence of 
other stress signals, PKR is activated by its protein activator (PACT)13,14,25 in a 
dsRNA-independent manner. Two evolutionarily conserved amino terminal 
dsRNA binding motifs (dsRBMs) of PKR1,124,125 mediate its interactions with 
dsRNA as well as with PACT and other regulatory proteins. Upon binding dsRNA 
or PACT, PKR undergoes a conformational change unveiling the ATP binding 
site within its kinase domain (KD) which results in the autophosphorylation and 
activation of PKR1,15,31. In the absence of stress, however, PKR is inhibited 
through direct interactions with the transactivation response element (TAR) RNA 
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binding protein (TRBP) which are also facilitated by the dsRBMs on the amino 
termini of each protein46,126. 
TRBP is a dsRNA binding protein that was initially discovered due to its 
strong binding affinity to the TAR RNA element of HIV126. Since then, TRBP has 
been well characterized for its ability to inhibit PKR both by sequestration of 
dsRNA under conditions of viral infection, and by direct interactions with PACT 
as well as PKR mainly in the absence of cellular stress47,127,128. These 
interactions are facilitated by the conserved dsRBM motifs of TRBP such that the 
two amino terminal motifs facilitate dsRNA and protein-protein interactions, while 
the third motif that does not bind dsRNA mediates interactions with dicer, merlin, 
and PACT42,43,46. In the absence of stress, TRBP positively regulates translation 
by inhibiting PKR through the formation of both TRBP-PACT and TRBP-PKR 
heterodimers, consequently preventing PKR from being activated47,49,52.  
PACT is best characterized as a stress-modulated protein activator of 
PKR bringing about PKR activation via a direct, dsRNA-independent interaction 
in response to ER stress, oxidative stress, and serum deprivation25,35. Similar to 
TRBP, PACT contains three copies of the conserved dsRBMs such that the two 
amino terminal motifs, dsRBM1 and 2, are critical for dsRNA binding and protein-
protein interactions and a carboxy terminal dsRBM3 motif that does not bind 
dsRNA being required for PKR activation25,37,38. Within dsRBM3, two serine 
residues, S246 and S287, serve as phosphorylation sites to induce PACT-PACT 
homomeric and PACT-PKR heteromeric interactions52,53. In the absence of 
stress, PACT is constitutively phosphorylated on S246 and is bound to TRBP 
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and thus is unable to activate PKR 53. In response to cellular stress, PACT is 
phosphorylated on S287 by a yet uncharacterized kinase which promotes its 
dissociation from TRBP to trigger PACT-PACT homomeric interactions43,49,52,53. 
Such PACT-PACT homodimers are required for PKR activation and their 
formation is triggered by the stress-induced phosphorylation of PACT's 
dsRBM349,52,53. The PACT-PACT homodimers with the S246 and S287 
phosphorylations bind PKR with higher affinity thereby bringing about PKR 
activation49. The dsRBM3 of PACT is thus essential for PKR activation and 
interacts directly with the PACT-binding motif (PBM) within the KD of PKR 15,31,49. 
Once activated, PKR phosphorylates the alpha subunit of eIF2 on serine 51 
resulting in the attenuation of general protein synthesis1. This triggers all the 
downstream ISR events such as but not limiting to ATF4 and CHOP induction 
which in turn regulate cellular fate either restoring homeostasis or inducing 
apoptosis.  
Recently, several PACT mutations have been identified in patients (OMIM: 
DYT16 (612067)), with a neuromuscular movement disorder dystonia 16 
(DYT16) 62,67,129. PACT is encoded by the gene Prkra and currently the list of 
Prkra mutations leading to DYT16 has grown to eight in a worldwide occurrence 
60,63,65. The dystonias are a heterogeneous group of movement disorders in 
which the affected individuals exhibit repetitive and painful movements of the 
affected limbs, as well as compromised posture and gait patterns59,99. DYT16 is a 
rare early-onset dystonia parkinsonism disorder characterized by progressive 
limb dystonia, laryngeal and oromandibular dystonia and parkinsonism. Although 
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DYT16 was originally described to have an autosomal recessive inheritance 
pattern, four dominantly inherited variants of DYT16 have been reported in 
patients after the initial report. Previously, our lab has reported on how a 
recessively inherited P222L mutation increases cell susceptibility to ER stress 
through the dysregulation of eIF2α stress response signaling in DYT16 patient 
derived lymphoblasts69. Furthermore, using an in-vitro approach we have 
demonstrated that a dominantly inherited frameshift mutation expresses a 
truncated PACT protein that disrupts PACT-TRBP heterodimers resulting in an 
increase in PACT mediated PKR activation leading to an enhanced sensitivity to 
ER stress via dysregulation of the eIF2α stress response signaling pathway130. In 
accordance with our findings, subsequent reports also identified the 
dysregulation of eIF2α signaling in both DTY1 and DYT674,120,131,132. Collectively, 
these findings indicate a potential common link among several forms of dystonia. 
In the present study we characterize the effects of three recessively 
inherited DYT16 point mutations (C77S, C213F, C213R) and two dominantly 
inherited DYT16 point mutations (N102S and T34S) on their ability to regulate 
PKR activation and ISR. Our data demonstrates that although these DYT16 point 
mutations have no effect on PACT’s dsRNA binding ability and PACT-TRBP 
interactions, the dominant mutations show enhanced ability to interact with PKR. 
Most significantly, all the DYT16 mutations under study demonstrated a 
heightened capacity to form PACT-PACT homodimers in the absence of stress. 
Furthermore, using lymphoblasts derived from a compound heterozygous DYT16 
patient containing both C213R and P222L mutations as independent alleles, we 
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identified stronger binding affinity between PACT and PKR in the DYT16 patient 
cells and a dysregulation of the eIF2α stress response signaling and downstream 
ISR genes. The DYT16 patient lymphoblasts also demonstrated an increase in 
cell susceptibility to ER stress that could be rescued in the presence of luteolin, a 
potent inhibitor of PACT-PKR interactions. Our work further strengthens the case 
for involvement of dysregulated eIF2α signaling as a mechanism in the disease 
etiology and lays the groundwork for exploring possible therapeutic options for 
DYT16. 
3.3 MATERIALS AND METHODS 
Cell Lines and Antibodies– Both HeLaM and COS-1 cells were cultured 
in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% Fetal Bovine 
Serum and penicillin/streptomycin. wt and DYT16 Patient B-Lymphoblasts were 
cultured in RPMI 1640 medium containing 10% FBS and penicillin/streptomycin. 
Both wt and DYT16 patient lymphoblast cell lines were Epstein-Barr Virus-
transformed to create stable cell lines as previously described133. All 
transfections were carried using Effectene transfection reagent (Qiagen) per 
manufacturer protocol. The antibodies used were as follows: PKR: anti-PKR 
(human) monoclonal (71/10, R&D Systems), P-PKR: anti-phospho-PKR (Thr-
446) monoclonal (Abcam, [E120]), eIF2α: anti-eIF2α polyclonal (Invitrogen, 
AHO1182), p-eIF2α: anti-phospho-eIF2α (Ser-51) polyclonal (CST, #9721), 
PACT: Anti-PACT monoclonal (abcam, ab75749), ATF4: Anti-ATF4 monoclonal 
(CST, #11815), CHOP: anti-CHOP monoclonal (CST, #2895), Cleaved PARP: 
anti-Cleaved-PARP monoclonal (CST, #32563), FLAG-HRP: anti-FLAG 
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monoclonal M2-HRP (Sigma A8592), MYC-HRP: anti-MYC monoclonal (Santa 
Cruz, 9E10), β-Actin: Anti- β-Actin-Peroxidase monoclonal (Sigma-Aldrich, 
A3854). 
Generation of DYT16 Point Mutations– We generated each DYT16 
mutant construct using site specific mutagenesis through PCR amplification 
changing the codon within the PRKRA gene to be consistent with DYT16 patients 
and code for the appropriate amino acid substitution. The following site-specific 
mutagenic primer pairs were used:  
C77S Sense: 5’-GCT CTA GAC ATA TGG AAA TGT CCC AGA GCA GGC AC-
3’ 
C77S Antisense: 5’-GCC TCT GCA GCT CTA TGT TTC GCC AGC TTC TTA 
CTT GTA CCT TCA CCT GTG GAG GTT ATG TCA CCA ACG G-3’ 
C213F Sense: 5’-GCT CTA GAC ATA TGG AAA TGT CCC AGA GCA GGC AC-
3’ 
C213F Antisense: 5’-GGA GAA TTC CTC AAG GAA TGC CAA GTA AAT CCT 
AAA GAA TGT CC-3’ 
C213R Sense: 5’-GCT CTA GAC ATA TGG AAA TGT CCC AGA GCA GGC AC-
3’ 
C213R Antisense: 5’-GGA GAA TTC CTC AAG GAA TGC CAA GTA CGT CCT 
AAA GAA TGT CC-3’ 
N102S Sense: 5’-GCT GCA GAG GCT GCC ATA AAC ATT TTG AAA GCC 
AGT GCA AGT ATT TGC TTT GC -3’ 
N102S Antisense: 5’-GGG GAT CCT TAC TTT CTT TCT GCT ATT ATC-3’ 
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T34S Sense: 5’-GCT CTA GAC ATA TGG AAA TGT CCC AGA GCA GGC AC-
3’ 
T34S Antisense: 5’-CGT GTA ATA CCT GAA TCG GTG ATT TCC CTG GCT 
TAG C-3’ 
To generate each construct, we performed PCR amplification in order to 
change the corresponding codon sequence to code for the amino acid residue 
consistent with the DYT16 patients. Each PCR product was then subcloned into 
pgEMT-easy vector (Promega) and sequences were validated through DNA 
sequencing from Eton Biosciences. After sequence validation, we generated full 
length DYT16 ORFs through cutting: (i) partial DYT16 ORF in pgEMT-easy with 
construct specific restriction enzymes, (ii) Amino terminal FLAG or Myc-tagged 
wt PACT in BSIIKS+ with compatible restriction sites. Cloning scheme was as 
follows: C77S in pgEMT-easy cut with NdeI-PstI ligated into FLAG/Myc-PACT-
BSIIKS+ cut with PstI-BamHI. C213F and C213R in pgEMT-easy cut with NdeI-
EcoRI ligated into FLAG/Myc-PACT-BSIIKS+ cut with EcoRI-BamHI. N102S in 
pgEMT-easy cut with NdeI-PstI and ligated into FLAG/Myc-PACT-BSIIKS+ cut 
with PstI-BamH1. T34S in pgEMT-easy cut with NdeI-TfiI ligated into FLAG/Myc-
PACT-BSIIKS+ cut with TfiI-BamHI. Once full length DYT16 ORFs were 
generated with amino terminal FLAG or myc tags we then subcloned each ORF 
into pCDNA3.1- using XbaI-BamHI restriction sites. All DYT16 constructs were 
also cloned into mammalian two-hybrid system vectors and pET15b (Novagen) 
using NdeI-BamHI restriction sites. TRBP and Flag-K296R (PKR) constructs 
were generated as previously described49. 
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Expression and purification of PACT from E. coli – The ORFs of both 
wt PACT and all DYT16 point mutations were subcloned into pET15b (Novagen) 
to generate an in-frame fusion protein with a hexahistidine (his) tag. 
Recombinant proteins were then expressed and purified as previously 
described25. 
dsRNA Binding Assay – Both wt PACT and DYT16 PACT constructs in 
pCDNA3.1- were in-vitro translated using the TNT-T7-coupled rabbit reticulocyte 
system from Promega while incorporating an 35S-Methionine radiolabel and the 
dsRNA binding ability was measured using poly(I:C) conjugated agarose beads. 
We diluted 4 ul of in-vitro translation in 25 ul of binding buffer (20 mM Tris–HCl, 
pH 7.5, 0.3 M NaCl, 5 mM MgCl2, 1 mM DTT, 0.1 mM PMSF, 0.5% NP-40, 10% 
glycerol) and incubated in 25 ul of poly(I:C)-agarose beads and incubated at 
30oC for 30-minutes. We then washed the beads 4 times with 500 ul of binding 
buffer and bound proteins were analyzed via SDS-PAGE gel electrophoresis and 
autoradiography. The competition assay was performed incubating either soluble 
single-stranded RNA, poly(C), or dsRNA, poly(I:C), with the in-vitro translated 
proteins before the adding the poly(I:C)-agarose beads. To ensure the presence 
of PACT was due to the dsRNA binding capacity we assayed in-vitro translated 
35S-Methionine labeled firefly luciferase which has no dsRNA binding ability. T-
lanes represent total in-vitro translated radiolabeled proteins, whereas, B-lanes 
represent fraction of labeled protein that remained bound to poly(I:C)-agarose 
beads after washing. Bound fraction was quantified using Typhoon FLA7000 by 
analyzing relative band intensities of both T and B-lanes. Percentage of PACT 
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was bound to beads was then determined by dividing values obtained from B-
lanes by values obtained by T-lanes and then plotted as bar graphs.  
PKR Activity Assay – HeLa M cells were treated with IFN-β for 24-hours 
and harvested at 70% confluency. Cells were washed using ice-cold PBS and 
centrifuged at 600 g for 5-minutes. Cells were then resuspended in lysis buffer 
(20 mM Tris–HCl pH 7.5, 5 mM MgCl2, 50 mM KCl, 400 mM NaCl, 2 mM DTT, 
1% Triton X-100, 100 U/mL aprotinin, 0.2 mM PMSF, 20% glycerol) and 
incubated on ice for 5 minutes. Lysates were then centrifuged at 10,000 g for an 
additional 5-minutes. PKR was then immunoprecipitated from 100 ug of this 
lysate using anti-PKR monoclonal antibody (R&D Systems Technology: 
MAB1980) in a high salt buffer (20 mM Tris–HCl pH 7.5, 50 mM KCl, 400 mM 
NaCl, 1 mM EDTA, 1 mM DTT, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol, 
1% Triton X-100) at 4oC on a rotating wheel for 30-minutes. We then added 10 ul 
of Protein A-Sepharose beads to each immunoprecipitate followed by an 
additional 1-hour incubation under the same conditions. Protein A-Sepharose 
beads were then washed 4 times in high salt buffer followed by an additional two 
washes in activity buffer (20 mM Tris–HCl pH 7.5, 50 mM KCl, 2 mM MgCl2, 2 
mM MnCl2, 100 U/ml aprotinin, 0.1 mM PMSF, 5% glycerol). PKR activity assay 
using PKR bound to protein A-Sepharose beads was then conducted by 
incorporating: 500 ng of purified eIF-2 as the PKR substrate, 0.1 mM ATP, 10 uCi 
of [γ-32P] ATP, and increasing amounts of either recombinant wt PACT or 
recombinant DYT16 PACT (400 pg – 4 ng) as the PKR activator. Reaction was 
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then incubated at 30°C for 10 min and resolved on a 12% SDS-PAGE gel and 
analyzed via autoradiography.  
Western Blot Analysis – Lymphoblasts derived from a compound 
heterozygous DYT16 patient containing both P222L and C213R mutations on 
independent alleles were cultured alongside lymphoblasts derived from a family 
member containing no mutations in PACT as our control cells. Cells were 
cultured at a concentration of 300,000 cells/mL of RPMI media containing 10% 
fetal bovine serum and penicillin/streptomycin. To analyze cellular response to 
ER stress, we treated cells with 5 ug /mL of tunicamycin (Santa Cruz) over a 24-
hour time course and harvested cells in RIPA (150 mM NaCl, 1.0% IGEPAL® 
CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) buffer 
containing a 1:100 dilution of protease inhibitor (Sigma) and phosphatase 
inhibitor (Sigma). Concentration of total protein extract was then determined 
through BCA assay and appropriate amounts resolved on SDS-PAGE denaturing 
gels to detect the proteins of interest. Proteins were detected via 
chemiluminescence and antibodies indicated above.  
Co-Immunoprecipitation Assays with Endogenous Proteins – For co-
immunoprecipitation (co-IP) of endogenous proteins DYT16 and wt lymphoblasts 
were seeded at a concentration of 300,000 cells/mL in RPMI complete media 
and treated with 50 μM of luteolin (Santa Cruz) over a 24 hour time course. Cells 
were then harvested and whole cell extract was immunoprecipitated using anti-
PKR antibody (71/10, R&D Systems) conjugated to protein A sepharose beads 
(GE Healthcare) overnight at 4oC on a rotating wheel in IP buffer (20 mM Tris-
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HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 20% Glycerol). 
Immunoprecipitation was carried out using 100 ng of anti-PKR antibody and 10 ul 
of protein A sepharose beads slurry per immunoprecipitation. 
Immunoprecipitates were then washed 3 times in 500 ul of IP buffer followed by 
resuspension and boiling for 5 minutes in 2x Laemmli buffer (150 mM Tris–HCl 
pH 6.8, 5% SDS, 5% β-mercaptoethanol, 20% glycerol). Samples were then 
resolved on 10% SDS-PAGE denaturing gel and probed with anti-PACT antibody 
to determine co-IP efficiency and anti-PKR antibody to determine equal amounts 
of PKR were immunoprecipitated. Input blots of whole cell extract without 
immunoprecipitation are shown to indicate equal amounts of protein in each 
sample.  
Co-Immunoprecipitation Assays in HeLa Cells – In all cases HeLa M 
cells were seeded at 20% confluency in 6-well dishes 24-hours prior to co-
transfecting 250 ng of each flag or myc tagged construct using Effectene 
transfection reagent (Qiagen). Cells were harvested 24-hours post transfection in 
IP buffer. Whole cell extract was then immunoprecipitated overnight at 4oC on a 
rotating wheel in either pre-conjugated anti-flag agarose beads (Sigma) or pre-
conjugated anti-myc agarose beads (Thermo Scientific). Immunoprecipitates 
were then washed 3-5 times in IP buffer followed by resuspension and boiling for 
5 minutes in 2x Laemmli buffer. Samples were then resolved on 10% SDS-PAGE 
denaturing gels and transferred onto PVDF membranes. To evaluate PACT-
PACT homodimerization and PACT-TRBP heterodimerization, flag-tagged 
constructs were immunoprecipitated using 15 ul of pre-conjugated flag agarose 
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beads and blots were initially probed with anti c-myc antibody to detect co-IP 
(PACT), followed by re-probing with anti-flag antibody to detect efficiency of IP 
(PACT or TRBP). PACT-PACT homodimerization co-IPs were incubated at 50oC 
for 30 minutes in stripping buffer (62.5 mM Tris-HCl pH 6.8, 10% SDS, 0.75% β-
mercaptoethanol) prior to re-probing with anti-flag antibody. To evaluate PACT-
PKR interactions, we co-transfected myc-tagged PACT constructs in pCDNA3.1- 
with a flag tagged dominant negative PKR mutant, K296R, also in the 
pCDNA3.1- backbone. We then immunoprecipitated whole cell lysates in 15 ul of 
pre-conjugated myc-agarose beads and resolved on 10% SDS-PAGE denaturing 
gels as described above. Blots were initially probed with anti-flag antibody to 
detect co-IP (PKR) followed by re-probing with anti-myc antibody to determine 
equal amount of IP (PACT) per sample. Input blots of whole cell lysate exempt 
from immunoprecipitation are shown to demonstrate equal expression of each 
construct prior to immunoprecipitation. 
Mammalian-2-Hybrid – In all cases, wt PACT, DYT16, TRBP, or PKR 
ORFs were subcloned into both pSG424 expression vector such that it created 
an in-frame fusion to a GAL4 DNA binding domain (GAL4-DBD), and 
pVP16AASV19N expression vector such that it maintains an in-frame fusion to 
the activation domain of the herpes simplex virus protein VP16 (VP16-AD). COS-
1 cells were then transfected with: (i) 200 ng each of the GAL4-DBD and the 
VP16-AD constructs, (ii) 200 ng of pg5Luc (Firefly luciferase) reporter construct, 
(iii) 1 ng of pRL Null vector (Renilla luciferase) (Promega) to normalize for 
transfection efficiencies. Cells were then harvested 24-hours post transfection 
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and assayed for both firefly and renilla luciferase activity using Dual-Luciferase® 
Reporter Assay System (Promega). Fusion proteins were assayed for interaction 
in all combinations.  
Caspase 3/7 Activity Assays – Both wt and Patient derived lymphoblasts 
were seeded at a concentration of 300,000 cells/mL of RPMI complete media 
and treated with a concentration of 5 ug /mL of tunicamycin over a 24-hour time 
course. Samples were collected at each indicated time point and mixed with 
equal parts Promega Caspase-Glo 3/7 reagent (Promega (G8090)) and 
incubated for 45 minutes. Luciferase activity was then measured and compared 
to cell culture medium alone as our negative control. All values were normalized 
to luciferase activity detected in negative control. To address the effect of 
inhibiting PACT-PKR interaction on cell viability, we cultured wt and Patient 
lymphoblasts as described above in 50 μM of luteolin for 24-hours followed by 
treatment with 5 ug /mL of tunicamycin in luteolin free media over the same time 
course. 
3.4 RESULTS 
DYT16 mutations do not affect PACT’s dsRNA-binding activity. The 
majority of DYT16 mutations characterized in the present study occur outside of 
PACT’s highly conserved dsRBMs (Fig. 3.1 A). Four of the mutations associated 
with the recessively inherited DYT16 (C77S, C213F, C213R, and P222L) result 
in the loss of a cysteine or proline residues which could have dramatic 
consequences on the 3-dimensional conformation of the protein (Fig. 3.1 A). 
Furthermore, the two dominantly inherited mutations (N102S and T34S) occur on 
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the flanking ends of PACT’s first dsRBM that is most critical for dsRNA binding 
and protein-protein interactions (Fig. 3.1 A)25,39,52. As seen in Fig. 3.1 B and C, 
the DYT16 point mutants show no change in their dsRNA binding capabilities in 
comparison to the wt PACT (lanes 1-14). In order to ascertain the specificity of 
the dsRNA-binding assay, we used in vitro translated firefly luciferase, which has 
no dsRNA-binding activity as a negative control (lanes 19-20). Additionally, we 
demonstrate the specificity of the interaction for dsRNA by adding excess dsRNA 
or ssRNA as competitors. As seen in lanes 15-18, the binding to dsRNA 
immobilized on beads can be effectively competed by exogenously added 
dsRNA but not single-stranded (ss) RNA (lanes 15-18).  
DYT16 mutants activate PKR more efficiently. PACT is best 
characterized for its ability to activate PKR under conditions of cellular 
stress25,35,47. Therefore, we next evaluated the consequence of each of the 
DYT16 mutations for PACT’s ability to activate PKR using an in vitro PKR activity 
assay. His tagged wt PACT and DYT16 mutant proteins were expressed and 
purified from bacterial cells using nickel affinity chromatography. The purified 
recombinant proteins were used as activators in an in vitro PKR activity assay by 
adding increasing amounts to PKR immunoprecipitated from HeLa cells. We are 
then able to determine efficiency of PKR activation by comparing PKR 
autophosphorylation in the presence of wt PACT and the various PACT mutants 
(Fig. 3.2 A). Basal levels of activated PKR are observed in lanes 1 and 10 (upper 
panel) and lanes 1 and 8 (lower panel) in the absence of any added activator. 
When the purified recombinant PACT proteins are added, a dose dependent 
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increase (left: 400 pg, right: 4.0 ng) in activated autophosphorylated PKR is 
observed (lanes 2-9, 11-16 for upper panel and lanes 2-7, 9-12 for lower panel). 
The amount of radioactivity present in PKR bands was quantified using a 
phosphorimager analysis and is shown in Fig. 3.2 B. In all cases, recessive 
mutations demonstrated a slightly increased capacity to activate PKR (Fig. 3.2 A, 
lanes 4-12 and Fig. 3.2 B) as compared to wt PACT (Fig. 3.2 A, lanes 2-3). 
Interestingly, when tested in combinations as reported in DYT16 patients, the 
recessive mutants showed significantly enhanced ability to activate PKR (Fig. 3.2 
A upper panel lanes 13-16, and Fig. 3.2 B) The dominant mutants (lower panel) 
showed enhanced ability to activate PKR only at 4 ng but not at 400 pg (Fig. 3.2 
A, lower panel lanes 4-7). Interestingly, when tested in combination with wt 
PACT, both the dominant mutants demonstrated significantly higher PKR 
activation (Fig. 3.2A lower panel: lanes 9-12, and Fig. 3.2 B). These results 
indicate that the DYT16 point mutants have enhanced ability to activate PKR as 
compared to wt PACT. 
DYT16 patient derived lymphoblasts are more susceptible to ER 
stress. AS the DYT16 mutant proteins exhibited an increased ability to activate 
PKR, we next utilized the lymphoblast lines derived from a DYT16 patient and his 
normal, wt parent to determine the effect of one particular DYT16 mutation 
combination on cell viability in response to stress. It is important to note that 
DYT16 is a rare, early-onset movement disorder and patient cells are not 
available from most of the DYT16 patients. Here we characterize the effect of ER 
stress on DYT16 patient derived lymphoblast cells expressing both P222L and 
 
77 
C213R mutations on independent alleles. We compared these cells to wt 
lymphoblast cell lines derived from an unaffected family member. Consequently, 
we utilized the ER stress inducing agent, tunicamycin (TM), which results in the 
accumulation of misfolded proteins in the ER due to inhibition of protein 
glycosylation17. In case of wt lymphoblasts, over a 24-hour time course in 
response to TM treatment we observed a marginal increase in expression of 
cleaved PARP1, a marker of cellular apoptosis (Fig. 3.2 C, lanes 6-7) indicating 
efficient recovery and homeostasis. In contrast to this, in the DYT16 patient 
derived lymphoblasts, there was a dramatically significant increase in cleaved 
PARP1 in response to tunicamycin (Fig. 3.2 C, lanes 13-14). To further validate 
these results, we performed caspase 3/7 activity assays under the same 
conditions to measure cell apoptosis. In wt lymphoblasts we detect caspase 
activity at 24 h but not at 6 h post-treatment (Fig. 3.2 D, blue bars). In contrast, 
the DYT16 patient lymphoblasts demonstrate significantly elevated caspase 
activity at 6h which further increases at 24 h post-treatment (Fig. 3.2 D, red bars). 
Thus, further supports that the DYT16 patient lymphoblasts are significantly more 
susceptible to ER stress and exhibit increased apoptosis as compared to wt cells 
possibly due to a failure to restore homeostasis. 
eIF2α phosphorylation and ISR is dysregulated in DYT16 patient 
lymphoblasts. In order to elucidate the underlying mechanism driving 
heightened sensitivity to ER stress in DYT16 lymphoblasts, we performed 
western blot analysis on cells treated under the same conditions as figure 2C-D 
probing for markers of cellular stress response (Fig. 3.3). We compared the 
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kinetics of both eIF2α phosphorylation and PKR activation in the DYT16 
lymphoblasts to the wt lymphoblasts from the unaffected family member. In wt 
lymphoblasts (left) we observe a low basal level of eIF2α phosphorylation in the 
untreated cells (Fig. 3.3 A, lane 1) followed by increased eIF2α phosphorylation 
at 1-4 hours post treatment (lanes 2-4) and then restoration to basal levels by 8 
hours (lane 5). In contrast to this, in the DYT16 lymphoblasts (right), we observe 
a similar increase in eIF2α phosphorylation 1 hour after treatment (lane 7), 
however, the eIF2α phosphorylation is sustained even at 8-hours post treatment 
(lanes 8-10). We also studied the time course of PKR activation in DYT16 patient 
lymphoblasts under the same conditions. In wt lymphoblasts (left) we observe 
PKR activation at 1 hour after TM treatment that is sustained until 4 hours (lanes 
1-4) and shows a slight decrease by 8 hours (Fig. 3.3 A). In contrast to this, the 
DYT16 lymphoblasts (right) exhibit a dramatically elevated level of activated PKR 
even in untreated cells (lane 6) that does not show any stress-dependent 
increase after treatment with TM (lanes 7- 10). As we noted the differences in 
eIF2α and PKR phosphorylation responses between wt and DYT16 
lymphoblasts, we examined if the downstream effects of eIF2α phosphorylation 
also show similar differences. In wt lymphoblasts (left), ATF4 is undetectable in 
untreated cells (Fig. 3.3 B, lane 1) and its expression increases in a time 
dependent manner from 1-8 hours post treatment (lanes 2-5) and declines at 12 
and 24 hours after treatment (lanes 6-7). In contrast, in the DYT16 patient 
lymphoblasts (right) although we observe increased expression of ATF4 from 1-8 
hours post treatment (lanes 9-11), it persists at high levels even at 12 hours post 
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treatment and shows only a small decline at 24 hours after treatment. Finally, we 
compared levels of CHOP, an ATF4-induced pro-apoptotic protein, in response 
to TM treatment in wt and DYT16 lymphoblasts. Collectively these results 
demonstrate a dysregulation of ISR pathway due to the prolonged 
phosphorylation of eIF2α, elevated levels of activated PKR, the prolonged 
elevated levels of ATF4 translation, and delayed but sustained induction of 
CHOP. 
Effect of DYT16 mutations on PACT-PKR interactions. In light of the 
heightened basal levels of PKR activation observed in the DYT16 patient cells 
(Fig. 3.3 A), we next wanted to investigate the effect of these DYT16 mutations 
on PACT-PKR interactions. To address this, we performed co-
immunoprecipitation (co-IP) assays using cells expressing a combination of myc-
epitope tagged wt or DYT16 mutant PACT and flag-epitope tagged PKR. PKR is 
expressed at low basal levels in cells and both increased PKR activation and 
increased PKR expression levels are toxic to cells due to increased apoptosis. 
Thus, in order to evaluate PACT-PKR heterodimer formation we utilized an 
expression vector encoding Flag-tagged K296R, a catalytically inactive, PKR 
mutant, which has been established to affect PKR’s kinase activity without 
affecting PACT-PKR interactions. Previously our lab has reported that the 
recessively inherited DYT16 mutation, P222L, shows an increased ability to form 
PACT-PKR heterodimers relative to wt PACT69. Here our results show that the 
other recessively inherited mutations (C77S, C213F, and C213R) show no 
difference in their ability to interact with PKR relative to wt PACT (Fig. 3.4 A, 
 
80 
lanes 7-10). In the absence of myc-PACT, no flag-PKR is immunoprecipitated 
confirming that there is no non-specific binding of flag-PKR to the beads in the 
absence of myc-PACT (co-IP panel, lane 6). Lanes 1-5 demonstrate equal 
amounts of Myc-PACT proteins were immunoprecipitated in each lane (top 
panel) while input gels (lower panel) demonstrate equal expression from each 
myc-PACT expression construct (lanes 2-5) and Flag-PKR (lanes 6-10). In 
contrast, we do observe an increase in the PACT-PKR heterodimer formation in 
case of dominantly inherited mutations (N102S and T34S) under the same 
conditions (Fig. 3.4 B). As compared to wt PACT (lane 2), co-IP of the dominant 
mutants N102S and T34S (lanes 3-4) is significantly increased. No co-IP of myc-
PACT is seen in the absence of flag-PKR (lane 1), thus demonstrating that there 
is no non-specific interaction of PACT proteins with the beads in the absence of 
flag-PKR. Lanes 6-8 (upper IP panel) demonstrate equal amounts of flag-PKR 
was immunoprecipitated in each lane, while input panels demonstrate equal 
expression of all constructs (lower panel, lanes 1-4, and 6-8). 
In order to validate the co-immunoprecipitation results, we tested the 
PACT-PKR interactions using the mammalian-two-hybrid (M2H) assay. In 
agreement with co-IP data, our results demonstrate that the recessively inherited 
mutations C77S, C213F and C213R have no difference in their ability to interact 
with PKR (Fig. 3.4 C). Consistent with our previously reported data, the P222L 
mutant demonstrates a stronger binding to PKR as indicated by greater induction 
of the luciferase reporter gene compared to wt PACT (Fig. 3.4 C). In the case of 
the P222L mutation, we observed about 2.5-fold increase in the PKR interaction 
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as compared to wt PACT, whereas, the other recessive mutants have similar 
PKR interaction as the wt PACT. Similarly, our results from the co-IP data were 
confirmed in case of the dominant mutations (Fig. 3.4 D). The T34S mutant 
showed about 2.25-fold increase and the N102S mutant showed about 4.25-fold 
increase in PKR interaction relative to wt PACT (Fig. 3.4 D).  
Effect of DYT16 mutations on PACT-PACT interactions. PACT-PACT 
interactions are critical for the interaction with and activation of PKR. 
Consequently, using the same protein-protein interaction studies outlined in Fig. 
3.4 we addressed whether PACT-PACT interactions were affected by the DYT16 
mutations (Fig. 3.5). We co-expressed myc- or flag-epitope tagged PACT 
proteins by transient transfection of the respective expression constructs in 
combinations as reported in patients. Our data shown in Fig. 3.5 A-C 
demonstrates that all DYT16 mutants show a dramatic increase in their ability to 
form PACT-PACT homodimers in the absence of stress as compared to wt PACT 
(Fig. 3.5). In the case of the recessively inherited mutations, we observe minimal 
wt PACT homodimerization (Fig. 3.5 A, lane 2) with this being variable and no 
interaction being detected in few experimental repeats as it is established that in 
the absence of stress, PACT-PACT dimerization is usually absent. The 
recessively inherited DYT16 mutations show enhanced C77S-C213F and P222L-
C213R interactions as compared to wt PACT-wt PACT interactions (compare 
lanes 3-4 to lane 2). In case of the dominantly inherited mutations we tested their 
ability to form wt PACT-mutant dimers (Fig. 3.5 B), as well as mutant-mutant 
dimers (Fig. 3.5 C). We did not observe any wt PACT homodimerization in the 
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absence of stress (Fig. 3.5 B and C, lane 2), however, both the dominant DYT16 
mutants N102S and T34S showed enhanced interaction with wt PACT (Fig. 3.5 
B, lanes 3-4) with N102S showing the strongest interaction with wt PACT. When 
evaluating these dominant mutations for their ability to interact with themselves, 
we observe very strong interaction between N102S-N102S and T34S-T34S (Fig. 
3.5 C, lanes 3-4) as compared to wt PACT-wt PACT with the strongest 
interaction being T34S-T34S. We do not observe any co-IP of myc tagged wt 
PACT in the absence of flag tagged wt PACT (lane 1) demonstrating the 
absence of any non-specific binding to the beads (Fig. 3.5 A-C). The IP panels 
show that equal amounts of flag-tagged PACT protein is immunoprecipitated in 
each lane (Fig. 3.5 A-C, upper panel, lanes 5-8), and input blots indicate equal 
expression of each construct (Fig. 3.5 A-C, lower panel, lanes 1-8). 
To further confirm our co-IP data we tested the interaction between 
DYT16 PACT mutants utilizing the M2H (Fig. 3.5 D-E). As seen in Fig. 3.5 D and 
E, in the patient specific combinations all the recessive mutants show enhanced 
interactions relative to wt PACT-wt PACT interaction (Fig. 3.5 D). The P222L-
C213R and C213F-C77S interactions are ~5-fold and ~9-fold higher than wt 
PACT-wt PACT interaction respectively (Fig. 3.5 D). Furthermore, the dominant 
mutants T34S and N102S also show enhanced interactions (Fig. 3.5 E). The wt 
PACT-T34S and N102S-wt PACT interactions are ~10-fold and ~30-fold higher 
than wt PACT-wt PACT interactions. Finally, the T34S-T34S and N102-N102S 
interactions are enhanced ~10-fold and ~20-fold respectively compared to wt 
PACT-wt PACT interactions.  
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PACT’s ability to interact with TRBP is not affected by the DYT16 
mutations. In the absence of stress TRBP binds PACT thereby preventing the 
formation of PACT-PACT homodimers that result in PKR interaction and 
activation. Thus, changes in PACT's interaction with TRBP can consequentially 
affect PKR activation. Previously, our lab has reported that the recessively 
inherited DYT16 P222L mutation increases PACT’s binding affinity to TRBP 
ultimately resulting in delayed PKR activation69. We determined the consequence 
of the DYT16 mutations under study on PACT-TRBP heterodimer formation and 
our results indicate that the recessively inherited mutations, C77S, C213F, and 
C213R (Fig. 3.6 A, lanes 2-5) as well as the dominantly inherited N102S and 
T34S mutations (Fig. 3.6 B, lanes 2-4) have equal binding affinity to TRBP 
relative to wt PACT. As we do not detect the presence of myc-wt PACT in the 
absence of flag-TRBP expression (lane 1, Fig. 3.5 A and B) we can rule out any 
nonspecific binding of PACT to the beads. Finally, immunoprecipitation blots 
indicating that equal amount of myc-TRBP protein was immunoprecipitated (Fig. 
3.5 A and B, IP panels, lanes 7-10 and lanes 6-8) and input blots demonstrating 
equal protein expression are shown (Fig. 3.5 A and B, input panels, lanes 1-10 
and lanes 1-8). 
We also validated these results using the M2H to determine the relative 
strengths of PACT-TRBP interactions. Consistent with our previously reported 
data, the P222L mutation shows ~2-fold increase in interaction with TRBP 
relative to wt PACT (Fig. 3.6 C). The other recessively inherited mutations, 
however, show no difference in their ability to interact with TRBP relative to wt 
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PACT (Fig. 3.6 C). Consistent with the co-IP data, we also do not observe any 
difference in the PACT-TRBP interaction for the dominantly inherited mutations 
relative to wt PACT (Fig. 3.6 D).  
DYT16 Patient lymphoblasts show a stronger PACT-PKR interactions and 
its disruption rescues their higher sensitivity to ER stress. In light of the increased 
PACT-PACT interaction independent of cellular stress observed in fig. 5 and the 
elevated basal levels of activated PKR observed in fig. 3, we next wanted to 
investigate if the PACT-PKR interaction in patient derived lymphoblasts is also 
stronger as compared to wt lymphoblasts derived from the unaffected family 
member. In order to address this question, we treated these cells with luteolin, a 
flavonoid that has been established to efficiently inhibit or disrupt PACT-PKR 
interactions134. As seen in Fig. 3.7 A, in the wt lymphoblasts we can detect some 
PACT-PKR interaction (upper panel) prior to luteolin treatment (lane 2), and at 1-
hour after luteolin treatment PACT-PKR interactions are barely detectable (lane 
3). We observe a time dependent decrease in the PACT-PKR interaction from 1-
8 hours (lanes 3-5), and at 24h after luteolin treatment the interaction can no 
longer be detected (lane 6). In the DYT16 patient lymphoblasts, we observe 
much higher PACT-PKR interaction prior to luteolin treatment (lane 8) and the 
interaction persists until 2 hours (lanes 9-10) and then decreases slowly at 4 and 
8 hours after luteolin treatment (lanes 11-12). We do see the loss of PACT-PKR 
interactions at 24 hours after treatment in the DYT16 patient lymphoblasts (lane 
12). Immunoprecipitation blots (lower panel) demonstrate equal amounts of PKR 
were immunoprecipitated in all lanes (lanes 1-12), and the input blots 
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demonstrate that equal amount of protein was present in all 
immunoprecipitations. We do not detect the presence of PACT or PKR in 
samples incubated overnight in the absence of PKR antibody thus demonstrating 
that there is no nonspecific binding of PACT to the beads in the absence of PKR 
immunoprecipitation (lanes 1 and 7). These results confirm that PACT-PKR 
interaction is stronger in DYT16 patient cells as compared to the wt cells and that 
a 24 h treatment with luteolin disrupts the interaction in wt as well as DYT16 
cells. 
Prevalence of PACT-TRBP heteromeric interactions promote cell survival 
while both PACT-PACT homomeric and PACT-PKR heteromeric interactions 
promote apoptosis. Our data indicates that there is an increase in both PACT-
PACT (Fig. 3.5) and PACT-PKR interactions (Fig. 3.4 and Fig. 3.7 A), and the 
DYT16 patient lymphoblasts are more susceptible to ER stress induced 
apoptosis (Fig. 3.2 D). Therefore, we next wanted to determine if disrupting the 
PACT-PKR interaction in the DYT16 patient lymphoblasts would lead to an 
increase in cell viability in response to ER stress. As a 24 h treatment with 
luteolin of both wt control and DYT16 patient lymphoblasts could completely 
disrupt PACT-PKR interactions (Fig. 3.7 A, lanes 6 and 12), we tested if prior 
luteolin treatment would be protective for DYT16 patient lymphoblasts after ER 
stress. As seen in Fig. 3.7 B, the wt control lymphoblasts we do not detect any 
caspase 3/7 activity in our untreated samples or at 6-hours after TM treatment 
but there is a significant increase in caspase activity is detected at 24 h post 
treatment (Fig. 3.7 B, blue bars). The cells treated for 24 hours in luteolin prior to 
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TM treatment show a marked reduction in caspase 3/7 activity (Fig. 3.7 B, red 
bars). In contrast, the DYT16 patient cells show higher basal levels of caspase 
3/7 activity prior to TM treatment that is further enhanced at 6 hours post-
treatment. We see the most abundant caspase 3/7 activity in DYT16 cells treated 
for 24-hours in TM (Fig. 3.7 B, blue bars) that is dramatically reduced when cells 
are treated with luteolin 24-hours prior to treatment (Fig. 3.7 B, red bars). These 
results demonstrate that disrupting PACT-PKR interactions with luteolin in 
DYT16 cells can protect the cells from ER stress-induced apoptosis.  
3.5 DISCUSSION 
DYT16 is an early-onset, generalized dystonia caused by mutations in the 
Prkra gene, which encodes for PACT85, a stress-modulated activator of PKR35. In 
response to cellular stress, PACT activates PKR leading to eIF2α 
phosphorylation and inhibition of general protein synthesis35. Although primarily a 
protective response to restore homeostasis, if PKR remains active for prolonged 
periods it triggers cell death via apoptosis17,105. Our previous work has 
established that the regulation of PKR activation in response to stress depends 
on shifting the PKR inhibitory (PACT-TRBP and TRBP-PKR) interactions to PKR-
activating (PACT-PKR and PACT-PACT) interactions soon after the cell 
encounters the initial stress signal135. This is regulated by stress-induced PACT 
phosphorylation at serine 287, which dissociates PACT from TRBP and allows 
for its interaction with PKR52,136. Previously we investigated the effects of a 
recessively inherited DYT16 missense mutation P222L on PACT-induced PKR 
activation in response to ER stress69. Our results indicated that P222L activates 
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PKR more robustly and for longer duration but with initial lag and slower kinetics 
as compared to wt PACT. In addition, the affinity of PACT-TRBP, PACT-PACT 
as well as PACT-PKR interactions was also enhanced in DYT16 patient 
lymphoblasts homozygous for P222L mutation. The initial lag in PKR activation 
and eIF2 phosphorylation was due to stronger TRBP-PACT interaction 
ultimately leading to a delayed and prolonged intense PKR activation due to 
stronger PACT-PACT and PACT-PKR interactions causing enhanced cellular 
death. In addition, our previous work on a dominant frameshift DYT16 mutation 
that results in truncation of the PACT protein after 88 amino acids63 also 
demonstrated a dysregulation of PACT-PKR-eIF2 pathway137. The truncated 
mutant PACT protein formed aggregates in cells and caused PKR activation by 
displacing TRBP from PACT-TRBP complexes to promote PACT-PKR 
interaction, eIF2 phosphorylation, caspase activation and apoptosis. 
In the present study we evaluated the effects three recessive (C77S, 
C213R, and C213F)66 and two dominant (T34S and N102S)65 DYT16 mutations 
on PKR activation. Our results establish that similar to two previously examined 
DYT16 mutants69,137, dysregulation of ISR is also a common feature of all five 
DYT16 mutations. However, there are some important differences in the 
mechanism by which the dysregulation of ISR occurs. Similar to the P222L 
mutant, all five mutants show stronger PACT-PACT interactions as well as 
enhanced PKR activation. But unlike the previously studied P222L and the 
frameshift DYT16 mutants, none of these five mutants exhibited any changes in 
PACT-TRBP interactions. The recessive mutants tested in combinations as 
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found in DYT16 patients, as well as the two dominant mutants exhibited marked 
enhancement of PACT-PACT interactions in both co-IP and mammalian two 
hybrid assays (Fig. 3.5). Using DYT16 lymphoblasts from a compound 
heterozygote patient, we observe that the enhanced PACT-PKR interactions 
(Fig. 3.7) and elevated PKR kinase activity (Fig. 3.2 A and B) leads to a 
dysregulation of ISR and increased apoptosis in response to ER stress (Fig. 3.2, 
C and D).  
These results further strengthen the case for a maladaptive ISR as 
disease etiology for DYT16. Our previous study on the DYT16 patient cells 
carrying a homozygous P222L mutation was the first report on dysregulated 
eIF2 signaling in any type of dystonia69. Subsequently DYT174,121, DYT6121 as 
well as DYT11138 studies also suggested the maladaptive ISR pathway as a point 
of convergence for neuronal dysfunctions observed in dystonia. Two independent 
studies support the involvement of aberrant eIF2α signaling in brain to DYT1 
synaptic defects. Using an unbiased proteomics approach abnormal eIF2α 
pathway activation in DYT1 mouse and rat brain was identified, which also 
correlated with human brain samples121. Rittiner et al. used an RNAi-based 
functional genomic screening in HEK293T cells that also indicated dysregulated 
eIF2α pathway in DYT1. Moreover, in this study, pharmacological restoration of 
eIF2α signaling was reported to restore the cortico-striatal long term synaptic 
depression (LTD) in DYT1 knock-in mice74. In addition, this report also examined 
patients with focal cervical dystonia and reported sequence variants in ATF4, 
which is a direct target of eIF2 signaling74. RNA-Seq analysis to identify the 
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effect of heterozygous DYT6 Thap1 mutations on the gene transcription 
signatures in neonatal mouse striatum and cerebellum identified eIF2α signaling 
as one of the top dysregulated pathways. The neuronal plasticity defects in DYT6 
could also partially be corrected by salubrinal, a selective inhibitor of the eIF2α 
phosphatase which downregulates the ISR in a timely manner121. A gene-
expression analysis in adult cerebellar tissue from a mouse model of DYT11 also 
has identified genes associated with protein translation among the top down-
regulated mRNAs138. 
Stress-induced eIF2 phosphorylation by any of the four ISR kinases 
results in a suppression of general translation, but at the same time selectively 
stimulates the translation of some specific mRNAs139. Typically, these mRNAs 
have long 5′-UTR with complicated secondary structure and one or more short 
upstream open reading frames (uORFs). Such mRNAs are preferentially 
translated when eIF2α is phosphorylated and initiation from other mRNAs is 
suppressed. Thus, eIF2α phosphorylation during cell stress not only achieves 
conservation of energy by a reduction of total translation but also allows new 
synthesis of a few proteins such as transcription factors ATF4 and CHOP whose 
translation is upregulated by eIF2α phosphorylation140,141. These in turn induce 
the transcription of several genes either coding for ER enzymes and chaperones 
to cope with the accumulated unfolded proteins in the ER, or trigger apoptosis 
when homeostasis cannot be achieved due to intense or prolonged stress142. 
The dysregulation of ISR observed in DYT16 patient lymphoblasts although 
present in all cell types of the patients, it is likely to be especially detrimental to 
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neuronal function. There is large amount of evidence indicating that in neurons, 
eIF2 phosphorylation driven translational changes are an essential feature of 
normal neuronal functions in the absence of stress and all four eIF2 kinases 
participate either individually, synergistically or even interchangeably in 
regulating neuronal activity143. The eIF2 phosphorylation dependent translation 
regulation allows the neurons to quickly change protein compositions at the 
synapse in a stimulus-dependent manner, and such regulation is known to be 
important for maintaining healthy neuronal functions. For example, ATF4, which 
presumably is the most important protein known to be regulated at translational 
level by eIF2 phosphorylation, is known to be associated with regulation of 
neuronal activity in the absence of stress144. When PKR- mediated eIF2 
phosphorylation was specifically increased in hippocampal CA1 pyramidal cells 
by a chemical inducer, ATF4 expression increased significantly145. Increased 
levels of ATF4 led to impairment of hippocampal long-term potentiation (L-LTP) 
and memory consolidation. Despite the well-established role of ATF4 as a 
suppressor of synaptic plasticity, it has to be understood that the changes in 
ATF4 concentrations are complicated and sometimes can be bidirectional. For 
example, the GCN2-/- mice have decreased eIF2 phosphorylation, and thus 
have decreased ATF4 in hippocampal neurons146. These mice showed strong 
and sustained L-LTP and their spatial memory was improved compared to 
control wt mice. Thus, it may seem that low levels of ATF4 make neurons more 
sensitive to stimulation and their potentiation occurs too easily. It is certainly 
possible that neuronal activity-dependent shifts in ATF4 levels are important for 
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LTP to take place normally. Any perturbation in such shifts, in either direction due 
to lower or higher ATF4 may be detrimental for normal neuronal functions. This 
becomes relevant to dystonia as both higher and lower ATF4 levels seem to be 
detrimental in different forms of dystonia. Rittiner et al observed reduced ATF4 
induction in DYT1 cells and also identified the presence of inactivating mutations 
in ATF4 in sporadic cervical dystonia patients74. In our DYT16 lymphoblasts, we 
observe a sustained and higher level of ATF4 expression in response to ER 
stress (Fig 3.3). This was true both in P222L homozygous as well as P222L (data 
not shown) and C213R compound heterozygous DYT16 patients. Our studies 
are thus strongly indicative that a dysregulation of ATF4 expression occurs in 
DYT16 and this could derail normal healthy neuronal function.  
PKR has emerged as a major player in several neurodegenerative 
diseases in recent years as aberrant elevated PKR activation has been observed 
in human patients in post-mortem studies as well as in several mouse models147-
149. Increased levels of PKR phosphorylation have been detected in the brains of 
patients with neurodegenerative diseases such as Alzheimer’s disease (AD)113, 
Parkinson’s disease, Huntington’s disease54,55, dementia150, and prion 
disease151. Activated PKR was recently shown to be responsible for the 
behavioral and neurophysiological abnormalities in a mouse model of Down 
syndrome and PKR inhibitory drugs partially rescued the synaptic plasticity and 
long-term memory deficits in mice152. Drugs that target the eIF2 signaling 
pathway have shown benefits in many mouse models for neurodegenerative 
diseases and in particular, inhibiting PKR has proven to be effective, showing 
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rescue of synaptic and learning deficits in two different AD mouse models153. In 
case of DYT16 we wanted to take a more specific approach as C16, a widely 
used chemical inhibitor of PKR has been documented to have off target effects144 
thus questioning its suitability in treating DYT16. We have previously reported 
that luteolin disrupts the PACT-PKR interaction efficiently and can inhibit stress-
induced ISR and inflammation154. We tested if luteolin is able to rescue the 
DYT16 cells from stress induced apoptosis. Luteolin was able to dissociate 
PACT-PKR interactions efficiently in both normal as well as DYT16 lymphoblasts 
(Fig. 3.7). The observation that it takes significantly longer to disrupt PACT-PKR 
interactions in DYT16 patient cells as compared to normal wt cells, further 
supports that PKR interacts much stronger with P222L and C213R mutant PACT 
molecules. Luteolin treatment rescues the higher apoptosis phenotype in DYT16 
cells and offers a promising lead into possible future therapies aimed at 
disrupting PACT-PKR interactions. In addition to DYT16, such therapies may 
also show promise in AD as PACT mediated PKR activation has been implicated 
in AD116.  
The results presented here not only strengthen our previous research on 
DYT16, they also demonstrate the merit in developing drugs to disrupt PACT-
PKR interactions for possible clinical application in the future. Further efforts to 
discover compounds similar to luteolin that disrupt PACT-PKR interactions at 
lower concentrations or to develop specific peptides for this purpose may be 
fruitful. In this regard, it is worth mentioning that an interaction between dsRBM3 
of PACT with PKR's catalytic domain is essential for PKR activation and a 
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disruption of such an interaction may also prove beneficial as it would block 
PKR's catalytic activity even after PACT-PKR interactions have taken place. In 
combination with luteolin such peptides could offer valuable therapeutic options 
by lowering the effective luteolin dose significantly. 
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Figure 3.1: Effect of DYT16 mutations on dsRNA-binding. (A) Schematic 
representation of DYT16 mutations: Three conserved dsRBMs that bind dsRNA (M1 and 
M2) are shown in grey and the third domain lacking dsRNA-binding (M3) is shaded blue 
with the two phosphorylation sites represented as dark blue lines. Dominant mutations are 
indicated in red while recessive mutations are indicated in green.  
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Figure 3.1: Effect of DYT16 mutations on dsRNA-binding. (Continued) (B) dsRNA-
binding assay: The 35S-methionine labeled wild type PACT and DYT16 mutant proteins 
were in-vitro translated from 100 nG of appropriate plasmid DNAs, using rabbit reticulocyte 
lysate. dsRNA binding activity of wt PACT and point mutants was measured by a 
poly(I)·poly(C)-agarose binding assay with in vitro translated 35S-labeled proteins. T, total 
input; B, proteins bound to poly(I)·poly(C)-agarose. Competition lanes (15-18): -: no 
competitor, competition with 100-fold molar excess of single-stranded RNA (ss) or dsRNA 
(ds). The minor bands below the parent PACT bands represent products of in vitro 
translation from internal methionine codons and thus are not produced in similar quantities 
in all translation reactions and thus are of variable intensity in lanes 1-3. Lanes 19 and 20 
represent binding of firefly luciferase protein to dsRNA, used as a negative control to 
demonstrate specificity. C, quantification of the dsRNA binding assay. Bands were 
quantified by phosphorimaging analysis, and % bound was calculated. Error bars: S.D. 
from three independent experiments. The p values were calculated using statistical 
analyses indicated no significant difference between % dsRNA-binding of wt and point 
mutants.  
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Figure 3.2: Effect of DYT16 mutations on PKR activation and cell fate. (A) PKR 
kinase activity assay was performed using PKR immunoprecipitated from HeLa cells 
with a monoclonal PKR antibody (R&D Systems) and protein-A-sepharose beads. 
Recombinant wild type PACT or DYT16 mutant protein either 400 pg or 4 ng was 
used as PKR activator. Lanes 13-16 (upper panel) and Lanes 9-12 (lower panel): 
PACT mutants in combinations reported in DYT16 patients were used as PKR 
activator with 200 pg or 2 ng of each mutant protein.  
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Figure 3.2: Effect of DYT16 mutations on PKR activation and cell fate. 
(Continued) (B) Quantification of kinase activity assay. Radioactivity in each band 
was quantified using phosphoimaging analysis and the relative signal intensities are 
plotted. The p values calculated using Student's t-tests are as indicated. (C) Western 
blot analysis for cleaved PARP1. Whole cell extracts from normal (wt) and DYT16 
patient derived lymphoblasts treated with 5 μg/mL of tunicamycin (TM) were 
analyzed at indicated time points. (D) Caspase-Glo 3/7 activity. Lymphoblast lines 
established from wt and DYT16 patient were treated with 5 μg/mL tunicamycin and 
the caspase 3/7 activities were measured at indicated time points. Blue bars: wt 
cells, and red bard: DYT16 cells. Student's t-tests were performed, and the p values 
are as indicated. 
 
 
 
98 
Figure 3.3: PKR activation, eIF2α phosphorylation, ATF4 and 
CHOP induction in response to tunicamycin in normal and 
dystonia patient lymphoblasts. (A) Western blot analysis for p-
PKR and p-eIF2α. Whole cell extracts from normal (wt) and 
DYT16 patient derived lymphoblasts treated with 5 μg/mL of 
tunicamycin (TM) were analyzed at indicated time points. Blots 
were probed for p-eIF2α, total eIF2α, p-PKR, and total PKR. Best 
of four representative blots are shown. (B) Western blot analysis 
for ATF4 and CHOP under the same conditions as 3.3A. Beta-
actin was used as a loading control to ensure equal amounts of 
protein was loaded in each lane 
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Figure 3.4: Effect of DYT16 mutations on PACT-PKR interaction. (A & 
B) Co-immunoprecipitation assays: HeLa cells were co-transfected with the 
trans dominant negative Flag-PKR (K296R) and Myc-PACT expression 
plasmids in pCDNA3.1-. Twenty-four hours post-transfection, cells were 
harvested and myc-PACT 
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Figure 3.4: Effect of DYT16 mutations on PACT-PKR interaction. 
(Continued) (A) or flag-PKR(B) was immunoprecipitated with myc-agarose 
or flag agarose beads. The immunoprecipitates were then analyzed by 
western blot analysis with anti-flag or anti-myc antibodies (co-IP panel). 
Input gels show expression levels of proteins without immunoprecipitation. 
(A) Recessive DYT16 mutants and (B) Dominant DYT16 mutants. (C and 
D) Mammalian two-hybrid assays. HeLa cells were transfected with 250 ng 
of each of the two test plasmids encoding proteins to be tested for 
interaction, 50 ng of the reporter plasmid pG5Luc, and 1 ng of plasmid 
pRL-Null to normalize transfection efficiency. Cells were harvested 24 h 
after transfection, and cell extracts were assayed for luciferase activity. 
The plasmid combinations are as indicated, PKR was expressed as a 
GAL4 DNA-binding domain fusion protein (bait) and all PACT proteins 
were expressed as VP16-activation domain fusion proteins. The 
experiment was repeated twice with each sample in triplicate, and the 
averages with standard error bars are presented. Student's t-tests were 
performed to calculate p values and they are as indicated. RLU, relative 
light units. 
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Figure 3.5: Effect of DYT16 mutations on PACT-PACT interactions. (A-C) Co-
Immunoprecipitation assays to measure PACT-PACT interaction with mutant protein 
combinations seen in DYT16 patients. HeLa cells were co-transfected with Flag-PACT and 
Myc-PACT expression plasmids in pCDNA3.1-. Twenty-four hours post-transfection, cells 
were harvested, and flag-PACT was immunoprecipitated with flag agarose beads. The 
immunoprecipitates were then analyzed by western blot analysis with anti-myc antibodies 
(co-IP panel). Input gels show expression levels of proteins without immunoprecipitation.  
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Figure 3.5: Effect of DYT16 mutations on PACT-PACT interactions. (Continued) 
(A) Recessive DYT16 mutants, (B) Dominant DYT16 mutant interactions with wt PACT 
and (C) Dominant DYT16 mutant interactions with dominant mutants (homomeric 
interactions). Input gels show expression levels of proteins without immunoprecipitation. 
(D and E) Mammalian two-hybrid assays. HeLa cells were transfected with 250 ng of 
each of the two test plasmids encoding proteins to be tested for interaction, 50 ng of the 
reporter plasmid pG5Luc, and 1 ng of plasmid pRL-Null to normalize transfection 
efficiency. Cells were harvested 24 h after transfection, and cell extracts were assayed 
for luciferase activity. The plasmid combinations are as indicated, various PACT 
proteins were expressed as a GAL4 DNA-binding domain fusion proteins (bait) and also 
as VP16-activation domain fusion proteins. The experiment was repeated twice with 
each sample in triplicate, and the averages with standard error bars are presented. 
Student's t-tests were performed to calculate p values and they are as indicated. RLU, 
relative light units. 
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Figure 3.6: Effect of DYT16 mutations on PACT-TRBP interactions. (A, B) 
Co-Immunoprecipitation assays. HeLa cells were co-transfected with Flag-
TRBP and Myc-PACT expression plasmids in pCDNA3.1-. Twenty-four hours 
post-transfection, cells were harvested and flag-TRBP was 
immunoprecipitated with flag-agarose beads. The immunoprecipitates were 
then analyzed by western blot analysis with anti-myc antibodies (co-IP panel) 
and anti-flag antibody (IP panel). Input gels show expression levels of proteins 
without immunoprecipitation. (A) Recessive DYT16 mutants, (B) Dominant 
DYT16 mutants. (C and D) Mammalian two-hybrid assays. HeLa cells were 
transfected with 250 ng of each of the two test plasmids encoding proteins to 
be tested for interaction, 50 ng of the reporter plasmid pG5Luc, and 1 ng of 
plasmid pRL-Null to normalize transfection efficiency. Cells were harvested 24 
h after transfection, and cell extracts were assayed for luciferase activity. The 
plasmid combinations are as indicated, TRBP protein was expressed as a 
GAL4 DNA-binding domain fusion protein (bait) and various PACT proteins as 
VP16-activation domain fusion proteins. The experiment was repeated twice 
with each sample in triplicate, and the averages with standard error bars are 
presented. RLU, relative light units. 
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Figure 3.7: Effect of luteolin on PACT-PKR interactions and caspase 
activation in response to tunicamycin. (A) co-immunoprecipitation of 
endogenous PKR and PACT proteins. Lymphoblasts from unaffected 
family member (wt) or dystonia patient (patient) were treated with 50 μM 
luteolin. The cell extracts were prepared at the indicated times, and 
endogenous PKR protein was immunoprecipitated using anti-PKR mAb 
and protein A-Sepharose, which immunoprecipitates total PKR. The 
immunoprecipitates were analyzed by western blot analysis with anti-
PACT monoclonal antibody (Co-IP panel). The blot was stripped and re-
probed with anti-PKR mAb to ascertain an equal amount of PKR was 
immunoprecipitated in each lane (IP panel). Input blot: Western blot 
analysis of total proteins in the extract with anti-PACT and anti-PKR 
mAbs showing equal amount of PACT and PKR in all samples.  
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Figure 3.7: Effect of luteolin on PACT-PKR interactions and caspase 
activation in response to tunicamycin. (Continued) (B) Effect of 
luteolin on Caspase 3/7 activity in lymphoblasts. Lymphoblasts from 
unaffected family member (wt) and DYT16 patient (patient) were treated 
for 24-hours in 50 μM Luteolin (red) or left untreated (blue) followed by 
treatment with 5 μG/ml tunicamycin. Caspase 3/7 activity was measured 
at the indicated time points after tunicamycin treatment. The p values 
calculated using Student's t-tests are as indicated. 
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CHAPTER 4: 
CHARACTERIZATION OF A RECESSIVELY INHERITED FRAMESHIFT 
MUTATION IN PACT WHICH LEADS TO EARLY ONSET DYSTONIA 16 
(DYT16) IN MICE1 
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4.1 ABSTRACT 
In response to stimuli from a diverse range of cellular stressors, protein 
synthesis is negatively regulated through the phosphorylation of the α subunit of 
the eukaryotic translation initiation factor 2 (eIF2α). The interferon induced 
double stranded RNA (dsRNA) binding protein kinase (PKR) is an eIF2α kinase 
that has been shown to be activated in response to viral stress, endoplasmic 
reticulum stress, oxidative stress, and serum starvation. Under non-viral stress 
conditions, PKR is activated through direct high affinity interactions with its 
protein activator, PACT. Mutations in PACT have been identified as the causative 
factor in the development of early onset primary dystonia subtype 16 (DYT16) in 
human patient populations. Recently, a recessively inherited de novo frameshift 
mutation, Prkralear-5J (hereafter termed lear-5J), was identified in the mouse 
PACT. Mice homozygous for this mutation exhibited craniofacial developmental 
abnormalities, reduced body size, kinked tails, and DYT16-like symptoms. In the 
present study we investigate the biochemical and developmental consequences 
of this lear-5J mutation within this novel DYT16 model system. We identify that 
this truncated variant of the PACT protein retains its ability to interact with PKR, 
however, its ability to stimulate PKR’s kinase activity is dramatically reduced in 
vitro. Furthermore, our results suggest the lear-5J mRNA is partially targeted for 
NMD both in the brains of these mice as well as MEFs. Surprisingly, we only 
detect the truncated protein the brains of these affected mice which could 
indicate proteostatic mechanisms are differentially regulated in the brain relative 
to other cell types. When examining the cerebellum lear-5J mice, our results 
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demonstrated abnormalities in the development of the folia. Finally, upon further 
examination of the cerebellum our results reveal a severe lack of dendritic 
arborization in the Purkinje neuron layer and reduced eIF2α phosphorylation in 
the brains of the lear-5J mice relative to unaffected controls. 
4.2 INTRODUCTION 
Translational regulation is a fundamental modulator of cellular 
homeostasis in response to environmental stimuli. One of the primary nodes of 
translational regulation is the prevention of the formation of the ternary complex 
which is required for the synthesis of cap dependent mRNAs1. In response to 
amino acid deprivation, viral infection, accumulation of unfolded proteins or 
reactive oxygen species, the alpha subunit of the eukaryotic translation initiation 
factor 2 (eIF2α) is phosphorylated resulting in the attenuation of general protein 
synthesis1. This post-translational modification is facilitated by a family four eIF2α 
kinases, such that the activity of each kinase is stimulated in a stress signal-
specific manner in order to trigger the integrated stress response (ISR)1. Under 
such conditions, specialized stress response mRNAs are induced and 
preferentially translated in a cap- and eIF2α -independent manner in order to 
recover from stress1. While transient eIF2α phosphorylation is favorable for 
recovery and cell survival, chronic or prolonged eIF2α phosphorylation is 
detrimental by inducing apoptosis1. 
The interferon induced double-stranded RNA (dsRNA) activated protein 
kinase (PKR) is an eIF2α kinase that has been extensively studied for its role in 
attenuating protein synthesis in response to viral infection, endoplasmic reticulum 
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(ER) stress, oxidative stress, and amino acid deprivation1,13,17,18,34,35. PKR’s 
kinase activity is stimulated through direct interactions with dsRNA, a replication 
intermediate used by many viruses, or its protein activator (PACT)13,14,25. Both of 
these interactions are facilitated by two highly conserved dsRNA binding motifs 
(dsRBMs) on the amino terminus of PKR13,14,25,124. Interactions with dsRNA and 
PACT induce a conformational change in PKR revealing a conserved carboxy 
terminal kinase domain (KD) which is then activated through a trans-
autophosphorylation event1,15,31. Conversely, in the absence of stress PKR is 
negatively regulated through direct interactions the HIV transactivation response 
element (TAR) RNA binding protein (TRBP)46,126. While interactions with dsRNA 
and PACT that activate PKR are pro-apoptotic, PKR-TRBP interactions that 
inhibit PKR are favorable to cell viability.  
PACT is a dsRNA binding protein that activates PKR through direct 
protein-protein interactions under conditions of oxidative stress, ER stress, and 
amino acid deprivation25,35. Similar to PKR, PACT contains two highly conserved 
amino terminal dsRBMs (dsRBM1 and 2) that facilitate dsRNA and protein-
protein interactions; however, PACT also contains a third carboxy-terminal 
dsRBM (dsRBM3) that does not bind dsRNA but is required for PKR 
activation25,37,38. Within PACT’s dsRBM3 are two serine residues that serve as 
sites for post translational modifications, S246 and S28753. While S246 is 
constitutively phosphorylated, S287 is only phosphorylated under conditions of 
cellular stress49,53. Under homeostatic conditions, PACT is in a heterodimeric 
complex with TRBP and thus low basal levels of active PKR are maintained 53. 
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Under the conditions of cellular stress outlined above, PACT is phosphorylated 
by an unknown kinase on S287 which results in the dissociation of PACT-TRBP 
heterodimers and promotes the formation of PACT-PACT homodimers which are 
essential for PKR activation31,49,52,53.  
PACT is the product of the PRKRA gene which is ubiquitously expressed 
in all cell types. Mutations in PACT have been shown to be directly causative of 
the neuromuscular disorder, early onset dystonia and parkinsonism subtype 16 
(DYT16)62,67,129. The dystonias are a group of heterogenous movement disorders 
consisting of 18 categories that are linked to mutations in 25 known genes60. The 
patient presentation of dystonia consists of repetitive movements, involuntary 
muscle contractions, as well as compromised posture and gate59. Previous 
studies in DYT1, DYT6, and DYT16 have all identified the dysregulation of eIF2α 
signaling in the etiology of the disorders74,131,132. Interestingly, recent studies 
have identified mutations in eIF2γ to be the causative factor in the intellectual 
disability disorder, MEHMO84,155. These patients also demonstrated dysregulation 
of eIF2 signaling surrounding the formation of the ternary complex resulting in the 
induction of ISR proteins84,155. Furthermore, these patients present with 
craniofacial development defects, reduced body size, ataxic gate, and lower limb 
spasticity155. Collectively, these studies suggest that the dysregulation of eIF2 
signaling results in severe neuromuscular and intellectual disability disorders.  
Recently, Palmer et al. described a spontaneous frameshift mutation 
(Lear5j) in the mouse Prkra gene which codes for the mouse homolog of 
PACT34,68. This frameshift mutation results in a truncation within the dsRBM2 
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functional domain of the PACT protein68. PACT is highly conserved among 
human and mouse differing only in 6 amino acids 4 of which have identical 
chemical properties34,36. These mice present with craniofacial developmental 
abnormalities, small ear size (giving the name "Lear" for "little ears") drastically 
reduced body size, kinked tails, and ascending dystonia that progresses until 
fatal at 3-6 weeks of age68. This mouse model provides an animal model to 
examine the molecular pathways involved in DYT16 and also test some possible 
therapeutic options. Although it remains unknown if an equivalent mutation in 
humans would also produce a dystonia phenotype and if such a mutation could 
be viable in human population. In the present study we undertook a very 
preliminary characterization of both the in vitro and in vivo consequences of this 
mutation. Ultimately, our findings demonstrate that the truncated protein is 
detectable in mouse brain but not in MEFs, there is more detectable mRNA in 
mouse brain relative to MEFs, and that the mutant PACT protein retains its ability 
to interact with and activate PKR albeit with much reduced efficiency in vitro. Our 
in vivo data evaluating the brains of these mice demonstrates somewhat 
defective foliation of the cerebellum. Upon further evaluation of this phenotype, 
we observed that the cerebellar Purkinje neuron layer has a dramatic reduction in 
the dendritic arborization. Finally, we identified a reduction in total 
phosphorylated eIF2α, elevated eIF2α phosphatase levels, and no detectable 
difference in ATF4 levels in Lear5j mice compared to wt control. Consistent with 
previously published data, our results demonstrate that dysregulating eIF2 
signaling pathway in mouse has severe consequences on development and may 
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contribute to the etiology of the observed neuromuscular phenotype similar to 
DYT16. 
4.3 MATERIALS AND METHODS 
Cell Lines and Antibodies – Both HeLaM and Mouse Embryonic 
Fibroblasts (MEFs) cell lines were cultured in Dulbecco's Modified Eagle's 
Medium (DMEM) containing 10% Fetal Bovine Serum and 
penicillin/streptomycin. All transfections were carried out using Effectene 
transfection reagent (Qiagen) per manufacturer protocol. Antibodies used were 
as follows: PKR: anti-PKR (human) monoclonal (71/10, R&D Systems), p-eIF2α: 
anti-phospho-eIF2α (Ser-51) polyclonal (CST, #9721), PACT: anti-PACT 
polyclonal (ProteinTech, 10771-1-AP), ATF4: Anti-ATF4 monoclonal (CST, 
#11815), FLAG-HRP: anti-FLAG monoclonal M2-HRP (Sigma A8592), β-Actin: 
Anti- β-Actin-Peroxidase monoclonal (Sigma-Aldrich, A3854), CreP: PPP1R15B 
rabbit polyclonal (ProteinTech, 14634-1-AP).  
Generation of lear-5J Frameshift Mutation – We generated the lear-5J 
frameshift mutation using site specific mutagenesis through PCR amplification 
such that antisense primer contained a single adenine insertion relative to the 
Prkra template DNA. The following site-specific mutagenic primers were used: 
lear-5J Sense: GCCTCGAGCACATATGTCCCATAGCAGGCATCG, lear-5J 
Antisense: 
GCGGATCCGAAATATTACTAAACTTGGCGAGAAATTTCTCAGCAGCATTTCT
CTTGGCTTGTTTTTTTTGATGCCCCCTTTC. The subsequent PCR product was 
then ligated into pgEMT-Easy vector (Promega) and the presence of the 
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mutation was validated through DNA sequencing services provided by Eton 
Biosciences. After sequence validation we generated amino terminal flag-tagged 
lear-5J constructs in pBSIIKS+ using NdeI and BamHI restriction sites. We next 
subcloned the Flag-lear-5J ORF into the mammalian expression construct, 
pCDNA3.1-, using XbaI-BamHI restriction sites.  
Expression and purification of PACT/lear-5J from E. coli – The ORFs 
of both wt PACT and lear-5J frameshift mutation were subcloned into pET15b 
(Novagen) to generate an in-frame fusion protein with a histidine tag. 
Recombinant proteins were then expressed and purified as previously 
described25. 
PKR Activity Assay – HeLa M cells treated with IFN-β for 24-hours and 
harvested at 70% confluency. Cells were washed using ice-cold PBS and 
centrifuged at 600 g for 5-minutes. Cells then resuspended in lysis buffer (20 mM 
Tris–HCl pH 7.5, 5 mM MgCl2, 50 mM KCl, 400 mM NaCl, 2 mM DTT, 1% Triton 
X-100, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol) and incubated on ice for 
5 minutes. Whole cell lysates were then centrifuged at 10,000 g for an additional 
5-minutes. PKR was then immunoprecipitated from 100 ug of this lysate using 
anti-PKR monoclonal antibody (R&D Systems Technology: MAB1980) in a high 
salt buffer (20 mM Tris–HCl pH 7.5, 50 mM KCl, 400 mM NaCl, 1 mM EDTA, 1 
mM DTT, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol, 1% Triton X-100) at 
4oC on a rotating wheel for 30-minutes. We then added 10 ul of Protein A-
Sepharose beads to each immunoprecipitate followed by an additional 1-hour 
incubation under the same conditions. Protein A-Sepharose beads were then 
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washed 4 times in high salt buffer followed by an additional two washes in activity 
buffer (20 mM Tris–HCl pH 7.5, 50 mM KCl, 2 mM MgCl2, 2 mM MnCl2, 100 U/ml 
aprotinin, 0.1 mM PMSF, 5% glycerol). The PKR activity assay using the PKR 
bound to protein A-Sepharose beads was then conducted by incorporating: 500 
ng of purified eIF-2 as the PKR substrate, 0.1 mM ATP, 10 uCi of [γ-32P] ATP, 
and increasing amounts of either recombinant wt PACT or recombinant lear-5J 
(400 pg – 4 ng) as the PKR activator. Reaction was then incubated at 30°C for 
10 min and resolved on a 12% SDS-PAGE gel and analyzed via 
autoradiography. 
Western Blot Analysis – Protein extracts were prepared from a fraction 
of the brains of wt mice, mice heterozygous for the lear-5J mutation, and mice 
homozygous for the lear-5J mutation using western lysis buffer (20 mM Tris–HCl 
pH 7.5, 5 mM MgCl2, 50 mM KCl, 400 mM NaCl, 2 mM DTT, 1% Triton X-100, 
100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol) containing a 1:100 dilution of 
protease inhibitor (Sigma) and phosphatase inhibitor (Sigma). Tissue was initially 
homogenized in the lysis buffer cocktail described above and incubated on ice for 
5 minutes followed by centrifugation at 13,000 g for 10 minutes. Concentration of 
total protein extract was then determined through Bradford assays and 
appropriate amounts were resolved on SDS-PAGE denaturing gels to detect the 
proteins of interest. Protein extract derived from MEFs were prepared from wt 
and lear-5J MEFs cultured as described above. Cells were initially seeded at 
40% confluency and harvested 24-hours later using the lysis buffer cocktail 
described above. Concentration of whole cell extracts were determined by 
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Bradford assays. Proteins were detected via chemiluminescence and antibodies 
indicated above.  
Reverse Transcriptase PCR – RNA was isolated from either: (i) a 
fraction of mouse brain derived from wt mice, lear-5J heterozygous mice, lear-5J 
homozygous mice or (ii) wt and lear-5J homozygous MEFs. In all cases, tissue or 
cells were incubated on ice for 5-minutes in RNA-Bee (Tel-Test, Inc) and in the 
presence of CIA (chloroform:isoamylacetate (24:1)). Lysates were then 
centrifuged at 12,000 g for 15-minutes at 4oC. The fraction of lysate containing 
RNA was then carefully collected and precipitated overnight in an equal volume 
of isopropanol at -20oC. Samples were then centrifuged at 12,000 g for 15 
minutes to pellet the RNA. Supernatant was removed and RNA pellet was 
washed 2x in 70% ETOH and centrifuged at 12,000g for 8 minutes at 4oC 
followed by a 1-hour incubation at room temperature to ensure RNA was devoid 
of alcohol contamination. Purified RNA pellets were then resuspended in 
nuclease free water. In order to compare relative levels of mRNA, cDNA was 
generated using 1 ug of total RNA, 75 nG of random hexamer, and reverse 
transcriptase (Thermo Scientific) per manufacturer protocol. Finally, relative 
mRNA levels of Prkra were then compared using Prkra specific primers and 
either S15 or GAPDH housekeeping primers were used to amplify these 
housekeeping genes to determine equivalent amounts of cDNA were loaded into 
each reaction. The following primer sequences were utilized: Prkra Sense: 
ATGTCCCATAGCAGGCATCGTGCCG, Prkra Antisense: 
CCTTCCTGGGAAAGGGTATATTCAGG, S15 Sense: 
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TTCCGCAAGTTCACCTACC, S15 Antisense: CGGGCCGGCCATGCTTTACG, 
GAPDH Sense: CATGGGTGGAATCATATTGGAAC, GAPDH Antisense: 
GGTCGGAGTCAACGGATTTGG.  
Co-Immunoprecipitation Assays with Endogenous Proteins – HeLa M 
cells were seeded at 20% confluency in 6-well dishes 24-hours prior to 
transfecting 500 ng of either flag-wt PACT or flag-lear-5J constructs using 
Effectene transfection reagent (Qiagen). Cells were harvested 24-hours post 
transfection and harvested in IP buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 
mM EDTA, 1% Triton X-100, 20% Glycerol). Whole cell extract was then 
immunoprecipitated overnight at 4oC on a rotating wheel using anti-PKR antibody 
(71/10, R&D Systems) conjugated to protein A sepharose beads (GE Healthcare) 
in IP buffer. Immunoprecipitates were then washed 3 times in IP buffer followed 
by resuspension and boiling for 5 minutes in 2x Laemmli buffer (150 mM Tris–
HCl pH 6.8, 5% SDS, 5% β-mercaptoethanol, 20% glycerol). Samples were then 
resolved on 12% SDS-PAGE denaturing gels and transferred onto PVDF 
membranes. Blots were initially probed for flag-PACT/lear-5J constructs (coIP) 
using anti-flag antibody (described above) followed by incubation in anti-PKR 
antibody (described above) to determine equal amounts of PKR were 
immunoprecipitated. Input blots of whole cell extract without immunoprecipitation 
are shown to indicate equal amounts of protein in each sample. 
Histology and Immunostaining – Brains derived from day 28 wt or lear-
5J homozygous mice were fixed at 4oC overnight in 4% paraformaldehyde in 
PBS. The fixative was then removed and tissues were then washed in PBS 
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followed by dehydration in absolute ethanol. Following the dehydration step, 
tissues were then permeabilized with methyl salicylate and embedded in paraffin. 
We then generated 6 μM sagittal sections from each tissue and evaluated 
through hematoxylin and eosin (H&E) staining156.  
Immunostaining was carried out as previously described and antibodies, 
dilutions, and detection methods are indicated in Table 1157. In brief, experiments 
utilizing mouse primary antibodies utilized blocking reagents from the M.O.M. kit 
(Vector Laboraties) and experiments utilizing primary antibodies from other 
species used the blocking reagent from tyramide signal amplification (TSA) kit 
no. 22 dissolved in PBS (Thermo Fisher Scientific) each per manufacturer 
protocol. In each case, primary antibodies were incubated overnight at 4oC in the 
appropriate blocking reagent. Samples were then incubated in species specific 
secondary antibodies in TSA block for 30 minutes at room temperature. Biotin-
conjugated secondary antibodies were incubated in streptavidin conjugates 
(Alexa Fluor 488, Alexa Fluor 594, or HRP) at a 1:100 dilution in TSA block at 
room temperature for 30 minutes (Thermo Fisher Scientific). Following this 
incubation, the streptavidin-HRP conjugates were either subjected to SigmaFast 
3,3’-diaminobenzidine (DAB) staining (Sigma-Aldrich) or TSA with Alexa Fluor 
488 (TSA kit no.22, Thermo Fisher Scientific) for 3 minutes in each case. 
Fluorescent detection methods were counterstained with 300 nM 4’,6-diamidino-
2-phenylindole (DAPI) for 5 minutes prior to mounting in fluorescence mounting 
media. DAB detection was counterstained with 0.5% methyl green in 0.1 M 
sodium acetate buffer (pH 4.2) for 5 minutes at room temperature.  
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4.4 RESULTS 
A single nucleotide insertion truncates PACT in dsRBM2 –The lear-5J 
mice arise from a spontaneously arisen, recessively inherited frameshift mutation 
in the Prkra gene encoding for the mouse homolog of PACT68. This mutation is 
caused by a single adenine insertion in codon 178 which leads to a premature 
stop codon within one of PACT’s functional motifs (Fig. 4.1A)68. Consequently, 
the frameshift introduces 7 extraneous amino acids before truncating the protein 
within dsRBM2 (Fig. 4.1A-B). The resultant protein contains a full copy of PACT’s 
dsRBM1 and only a partial copy of PACT’s dsRBM2 eliminating some of the 
residues within this domain considered to be important for protein-protein 
interactions (Fig. 4.1A-B). However, the truncated protein still retains the entire 
dsRBM1, which is most crucial for dsRNA-binding and protein-protein 
interactions. 
Lear-5J has both cytoplasmic and nuclear localization – The wt PACT 
protein is ubiquitously expressed with a predominant cytosolic distribution. 
Recently, our lab demonstrated that a human DYT16 frameshift mutant protein 
forms protein aggregates when overexpressed in human cells130. Therefore, we 
next tested the effect of overexpressing the truncated lear-5J protein in cells (Fig. 
4.2A). To address this question, we generated amino terminal GFP tagged wt 
PACT and lear-5J constructs. These expression constructs were then transiently 
transfected in HeLa cells and the cells were examined by fluorescence 
microscopy 24-hours post transfection (Fig. 4.2A). Interestingly, while majority of 
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wt PACT is localized to the cytoplasm (left), the lear-5J mutant protein can be 
detected in both the cytoplasm and nucleus (right). 
Lear-5J interacts with and activates PKR in vitro – Previously, our lab 
has reported that mutating specific hydrophobic residues within PACT’s dsRBM1 
significantly disrupts PACT-PKR interactions, while disrupting hydrophobic 
residues in dsRBM2 has minimal consequences for PACT-PKR interaction 39. In 
light of the lear-5J mutation truncating the protein within PACT’s dsRBM2, we 
wanted to address whether this truncated protein retains its ability to interact with 
PKR (Fig. 4.3A). To address this question, we performed co-immunoprecipitation 
assays (co-IP) from cells overexpressing either flag-tagged wt PACT or flag-
tagged lear-5J constructs. Our results indicate that despite the truncation, the 
lear-5J protein interacts with PKR with equal binding affinity to that of wt PACT 
under the conditions of this assay (upper panel, lanes 1-2) (Fig. 4.3A). In the 
absence of PKR, we do not detect flag-wt PACT or flag- lear-5J thus indicating 
that there is no binding to the beads nonspecifically in the absence of PKR 
protein (upper panel, lanes 3-4) (Fig. 4.3A). Lanes 1-2 (lower panel) indicate that 
equal amount of endogenous PKR was immunoprecipitated in both samples 
while lanes 3-4 (lower panel) indicate the presence of PKR only in the presence 
of PKR antibody (Fig. 4.3A). Input blot (left) demonstrates equal expression of 
Flag-wt PACT and Flag- lear-5J prior to immunoprecipitation (Fig. 4.3A).  
PACT activates PKR under conditions of cellular stress25,34,35,158. 
Therefore, we next tested the effect the lear-5J frameshift mutation has on its 
ability to activate PKR in vitro. While dsRBM1 and 2 are responsible for dsRNA 
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and protein-protein interactions, dsRBM3 is critical PACT’s ability to activate 
PKR38. To address this question, we performed in vitro PKR activity assays using 
either purified recombinant hexahistidine-tagged wt PACT or lear-5J to stimulate 
PKR activation. Both hexahistidine-tagged wt PACT and lear-5J proteins were 
expressed in bacteria and purified using affinity chromatography on Ni-agarose. 
Two different amounts of the purified recombinant proteins were tested for 
activation of PKR immunoprecipitated from HeLa cells (Fig. 4.3B). Our results 
indicate that at lower concentration (400 pg), lear-5J does not activate PKR 
above background (lanes 1-2), whereas, wt PACT results in a clear activation of 
PKR (lane 4). Interestingly, lear-5J activates PKR slightly at the higher 
concentration (4 ng) (lane 3). Although lear-5J is a less potent activator of PKR 
as compared to wt PACT (lanes 4-5), these results indicate that the truncated 
lear-5J protein can activate PKR with a reduced efficiency, which is a surprising 
result and we will need to validate and explore this further to understand the 
biochemical and biological significance of this if any. 
Lear-5J protein is detectable in mouse brain but not MEFs – 
Frameshift mutations are often silenced through the quality control mechanism 
nonsense mediated decay (NMD) of mRNAs with an early stop codon 159. We 
next wanted to address whether the lear-5J mutant protein and mRNA is 
detectable in mice, or if the gene is silenced through NMD. To address this 
question, we isolated protein and total RNA from the brains of wt, heterozygous 
lear-5J, and homozygous lear-5J mice. We performed western blot analysis 
utilizing a polyclonal antibody for PACT to recognize the truncated lear-5J protein 
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(Fig. 4.4A). wt PACT has a molecular weight of 36 kDa (upper band), whereas, 
the lear-5J truncated protein has a predicted molecular weight of 22 kDa (lower 
band) (Fig. 4.4A). Lane 1 shows whole cell protein extract derived from mice 
heterozygous for the lear-5J mutation where both wt PACT (upper band) and 
lear-5J (lower band) are detectable (Fig. 4.4A) as expected. Comparably, whole 
cell protein extract derived from two independent lear-5J homozygous mouse 
brains have no detectable wt PACT band at the 36 kDa marker, however, both 
have a detectable band at the predicted molecular weight for the truncated lear-
5J protein at 22 kDa (lanes 2-3) (Fig. 4.4A). Finally, we detect the presence of wt 
PACT but not the lear-5J truncated protein in whole cell protein extract derived 
from wt mice (lane 4). Blots were then probed for -actin to ensure equal protein 
loading (lower panel, lanes 1-4). To further validate that the bands observed in 
Fig. 4.4A are specific to lear-5J and the mRNA corresponding to the Prkra gene 
is present in the brain (and not degraded via NMD), we performed reverse 
transcriptase PCR (RT-PCR) on total RNA isolated from the brains of the mice 
described above in comparison to wt MEF. Our results indicate that compared to 
the wt mice (lane 2) the Prkra transcripts are present at reduced levels in lear-5J 
mice (lanes 3-4) (Fig. 4.4B). We observe the greatest reduction in mRNA levels 
in lear-5J homozygous mice (lane 4) (Fig. 4.4B). These results indicate that 
although NMD may be operative on lear-5J mRNA, it does not cause complete 
absence of the transcripts from lear-5J brains. This also offers support to the idea 
that the protein bands observed at the expected position in lear-5J brain extracts 
(Fig. 4.4A) are indeed the truncated mutant lear-5J protein. RT-PCR for the 
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ribosomal protein S15 was used as a positive control to ensure equal amount of 
cDNA was added to each PCR reaction (lower panel) (Fig. 4.4B).   
We next wanted to evaluate whether the truncated lear-5J protein was 
also present in MEFs derived from lear-5J mice. Therefore, we performed 
western blot and RT-PCR analysis on MEFs derived from mice of the same 
genotypes as Fig. 4A-B. HeLa cells over-expressing flag- lear-5J were used as a 
positive control (Lane 4) (Fig. 4.4C). Our results indicate that wt PACT is 
abundant in these cells (upper panel, lane 1), however, no lear-5J mutant protein 
is detectable in MEFs (lanes 2-3). To ensure equal protein loading we then 
probed for -actin as our loading control (lower panel, lanes 1-4). Finally, we 
wanted to determine if the observed absence of lear-5J protein in MEFs is due to 
the absence of Prkra mRNA, as it could be degraded completely via NMD. We 
assessed this using RT-PCR as described before. Our results (Fig. 4.4D) show a 
dramatic reduction in detectable Prkra mRNA in MEFs homozygous for the lear-
5J mutation (lane 2) compared to the wt control (lane 1). GADPH was used as 
the positive control to ensure equal quantities of cDNA were used for each 
reaction. These results indicate that MEFs could be more efficient at NMD of the 
aberrant mutant lear-5J transcript than neuronal cells. In addition, the neuronal 
cells may also be less efficient in degrading the truncated mutant protein as the 
mutant protein is clearly detected in brain extracts of lear-5J mice whereas no 
lear-5J protein is detected in lear-5J MEFs corresponding to the reduced but 
detectable levels of Prkra mRNA. 
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PACT is expressed in the mouse cerebellum: Studies have 
demonstrated that eIF2α plays an important role in regulating translation during 
the development of an organism, however, the functional contribution of PACT 
during development remains an open question8,82. The cerebellum is the best 
characterized region of the brain for coordinating motor control and 
proprioception. As dystonia is mainly thought to result from defects in neuronal 
circuits, we next wanted to evaluate the presence of PACT in the cerebellum of 
developing mouse brain. In order to address this question, we performed two 
forms of IHC: (i) 3,3’-diaminobenzidine (DAB) such labeling the protein brown 
(Fig. 4.5A), (ii) immunostaining for wt PACT (green) and DAPI (4′,6-diamidino-2-
phenylindole) (blue) (Fig. 4.5B). In both cases, our results show that wt PACT is 
abundantly expressed in the cerebellum (Fig. 4.5A-B). The cerebellum is 
subdivided into three layers: the granular layer, the Purkinje cell layer, and a 
sparse molecular layer that contains axons from neurons within the internal 
granular layer160. Notably, we observe the highest concentration of wt PACT in 
the Purkinje cell layer (brown) (Fig. 4.5A-B). In light of this observation, we 
further evaluated the expression of wt PACT within the Purkinje neurons by 
performing double immunostaining for the Purkinje neuron specific marker, 
calbindin (red), and PACT (green) counterstained with DAPI (blue) (Fig. 4.5C). In 
agreement with the data described above, we are able to accurately detect 
abundant levels of wt PACT (green) in the Purkinje neurons (red) (Fig. 4.5C).   
Lear-5J mice show defects in cerebellum development and 
deficiencies in Purkinje cell arborization – The cerebellum of all mammals 
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share a common developmental pattern in that it is divided into 10 distinct 
folia160. After establishing that wt PACT is abundantly expressed in mouse 
cerebellum, we next wanted to assess whether the lear-5J frameshift mutation 
has an effect on cerebellar development. To address this question, we compared 
mid-sagittal sections of wt and lear-5J cerebellum derived from 28-day old mice 
using Hematoxylin and Eosin (H&E) staining using brains of 2 lear-5J mice (Fig. 
4.6A-B). In both wt and lear-5J mice we observe the characteristic 10 folia within 
each of the cerebellum (Fig. 4.6A-B). Interestingly, while the total number of folia 
was unaffected in lear-5J mice compared to wt, the complexity of the folia was 
significantly reduced (Fig. 4. 6A-B). The folia within the cerebellum in the lear-5J 
mice demonstrate an elongated and less branched pattern relative to that of wt 
mice (Fig.6A-B). The most distinguishing factor when comparing these foliations 
is within folium IX. In wt mice, this folium is subdivided into three lobules (IXa, 
IXb, IXc)160. While we can observe these distinct lobules in cerebellar tissue 
derived from wt mice, we do not detect such lobules in the lear-5J cerebellum 
(Fig. 4.6A-B). Although these initial observations provide valuable insight into the 
development of lear-5J mice, it is worth noting that although both lear-5J mice 
brains that were evaluated were drastically different than the wt control, there 
was also substantial differences between the two lear-5J mice. Consequently, 
these more mice need to be evaluated to support these initial observations. Due 
to the abundance of wt PACT in the Purkinje cell layer identified in Fig. 4.5, we 
next wanted to determine if there were any aberrant phenotypes within this 
cerebellar layer between these two mice (Fig. 4.6C-H). To this end, we 
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performed immunostaining on sagittal sections of wt and lear-5J cerebellar tissue 
using calbindin (green) to specifically mark Purkinje cells and DAPI (blue) as the 
nuclear stain (Fig. 4.6C-F). In wt mice, we are able to accurately detect Purkinje 
cells lining the folia of the cerebellum (Fig. 4.6C). Upon magnification, we further 
observe that the wt Purkinje neurons demonstrate the characteristic arborizations 
branching from the cell body (Fig. 4.6C-D). By comparison, we do not observe 
any aberrant phenotype in the overall spatial organization of Purkinje neurons 
within the lear-5J mice (Fig. 4.6C, 6E). Interestingly, upon magnification we 
identified a dramatic reduction in the dendritic branching of each Purkinje neuron 
in the lear-5J mice compared to that of wt (Fig. 4.6D, 4.6F).  
Lear-5J cerebellum shows dysregulated eIF2 signaling: A 
perturbation of the basal eIF2 phosphorylation levels as well as dysregulation of 
stress-induced phosphorylation has been previously linked to the dystonia 
subtypes DYT1, DYT6, and DYT1674,120,131,132. It is well established that neurons 
maintain higher levels of phosphorylated eIF2 compared to most cell types in 
order to ensure that translation is tightly regulated in a stimulus-specific manner 
to regulate various neuronal functions possibly including muscle movement77. 
The mechanisms that regulate this phosphorylation state of eIF2, however, 
remain largely uncharacterized. Consequently, we next determined if the lear-5J 
mutation resulted in any changes in eIF2 phosphorylation in the mouse 
cerebellum. To answer this question, we performed immunostaining on mid-
sagittal sections of mouse cerebellum probing for phosphorylated eIF2, the 
constitutively expressed regulator of eIF2 phosphorylation (CreP), and ATF4 
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(Fig. 4.7A-D). Our results indicate that mice homozygous for the lear-5J mutation 
show a dramatic reduction in levels of phosphorylated eIF2 as compared to wt 
controls (Fig. 4.7A). In light of this observation, we next evaluated levels of a 
negative regulator of eIF2 phosphorylation, CreP. CreP is a regulatory subunit 
of the protein phosphatase 1 (PP1) which works in a complex to provides 
substrate specificity to its catalytic subunit PP1C towards eIF2. Interestingly, 
our results indicate that the lear-5J mice have elevated levels of CreP as 
compared to wt controls (Fig. 4.7B). To further evaluate this question, we 
examined events downstream of eIF2 phosphorylation. The ATF4 transcript 
contains upstream short ORFs that allow its preferential translation under 
conditions of eIF2 phosphorylation in response to ER stress. Therefore, we 
compared levels of ATF4 protein in lear-5J mice to wt controls (Fig. 4.7C-D). 
Under these conditions, we do not observe any detectable difference in relative 
ATF4 levels in lear-5J mice compared to that of wt (Fig. 4.7C-D).  
4.5 DISCUSSION 
PACT serves as a negative regulator of general protein synthesis under 
conditions of cellular stress as it triggers eIF2α phosphorylation via PKR 
activation34,36. Previous work from our lab have established how DYT16 
mutations in PACT lead to the dysregulation of eIF2α stress response signaling. 
In these studies, we identified that the recessively inherited P222L mutation 
leads to a delayed but heightened eIF2α phosphorylation to increase cell 
susceptibility to ER stress69. We further described that a dominantly inherited 
frameshift (FS) mutation in PACT results in insoluble protein aggregates, PKR 
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activation, and significant apoptosis in the absence of stress130. Interestingly, this 
truncated PACT protein lost its ability to directly interact with PKR and dsRNA, 
however, retained its ability to interact with wt PACT and TRBP in vitro. With 
respect to both the P222L mutation and the FS mutation, we observe the 
dysregulation in eIF2α stress response signaling69,130. In light of the aggregates 
previously observed from the DYT16 FS mutation, we wanted to address 
whether the lear-5J mutation would also form these insoluble protein aggregates. 
To this end, we expressed an amino terminal GFP tagged lear-5J in HeLa cells 
and compared the localization of the protein to GFP-wt PACT (Fig. 4.2A). While 
we do not observe any protein aggregates in the lear-5J expressing cells, we do 
observe the unusual nuclear localization of the lear-5J polypeptide in addition to 
the usual cytoplasmic localization of wt protein (Fig. 4.2A). 
In the present study, our objective was to determine if the recessively 
inherited lear-5J mutation results in the dysregulation of eIF2α signaling thus 
possibly contributing to underlying craniofacial abnormalities and DYT16-like 
symptoms. The accumulation of misfolded proteins and protein aggregates has 
been directly linked to many neurodegenerative and cognitive disorders. To 
combat this, two fundamental quality control systems exist within the cell in order 
to maintain homeostasis. Firstly, NMD serves as an RNA surveillance pathway 
that protects the organism from the deleterious effects of frameshift mutations by 
the selective degradation of transcripts containing premature termination codons 
(PTC). By selectively degrading such transcripts, the NMD pathway prevents the 
accumulation of truncated proteins commonly associated with proteopathies as 
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the PTC containing transcript is not translated into the truncated protein. The 
second protective mechanism within cells is the protein quality control (PQC) 
system. This homeostatic mechanism serves to prevent the accumulation of 
misfolded or truncated proteins through selectively degrading the defective 
proteins themselves. As the lear-5J mutation is a frameshift mutation encoding 
for a truncated protein, we wanted to investigate whether we could detect the 
PTC containing mRNA as well as the truncated protein. We identified the lear-5J 
truncated protein in the brains of lear-5J mice at equivalent levels to that of wt 
PACT in control mice (Fig. 4.4A). Furthermore, while we were also able to detect 
the mRNA in the brains of the mutant mice the relative abundance of the lear-5J 
PTC containing transcript was drastically reduced relative to wt Prkra transcript 
levels found in wt controls (Fig. 4.4B). To validate these findings, we conducted 
the same series of experiments in mouse embryonic fibroblasts (MEFs). 
Interestingly, while we saw the same decreased levels of the Prkra transcript 
between lear-5J MEFs compared to wt controls, we were unable to detect the 
truncated protein in these cells (Fig. 4.4C-D). As we are able to detect the lear-5J 
mRNA in both brain and MEFs, this indicates the NMD quality control system is 
not sufficient on its own to prevent accumulation of Prkra mRNA (Fig. 4.4B, 
4.4D). Because we are able to detect the truncated lear-5J protein in the brains 
of these mice but not MEFs, we postulate that the PQC system is less efficient in 
the brains of lear-5J mice compared to lear-5J MEFs (Fig. 4.4A, 4.4C).  
While it is well established that eIF2α phosphorylation plays an integral 
role in maintaining homeostasis within neurons, the underlying details of specific 
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mechanisms remain unknown. PACT is best characterized for its role in 
activating PKR under conditions of ER stress, oxidative stress, and serum 
starvation. After identifying that the truncated lear-5J protein is present in the 
brains of lear-5J, we next determined the consequences of this truncation on the 
biochemical properties of PACT. PACT’s ability to interact with and activate PKR 
is facilitated by PACT’s dsRBM that serve as functional domains39. PACT 
facilitates high affinity interactions with PKR via its two amino terminal dsRBMs 
(Fig. 4.1A). As the lear-5J frameshift mutation truncates the protein within 
dsRBM2, we initially wanted to evaluate the effect of this mutation on PACT’s 
ability to interact with PKR (Fig. 1B). Previous studies from our lab established 
the contribution of individual amino acid residues within dsRBM1 and dsRBM2 on 
PACT’s protein-protein interactions39,52. Consistent with these studies, our results 
demonstrate that despite the severe truncation in dsRBM2, lear-5J retains its 
ability to interact with PKR (Fig. 4.3A). While dsRBM1 is the most critical 
functional domain in PACT for protein-protein and dsRNA interactions, dsRBM3 
has been shown to be required for PACT’s ability to activate PKR. We next 
wanted to determine if the lear-5J mutation could activate PKR as it lacks the 
critical carboxy terminal dsRBM3. Much to our surprise the lear-5J mutation is 
able to weakly activate PKR independent of dsRBM3 under the conditions of this 
assay (Fig. 4.3B). it is worth noting that when resolving recombinant 
hexahistidine tagged lear-5J on SDS-PAGE gel we consistently observe 
multimers of this truncated protein. We cannot exclude the possibility that these 
aggregates are helping stabilize the conformational change in PKR required for 
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its activation in response to interaction with PACT or lear-5J. It is plausible that 
the PKR’s kinase activity is stimulated by PACT in a stress independent manner 
in order to contribute the basal state of eIF2α phosphorylation in neurons and the 
truncated lear-5J protein could disrupt such regulation. 
Rowe et. al previously described a Prkra-/- mouse model that does not 
demonstrate DYT16-like symptoms, however, it shares many overlapping 
developmental phenotypes with the lear-5J mice102. Both PACT -/- mice and lear-
5J +/+ mice exhibit (i) reduced body size, (ii) craniofacial abnormalities, (iii) under-
developed ears, (iv) and hearing loss68,102. The PACT-/- mice do not exhibit any 
dystonia phenotype. A noteworthy difference between the PACT -/- mice and lear-
5J mice lies within their genetic backgrounds. The PACT -/- mice are described on 
both a mixed and pure C57BL/6 background, whereas, the lear-5J +/+ mice are on 
the BTBR T+ Itpr3tf/J background68,102. This BTBR genetic background contains a 
mutation in the Itpr3 gene which codes for a inositol 1,4,5-triphosphate receptor 
type 3. This receptor plays a critical role in mediating intracellular calcium levels. 
As calcium signaling is directly linked to ER homeostasis, it is reasonable that the 
combination of calcium signaling dysregulation and lear-5J results in the 
additional DYT16-like phenotypes, especially since we have previously linked 
PACT mediated PKR regulation to play a central role in cellular fate in response 
to ER stress.  
The cerebellum is a region of the brain that is indispensable for motor 
control161. We focused our analysis of lear-5J brains to cerebellum as it is also 
recently shown to be important for dystonia phenotypes in other forms of 
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dystonia. When comparing the overall developmental pattern of the cerebellum 
between the lear-5J mice to wt mice we see an overall reduction in the 
complexity of the foliation (Fig. 4.6A-B). The fully developed cerebellum contains 
10 distinct folia some of which are subdivided into distinct lobules160. This degree 
of complexity has evolved in order to increase the surface area of this region, 
thus increasing both total cell number and circuit formation160. Although the lear-
5J mice have all 10 foliations, some of the foliar subdivisions are less defined 
(Fig. 4.6B). Interestingly, when evaluating the Purkinje neuron layer within the 
cerebellum we observed a severe deficiency in the arborization of the Purkinje 
neurons in lear-5J +/+ mice as compared to wt mice (Fig. 4.6C-F). The Purkinje 
neurons function as inhibitory neurons and are responsible for the output of all 
motor coordination signals to the cerebellar cortex162. They facilitate this control 
through their extensive arborization of dendrites from the cell body. Under normal 
conditions, this network of dendrites branching from the Purkinje cells facilitates 
communication between the deep nuclei and the spinal cord. Interestingly, 
previous studies have specifically identified that the dysregulation of either 
sodium or potassium pumps in Purkinje neurons leads to the rapid onset of 
dystonia and parkinsonism or ataxia163,164. Other studies have also shown a 
direct correlation between abnormal Purkinje neuron development in patients 
with autism and ataxias162,164-166. Our results suggest that the Purkinje neurons in 
lear-5J +/+ mice could be dysregulated as a consequence of the severe deficit of 
dendritic arborizations, thus could be contributing to the underlying DYT16-like 
phenotype (Fig. 4.6E-F). It is worth noting that the mutation in the Itpr3 receptor 
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mutation in the BTBR genetic background itself could be working in tandem with 
the lear-5J mutation to show the resultant dystonia phenotype.  
Our cerebellar immunohistochemistry results indicate that not only do the 
lear-5J mice have a reduction in their basal state of eIF2α phosphorylation, they 
also have elevated levels of CreP (Fig. 4.7A-B). These elevated phosphatase 
levels in conjunction with the weakened ability for lear-5J to activate PKR could 
be contributing to the underlying mechanism of the reduced levels of 
phosphorylated eIF2α in these neurons. Finally, as eIF2α is the primary node of 
the ISR, we wanted to address whether the cerebellar tissue in these mice were 
eliciting a stress response1. To this end, we performed immunostaining 
identifying activating transcription factor 4 (ATF4), which is preferentially 
translated in a cap-independent manner under conditions of stress (Fig. 4.7C-
D)1. While we do not observe any noticeable difference in ATF4 level between wt 
and lear-5J (Fig. 4.7C-D).  
The dysregulation of protein synthesis is an emerging theme in the field of 
neurodevelopment, intellectual disability disorders, and neurodegenerative 
disorders75-80,84,155. Neurodegeneration is a consequence of proteopathies 
associated with the accumulation of insoluble protein aggregates both intra- and 
extracellularly. PKR has been linked to the pathology of Alzheimer’s disease 
(AD), Parkinson’s disease (PD), and Huntington’s disease (HD)54,55,57,58. The 
pathology of AD is largely understood to be attributed to the accumulation of Aβ 
peptides and hyperphosphorylated tau proteins110. Previous studies have 
identified a correlation between the neurotoxic Amyloid beta (Aβ) peptide burden 
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and p-PKR levels in patient samples as well as the colocalization of 
hyperphosphorylated tau protein and p-PKR in AD patients110. The development 
of immunotherapies targeting the Aβ plaques in AD has shown promising insight 
in reducing the Aβ burden of immunized patients110. Interestingly, the reduction of 
Aβ plaques also correlated with a reduction of p-PKR in the immunized cohort167. 
HD results from expanded numbers of polygluatamine repeats in the huntingtin 
protein which leads to the accumulation of cytotoxic insoluble protein aggregates. 
Although clinical studies have identified elevated activated PKR in HD tissue, the 
underlying mechanism describing how PKR is activated in HD remains 
unknown168. It is worth noting that Peel et al. have shown PKR is capable of 
binding to CAG repeats within exon 1 of the mutant huntingtin transcript such that 
the interaction increased with the number of repeats54. Although the authors of 
this study indicate this interaction is capable of activating PKR, they also indicate 
that it is not the causative mechanism driving HD pathology, but rather a 
contributing factor54. The underlying pathology of PD lies within the loss of 
dopaminergic neurons and the accumulation of cytotoxic α-synuclein protein 
aggregates169. Three specific point mutations in α-synuclein (A30P, A53T, E46K) 
have been identified to cause the aggregation of α-synuclein and thus the 
causative factor in familial PD169. Several studies have demonstrated that the 
phosphorylation of serine 129 in α-synuclein induces the protein aggregation169. 
A recent study identified that PKR facilitates the α-synuclein S129 
phosphorylation170. Most recently, MEHMO (Mental retardation, Epileptic 
seizures, Hypogenitalism, Microcephaly and Obesity) syndrome identified the 
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dysregulation of the ternary complex through mutation in the gamma subunit of 
eIF2 (eIF2γ), resulting in a constitutive active ISR84,155. In some cases, these 
patients present with lower limb ataxia consistent with the observed phenotype in 
DYT1684,155. Collectively, these studies point to a common mechanism of 
translational dysregulation and the ISR in neuronal and neurodegenerative 
disease pathologies84,155.  
In the context of the dystonias, three DYT subtypes, DYT1, DYT6, and 
DYT16 have all implicated the dysregulation of translation through eIF2α 
signaling in the pathology of the disease74,120,129,132. In the present study, we 
characterized how a recessively inherited frameshift mutation, lear-5J, results in 
developmental abnormalities and could possibly contribute to DYT16-like 
phenotypes. We identified that this truncated variant of PACT possesses the 
ability to interact with and weakly activate PKR in vitro. Furthermore, we 
demonstrate that the lear-5J mRNA is targeted for NMD, however, we are able to 
detect both reduced levels of the mRNA and the truncated protein in the brains of 
these mice. Finally, we show the severe lack of dendritic arborization in the 
Purkinje neuron layer of the cerebellum with reduced eIF2α phosphorylation in 
lear-5J mice. In future studies, it would be highly beneficial to create this lear-5J 
mutation, as well as other causative DYT16 mutations, in a C57BL/6 genetic 
background. In the context of the lear-5J mice, this would clarify if the resulting 
phenotypes are a due to the truncated PACT protein alone or a combination of 
lear-5J mutation and the BTBR T+ Itpr3tf/J genetic background. In addition, the 
 
135 
lear-5J mice may offer a great mouse model for screening potential therapeutic 
options to alleviate the dystonia symptoms. 
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Table 1. Primary Antibodies and Detection Methodology 
Peptide/Protein Target Source Dilution Used Detection Method 
Calbindin mouse 1:300 Invitrogen goat anti-mouse secondary antibody, Alexa 
Fluor 488 or goat anti-rabbit secondary antibody, 
Alexa Fluor 594 for double immunostaining 
PACT rabbit 1:100 Invitrogen goat anti-rabbit secondary antibody, biotin 
followed by Invitrogen streptavidin, HRP, and DAB 
p-eIF2α rabbit 1:100 Invitrogen goat anti-rabbit secondary antibody, biotin 
followed by 
Invitrogen streptavidin, Alexa Fluor 488 
CreP rabbit 1:200 Invitrogen goat anti-rabbit secondary antibody, biotin 
followed by 
Invitrogen streptavidin, Alexa Fluor 488 
ATF4 mouse 1:500 Invitrogen goat anti-rabbit secondary antibody, biotin 
followed by 
Invitrogen streptavidin, Alexa Fluor 488 
Abbreviations: DAB: 3,3'-diaminobenzidine, HRP: horseradish peroxidase 
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Figure 4.1: Schematic representations of the lear-5J frameshift 
mutation in the Prkra gene. (A) Functional domains of PACT and lear-5J 
frameshift mutation. Orange boxes: highly conserved dsRBM1 and 
dsRBM2 that facilitate high affinity dsRNA interaction and protein-protein 
interactions. Green: dsRBM3 that does not bind dsRNA but has weak 
binding affinity to the PACT binding motif (PBM) within the catalytic (kinase) 
domain (KD) of PKR. The frameshift mutation resulting from a single 
nucleotide insertion results in the addition of 7 novel amino acid 
represented in red before the stop codon. (B) Frameshift mutation in Prkra 
ORF. Single adenine insertion at nucleotide position 534 results in a 
truncated protein with the original 178 AA PACT AA followed by 7 novel AA 
before a premature stop codon truncating the protein. This truncation 
occurs within the dsRBM2 functional domain. 
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Figure 4.2: Lear-5J protein accumulates both in cytoplasm and nucleus. (A) GFP-Tagged wt 
PACT (left) and GFP-Tagged lear-5J (right) constructs were transiently transfected in HeLa cells at 
40% confluency and imaged 24-Hours post transfection.  
 
139 
Figure 4.3: Lear-5J protein interacts with and activates PKR. (A) Co-
Immunoprecipitation of endogenous PKR and Flag- lear-5J overexpressed in 
HeLa cells. HeLa cells were transfected with Flag wt PACT or Flag-lear-5J in 
pCDNA3.1- expression constructs at 40% confluency and harvested 24-hour 
post transfection. Whole cell extracts were immunoprecipitated at 4OC 
overnight using 100 ng of anti-PKR antibody per IP. Samples were then 
analyzed via SDS-PAGE gel electrophoresis and western blot analysis 
probing for Flag tagged wt PACT or lear-5J (co-IP panel) using monoclonal 
anti-Flag-M2 (Sigma) antibody. To ascertain that an equal amount of protein 
was immunoprecipitated, blots were re-probed using an anti-PKR antibody (IP 
panel). Input blots without immunoprecipitation demonstrate equal amounts of 
each protein were present prior to IP. 
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Figure 4.3: Lear-5J protein interacts with and activates PKR. (Continued) 
(B) PKR kinase activity assay was performed using PKR immunoprecipitated 
from HeLa cells, recombinant lear-5J and wt PACT proteins, and 1 μCi of [γ-
32P] ATP per reaction. Either pure recombinant lear-5J (left) or wt PACT 
(right) protein was added as activator in amounts indicated above each lane. 
Phosphorylated PKR was visualized after SDS-PAGE and phosphorimager 
analysis. 
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Figure 4.4: Lear-5J truncated mutant protein can be detected in mouse 
brains but not MEFs. (Continued) (B) Reverse transcriptase PCR (RT-PCR) 
using total RNA from the brains of the indicated lear-5J genotypes compared 
with the mouse embryonic fibroblasts (MEFs) using S15 as the positive control 
to ascertain presence of equal amount of total RNA in all samples. (C) 
Western blot analysis of cell extracts derived from MEFs of the indicated lear-
5J genotypes and HeLa cells overexpressing Flag-Lear-5J protein. Blots were 
probed for PACT using a polyclonal antibody and the best of 3 representative 
blots is shown. The position of the full-length PACT and the truncated lear-5J 
protein is indicated by arrows. (D) RT-PCR using total RNA isolated from wt 
and homozygous lear-5J MEFs. GAPDH was used as a positive control to 
ascertain equal amount of total RNA was analyzed in each sample. 
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Figure 4.5: PACT protein is abundantly expressed in mouse 
cerebellum and especially in Purkinje neurons. (A) 
Immunohistochemistry on day 28 sagittal sections of wt C57BL/6 
cerebellum using anti-PACT antibody. Brown staining indicates 
presence of PACT protein.  
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Figure 4.5: PACT protein is abundantly expressed in mouse 
cerebellum and especially in Purkinje neurons. (B) 
Immunohistochemistry on Day 28 sagittal sections of cerebellum 
from wt C57BL/6 mice showing wild type PACT (green) 
counterstained with DAPI (blue) as the nuclear marker. (C) 
Immunohistochemistry of tissue described in B showing co-
localization of PACT staining with a Purkinje neuron-specific marker 
calbindin. PACT (red), DAPI (blue), and calbindin (green).  
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Figure 4.6: Lear-5J mutation affects cerebellar development and reduces arborization in Purkinje neurons. 
(A-B) Hematoxylin and eosin staining on day 28 sagittal sections of wt and lear-5J cerebellum. Fully developed 
mouse cerebellum has ten lobules denoted here as I-X. (C-F) Immunohistochemistry of Day 28 sagittal sections of 
mouse cerebellar tissue stained with purkinje neuron marker, calbindin (green), and nuclear stain DAPI (blue). 
Dashed boxes (left panel) indicate areas of magnification (right panel). 
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Figure 4.7: Lear-5J cerebellum exhibits dysregulation of eIF2α 
signaling. (A-D) Immunohistochemistry of Day 28 sagittal sections of BTBR 
(wt) (left) and lear-5J (right) mouse cerebellar tissue stained with the 
nuclear marker DAPI (blue) and protein of interest (green). (A) DAPI (blue), 
phosphorylated eIF2α (green), (B) DAPI (blue), CreP (green), (C-D) DAPI 
(blue), ATF4 (green). 
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CHAPTER 5:  
GENERAL DISCUSSION
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This dissertation focuses on how mutations in PACT contribute to the 
underlying pathomechanisms associated with early onset dystonia, DYT16. This 
work demonstrates how the interactions between a family of dsRNA binding 
proteins, PACT, TRBP, and PKR regulate cell fate decisions in response to cellular 
stress through their ability to control translation and induce the ISR. Taken in 
concert, our results highlight the critical role PACT plays in the maintenance of 
cellular homeostasis and development, as well as how the dysregulation of this 
protein family contributes to the etiology of DYT16.  
In chapter 2 of this dissertation we describe a mechanism whereby a 
dominantly inherited FS mutation in PACT identified in a DYT16 patient dysregulates 
eIF2α stress response signaling. Interestingly, our results show this FS mutation 
does not interact with PKR, however, when overexpressed in mammalian cells forms 
protein aggregates that lead to PKR’s activation, the phosphorylation of eIF2α, and 
caspase mediated apoptosis. We report that this FS mutation ablates PKR 
interactions, it results in higher affinity interactions with both wt PACT and TRBP in 
vitro. We go on to show that the FS protein is capable of disrupting PACT-TRBP 
heterodimers in vitro. Therefore, we proposed a mechanism where overexpressing 
this FS protein disrupts the inhibitory PACT-TRBP heterodimers while forming FS-
TRBP and possibly FS-wt PACT heterodimers in the absence of stress. As a 
consequence, this promotes the formation of PACT-PACT homodimers required for 
PKR activation and subsequent eIF2α phosphorylation ultimately leading to caspase 
mediated apoptosis. Many neurodegenerative diseases are caused by protein 
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aggregates in neurons, our findings demonstrate a need for further investigation in 
the possible role of PKR activation in neuronal loss within this context. 
In chapter 3 of this dissertation we outline the biochemical consequences five 
causative DYT16 point mutations have on PACT’s ability to activate PKR, interact 
with dsRNA, and form high affinity homomeric and heterodimeric protein-protein 
interactions. We then further describe maladaptive ISR kinetics in DYT16 derived 
patient cells as compared to the unaffected control cells. In all cases, our results 
indicate that the DYT16 mutations show a significant increase in their homomeric 
interactions in the absence of stress and enhanced PKR activation in vitro. Although 
none of these DYT16 mutations demonstrated a change in their ability to bind 
dsRNA or heterodimerize with TRBP, it is notable that only the dominantly inherited 
N102S and T34S mutations resulted in enhanced heterodimer formation with PKR. 
Then using DYT16 patient derived lymphoblasts we demonstrate in the absence of 
stress, PACT-PKR interactions are enhanced and observe an increase in basal 
levels of PKR activation. Consequently, in response to ER stress the DYT16 
lymphoblasts demonstrated a prolonged and more robust ISR that ultimately 
resulted in an increase in apoptosis in patient cells relative to unaffected controls. 
Finally, our study demonstrates for the first time that this hypersensitivity to ER 
stress observed in patient cells is partially rescuable through disrupting the high 
affinity PACT-PKR interactions with the flavonoid, luteolin. Our results here support 
the hypothesis that the dysregulation of the ISR could be a common modality in 
many forms of primary dystonia. We also provide the first insights into potential 
therapeutic targets for DYT16. 
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In chapter 4 of this dissertation we characterize a novel DYT16 mouse model 
resulting from a de novo mutation in the Prkra gene which codes for the mouse 
homolog of PACT. This recessively inherited frameshift mutation was identified by 
the Jackson Laboratories and termed “lear-5J” as mice homozygous for this 
mutation presented with small ears. Furthermore, these mice presented with severe 
craniofacial developmental abnormalities, underdeveloped ears, reduced body size, 
kinked tails, and DYT16-like symptoms. We investigated how this lear-5J truncated 
variant of PACT alters the protein’s ability to interact with and activate PKR, as well 
as identify any developmental abnormalities within the cerebellum. We demonstrate 
that the lear-5J truncated protein retains its ability to interact with PKR, however, its 
ability to stimulate PKR’s kinase activity is dramatically reduced in vitro. 
Furthermore, we show that the lear-5J mRNA is partially targeted for NMD both in 
the brains of these mice as well as MEFs, however, we only detect the truncated 
protein in the brains of affected mice. Our histological analysis on the cerebellum of 
lear-5J mice revealed abnormalities in the development of the folia as compared to 
unaffected wt mice. Finally, upon further examination of these cerebellum we 
identified a severe lack of dendritic arborization in the Purkinje neuron layer of the 
cerebellum and reduced eIF2α phosphorylation in the brains of the lear-5J mice 
relative unaffected controls. Although significantly more work needs to be pursued in 
order to further elucidate the underlying mechanisms contributing to the etiology of 
DYT16-like symptoms in these mice, this provides insights into the first model 
system for this disease that could prove to be a valuable tool for testing potential 
therapeutic interventions for DYT16 dystonia. 
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